Patent Grant
12156792
An individual may have limited or impaired mobility such that typical urination processes are challenging or impossible. For example, the individual may have surgery or a disability that impairs mobility. In another example, the individual may have restricted travel conditions such as those experience by pilots, drivers, and workers in hazardous areas. Additionally, fluid collection from the individual may be needed for monitoring purposes or clinical testing.
Bed pans and urinary catheters, such as a Foley catheter, may be used to address some of these circumstances. However, bed pans and urinary catheters have several problems associated therewith. For example, bed pans may be prone to discomfort, spills, and other hygiene issues. Urinary catheters be may be uncomfortable, painful, and may cause urinary tract infections.
Thus, users and manufacturers of fluid collection devices continue to seek new and improved devices, systems, and methods to collect urine.
Embodiments disclosed herein are directed to fluid collection assemblies, systems including the same, and methods of using the same are disclosed herein. In an embodiment, a fluid collection assembly is disclosed. The fluid collection assembly includes a fluid impermeable barrier defining a chamber, at least one opening, and at least one fluid outlet. The fluid impermeable barrier includes at least one proximal surface defining the at least one opening and at least one distal surface opposite the proximal surface. The fluid collection assembly also includes at least one porous material disposed in the chamber. The fluid collection assembly includes at least one inflation device that includes a bladder. The bladder is operably coupled to the fluid impermeable barrier. The bladder includes one or more walls defining at least one interior region, The bladder is configured to switch between a first state and at least a second state. A volume of the at least one interior region is greater when the bladder is in the second state than when the bladder is in the first state. Switching the bladder between the first state and the second state changes a curvature of at least a portion of the fluid impermeable barrier.
In an embodiment, a system is disclosed. The system includes a fluid collection assembly, a fluid storage container, and a vacuum source. the chamber of the fluid collection assembly, the fluid storage container, and the vacuum source are in fluid communication with each other via one or more conduits.
In an embodiment, a method of using a fluid collection assembly is disclosed. The method includes positioning at least one opening of the fluid collection assembly adjacent to a female urethral opening. The fluid collection assembly includes a fluid impermeable barrier defining a chamber, at least one opening, and at least one fluid outlet. The fluid impermeable barrier includes at least one proximal surface defining the at least one opening and at least one distal surface opposite the proximal surface. The fluid collection assembly also includes at least one porous material disposed in the chamber. The fluid collection assembly further includes at least one inflation device including a bladder and at least one valve. The bladder includes one or more walls defining at least one interior region. The method further includes flowing at least one inflation fluid through the at least one valve and into the at least one interior region of the at least one inflation device to change a curvature of the fluid impermeably barrier.
Features from any of the disclosed embodiments may be used in combination with one another, without limitation. In addition, other features and advantages of the present disclosure will become apparent to those of ordinary skill in the art through consideration of the following detailed description and the accompanying drawings.
The drawings illustrate several embodiments of the present disclosure, wherein identical reference numerals refer to identical or similar elements or features in different views or embodiments shown in the drawings.
Embodiments are directed to fluid collection assemblies, systems including the same, and methods of using the same are disclosed herein. An example fluid collection assembly includes a fluid impermeable barrier having at least one proximal surface configured to be adjacent to an patient (i.e., an individual using the fluid collection assembly) when the fluid collection assembly is in use and at least one distal surface opposite the proximal surface. The fluid impermeable barrier at least defines a chamber, at least one opening defined by the proximal surface, and at least one fluid outlet. The fluid collection assembly also includes at least one porous material disposed in the chamber and at least one inflation device. The inflation device includes a bladder. The bladder may be adjacent to the distal surface of the fluid impermeable barrier or between a conduit disposed in the chamber and the distal surface. The bladder is configured to switch between a first state and at least a second state. A volume of the bladder is greater when the bladder is the second state than when the bladder is in the first state. Switching the bladder between the first state and the second state changes a curvature of at least a portion of the fluid impermeable barrier.
During use, the fluid collection assembly is positioned adjacent to a urethral opening (e.g., vagina) of the patient. One or more bodily fluids (e.g., urine, blood, etc.) that are discharged from the urethral opening of the patient flow through the opening and into the chamber. The bodily fluids that enter the chamber are received into the porous material and are directed towards the fluid outlet. The bodily fluids may be removed from the chamber through the fluid outlet, for example, when a suction force from a vacuum source is applied to the fluid outlet.
Generally, the fluid collection assembly conforms to the shape of the region about the urethral opening to prevent gaps between the fluid collection assembly and the region about the urethral opening. For example, bodily fluids may leak (e.g., do not enter the chamber and/or do not remain in the chamber) through gaps between the fluid collection assembly and the region about the patient. Such leaks may be embarrassing to the patient using the fluid collection assembly, create unsanitary situations, and cause the skin of the patient to remain moist which may cause skin degradation (e.g., rash) and general discomfort.
The region of the patient about the urethral opening may vary in size and shape depending on the patient. Some conventional fluid collection assemblies are manually bent to conform to the shape of the region about the urethral opening to prevent gaps between the conventional fluid collection assemblies and the region about the patient. Contact between the thighs of the patient and the conventional fluid collection assemblies maintains the bent shape of the conventional fluid collection assemblies. However, skinny patients may have too small of thighs to maintain contact with the conventional fluid collection assemblies while forgetful patients (e.g., confused patients, young children, patients with dementia) may move their legs such that the thighs no longer contact the conventional fluid collection assemblies, either of which may cause the fluid collection assembly to loss the bent shape thereof.
Embodiments of the fluid collection assemblies disclosed herein are an improvement to such fluid collection assemblies. As previously discussed, the fluid collection assemblies disclosed herein include at least one inflation device. The inflation device is configured to control the curvature of at least a portion of the fluid impermeable barrier such that the fluid impermeable barrier generally conforms to the shape (e.g., curvature) of the region about the urethral opening. In other words, the inflation device allows the fluid collection assembly to maintain the shape thereof without relying on contact between the fluid collection assembly and the thighs of the patient. As such, the inflation device may minimize gaps between the fluid impermeable barrier and the region about the urethral opening through which bodily fluids may leak. For example, the inflation device includes a bladder that is configured to switch between a first state and at least a second state. The bladder switches from the first state to the second state by increasing a volume thereof and from the second state to the first state by decreasing the volume thereof. The bladder may increase and decrease the volume thereof by adding or removing, respectively, at least one inflation fluid (e.g., air, water, saline, or other suitable fluid) from the bladder. A curvature of the inflation device may change when switching the bladder between the first and second states thereof. For example, the bladder may exhibit a first shape (e.g., first curvature) when the bladder is in the first state and a second shape (e.g., second curvature) when the bladder is in the second state, wherein the first shape and the second shape are different. The shape of at least a portion of the rest of the fluid collection assembly (e.g., fluid impermeable barrier) generally corresponds to the shape of the bladder and, thus, the inflation device may control the shape of the fluid impermeable barrier.
The inflation device 116 includes a bladder 118. The bladder 118 includes one or more walls 117 defining an interior region 120. The inflation device 116 also includes at least one valve 122 in fluid communication with the interior region 120. The valve 122 is configured to selectively permit flow of an inflation fluid into and/or out of the interior region 120. For example, the valve 122 may allow an inflation fluid to enter the interior region 120 when it is desirable to increase the volume of the bladder 118 which, in turn, changes a shape (e.g., curvature) of the bladder 118 and at least a portion of the fluid impermeable barrier 102. The valve 122 may also enable removing the inflation fluid from the interior region 120 when it is desirable to decrease the volume of the bladder 118 which, in turn changes a shape (e.g., return to the initial shape) of the bladder 118 and at least a portion of the fluid impermeable barrier 102.
Adding or removing the inflation fluids into and from the interior region 120 changes the state of the bladder 118. The bladder 118 may exhibit at least a first state and a second state. The amount (volume or weight) of inflation fluids present in the interior region 120 is greater when the bladder 118 is in the second state than when the bladder 118 is in the first state. In an example, as shown in
The bladder 118 may exhibit one or more additional states (e.g., a third state, a fourth state, and so forth) besides the first and second states discussed above. In an embodiment, the one or more additional states may include less inflation fluids in the interior region 120 (e.g., is more deflated) than the first state (e.g., the first state is a partially inflated state). In such an embodiment, the one or more additional states may include a deflated or partially deflated state and may be formed by removing inflation fluids from the interior region 120 when the bladder 118 is in the first or second state. In an embodiment, the one or more additional states may include more inflation fluids in the interior region 120 (e.g., is more inflated) than the first state (e.g., the first state is a deflated or partially inflated state) and include less inflation fluids in the interior region 120 than the second state. In such an embodiment, the one or more additional states include a partially inflated state and may be formed by adding or removing inflation fluids to the interior region 120 when the bladder 118 is in the first state or second state, respectively. In an embodiment, the one or more additional states may include more inflation fluids in the interior region 120 than the second state (e.g., the second state is a partially inflated state). In such an embodiment, the one or more additional states may be an at least partially inflated state and may be formed by adding inflation fluids to the interior region 120 when the bladder 118 is in the first state or second state. It is noted that, in some embodiments, the bladder 118 may only include the first and second states.
As shown in
In an embodiment, not shown, the bladder 118 and the fluid collection assembly 100 may exhibit a curved shape (e.g., a radius of curvature less than about 40 cm, less than about 25 cm, etc.) when the bladder 118 is in the first state. The curved shape of the bladder 118 may be a concave curve relative to the opening 110. The bladder 118 and the fluid collection assembly 100 may exhibit the curved shape when the bladder 118 is in the first state, for example, when the fluid collection assembly 100 would exhibit the curved shape when the inflation device 116 is omitted from the fluid collection assembly 100. For instance, the bladder 118 may be flimsy and exert no force on the rest of the fluid collection assembly 100 that is sufficient to significantly modify a shape of the rest of the fluid collection assembly 100 when the bladder 118 is in the first (e.g., deflated) state. Switching the bladder 118 to the second state may either increase or decrease the radius of curvature of the bladder 118 depending on the shape that the bladder assumes when inflated. Similarly, switching the bladder 118 to the second state may either increase or decrease the average radius of curvature of the rest of the fluid collection assembly 100. Thus, the amount of inflation fluids in the interior region 120 may control the shape of the fluid collection assembly 100 and may be used to shape the fluid collection assembly 100 to exhibit a shape that corresponds to the shape of the region about the urethral opening.
The shape that the bladder 118 assumes when switching the bladder 118 from the first state to the second state may be controlled by configuring different portions of the bladder 118 to expand at different rates (hereafter referred to as “expansion rate”). The expansion rate may be determined by taking the absolute value of the length of at least a portion (e.g., all) of bladder 118 when the bladder 118 is in the first state minus the length of the same portion of the bladder 118 when the bladder 118 is in the second state, wherein the length is measured parallel to the longitudinal axis of the fluid collection assembly 100. In an embodiment, the walls 117 of the bladder 118 includes a first region 124 and a second region 126 opposite the first region 124. The first region 124 and the second region 126 generally face the same direction as the proximal surface 104 and the distal surface 106, respectively. The first region 124 and the second region 126 may exhibit different expansion rates. In an embodiment, as illustrated, the first region 124 exhibits an expansion rate that is less than the second region 126. As such, switching the bladder 118 from the first state to the second state causes a decrease an average radius of curvature of the bladder 118 (i.e., causes the bladder 118 to bend) because a length of the second region 126 increases more than a length of the first region 124 when the bladder 118 switches from the first state to the second state. In an embodiment, the first region 124 exhibits an expansion rate that is greater than the second region 126.
The shape (e.g., curvature) that the bladder 118 assumes when in the first state, second state, and, optionally, the one or more additional states depend on a number of factors. For example, the shape that the bladder 118 assumes when the bladder 118 is in a deflated (e.g., first) state may be dictated by the shape of the rest of the fluid collection assembly 100. For instance, the bladder 118 may be formed from a relatively flexible material which allows the bladder 118 to be inflated. However, without any inflation fluids in the interior region 120, the bladder 118 merely conforms to the shape of the fluid collection assembly 100. Increasing the quantity of the inflation fluids in the interior region 120 to or near a level where the inflation fluids cause the bladder 118 to stretch may increase the rigidity of the bladder 118 to the point that the bladder 118 may exhibit a shape that is different than the fluid collection assembly 100. The shape that the bladder 118 exhibits may be, for example, an arc (e.g., a portion of a circle, oval, or other curve), one or more bends between adjacent straight or curved portions, or any other suitable shape. The different shapes that the bladder 118 may exhibit may be controlled by selecting the expansion rates of at least one of the first and second regions 124, 126, different portions of the first region 124 (e.g., one portion of the first region 124 may exhibit an expansion rate that is different than another portion of the first region 124), or different portions of the second region 126 (e.g., one portion of the second region 126 may exhibit an expansion rate that is different than another portion of the second region 126). In an example, the bladder 118 may exhibit a generally circular arc in the second state when substantially all the first region 124 exhibits the substantially same expansion rate and substantially all of the second region 126 exhibits the substantially same expansion rate, wherein the expansion rates of the first and second regions 124, 126 are different. In an example, the bladder 118 may exhibit a generally oval arc, other arc, or a bend therein when a portion of the first region 124 exhibits a different expansion rate than another portion of the first region 124 and/or when a portion of the second region 126 exhibits a different expansion rate than another portion of the second region 126. The expansion rates of the first and second regions 124, 126 may be selected based on factors discussed in more detail with regards to
In an embodiment, as illustrated, the inflation device 116 is positioned such that the first region 124 is adjacent to the distal surface 106 of the fluid impermeable barrier 102. Positioning the first region 124 adjacent to the distal surface 106 allows the inflation device 116 to change the shape of at least a portion of the rest of the rest of the fluid collection assembly 100. Further, a width of the bladder 118 (e.g., measured perpendicular to a length of the bladder 118 and perpendicular to thickness measured between the first and second regions 124, 126) may increase when the bladder 118 switches from the first state to the second state. However, positioning the first region 124 adjacent to the distal surface 106 may prevent the increase in the width of the bladder 118 from increasing the maximum width of the fluid collection assembly 100 when the bladder 118 switches from the first state to the second state, wherein the width of the fluid collection assembly 100 is measured perpendicular to the width of the bladder 118. The maximum width of the fluid collection assembly 100 does not change when the bladder 118 switches from the first state to the second state because the width of the bladder 118 is less than the maximum width of the fluid collection assembly 100 and/or the width of the bladder 118 does not need to significantly increase to significantly change the shape of the bladder 118. It is noted that not increasing the maximum width of the fluid collection assembly 100 when switching the bladder 118 from the first state to the second state allows the fluid collection assembly 100 to be used comfortably with patient's having average or larger than average sized thighs. For example, patients having average or larger than average thighs do not have much space between the thighs to accommodate an increased width of the fluid collection assembly 100 without uncomfortably pressing into the thighs.
The fluid impermeable barrier 102 may include at least one lateral surface 128 extending between the proximal and distal surfaces 104, 106. The lateral surface 128 may be adjacent to a thigh of an patient when the fluid collection assembly 100 is worn by the patient. In an embodiment, as discussed, above, the bladder 118 may be positioned adjacent to the distal surface 106 and not adjacent to the lateral surface 128 to prevent the bladder 118 from increasing the maximum width of the fluid collection assembly 100. In an embodiment, the bladder 118 may be positioned adjacent to the lateral surface 128 of the fluid impermeable barrier 102. In such an embodiment, switching the bladder 118 from the first state to the second state may increase the width of the fluid collection assembly 100. Increasing the width of the fluid collection assembly 100 may improve contact between smaller than average thighs and the fluid collection assembly 100. Further, when the bladder 118 is positioned adjacent to the lateral surface 128, the fluid collection assembly 100 may require two inflation devices on opposing sides of the lateral surface 128 and both inflation devices may need to receive the same amount of inflation fluids to ensure that the fluid collection assembly 100 is symmetrically shaped thereby making the manufacturing and use of the inflation device 116 more complex. It is noted that gaps may form between the fluid collection assembly 100 and the patient when the fluid collection assembly 100 is shaped non-symmetrically.
The walls 117 of the bladder 118 are formed from a material is substantially impermeable to the inflation fluid (e.g., substantially impermeable to a gas and/or a liquid) which allows the bladder 118 to retain the inflation fluids without leaks. The walls 117 may also be formed from a flexible material. The flexible material of the walls 117 allows the bladder 118 and, by extension, the fluid collection assembly 100 to change a shape thereof. For example, the flexible material of the walls 117 allow the interior region 120 to increase a volume thereof when the interior region 120 receives an inflation fluid and decrease a volume thereof when inflation fluids are removed from the interior region 120 which, in turn, changes the shape of the bladder 118. Examples of materials that may form the walls 117 of the bladder 118 include silicone, rubber, latex, polychloroprene, nylon fabric, polypropylene, polyvinyl chloride, nitrile rubber, other suitable polymers, a metal foil, a composite, or combinations thereof. It is noted that the walls 117 may contact the patient and might be formed from a biocompatible material. In an embodiment, the walls 117 are configured to stretch (e.g., elastically or plastically stretch) so the walls 117 remain taut when the bladder 118 is at least partially inflated. In an embodiment, the wall 117 forms a plurality of wrinkles when the bladder 118 is at least partially deflated and adding inflation fluid into the interior region 120 decreases the wrinkles.
The valve 122 (illustrated schematically) may include any suitable valve configured to allow for the controllable addition and removal of inflation fluids from the interior region 120. In an embodiment, the valve 122 is a luer valve and includes a male-tapper fitting or a female-taper fitting. In an embodiment, the valve 122 includes a fluid impermeable membrane with a slit or opening formed therein. The slit or opening of the fluid impermeable membrane remains substantially closed when no external load is applied thereto but opens when an external load is applied thereto (e.g., an external load caused by pressing a syringe against the fluid impermeable membrane). In an embodiment, the valve 122 may include a mechanical valve, such as a ball valve, a butterfly valve, or any other suitable mechanical valve. The mechanical valve may be manually operated or controlled using a computer. In an embodiment, the valve 122 may include a one-way valve (e.g., check valve) to limit leaks from the bladder 118 and to make the fluid collection assembly 100 easier to use. In such an embodiment, the valve 122 may only add or remove (but not both) inflation fluid from the interior region 120 and, as such, the fluid collection assembly 100 including the check valve is configured for single use. In an embodiment, the valve 122 may include a two-way valve which allows the inflation fluid to be added and removed from the interior region 120. In such an embodiment, at least a portion of the fluid collection assembly 100 (e.g., the fluid impermeable barrier 102 and the inflation device 116) may be reusable.
In an embodiment, as illustrated, the valve 122 may extend outwardly from the bladder 118. For example, the valve 122 may extend from the bladder 118 thereby allowing a user (e.g., medical practitioner or patient) of the fluid collection assembly 100 to easily access the valve 122. As shown, the valve 122 may extend a short distance only from the fluid impermeable barrier 102, such as about 2 cm or less, about 1.5 cm or less, about 1 cm or less, about 0.75 cm or less, about 0.5 cm or less, about 0.25 cm or less, or in ranges of about 0.25 cm to about 0.75 cm, about 0.5 cm to about 1 cm, about 0.75 cm to about 1.5 cm, or about 1 cm to about 2 cm. However, the valve 122 may extend a significant distance from the fluid impermeable barrier 102, such as a distance that is about 2 cm or greater, about 5 cm or greater, about 10 cm or greater, about 50 cm or greater, about 100 cm or greater, about 500 cm or greater, about 1 m or greater, about 2 m or greater, or in ranges of about 2 cm to about 10 cm, about 5 cm to about 50 cm, about 10 cm to about 100 cm, about 50 cm to about 500 cm, about 100 cm to about 1 m, or about 500 cm to about 2 m. When the valve 122 extends a significant distance from the fluid impermeable barrier 102, the valve 122 may include a flexible tube which allows a user of the fluid collection assembly 100 to easily access to the valve 122 while the fluid collection assembly 100 is positioned adjacent to the urethral opening without having the user near the urethral opening (which the patient may find uncomfortable).
In an embodiment, as illustrated, the valve 122 extends from or near a second region 126 of the bladder 118. The valve 122 at or near the second region 126 may allow a user of the fluid collection assembly 100 to access the valve 122 when the fluid collection assembly 100 is adjacent to the urethral opening since, generally, the inner thighs of the patient may contact or obstruct the proximal and lateral surfaces 104, 128 of the fluid impermeable barrier 102. Further, the valve 122 at or near the second region 126 prevents or at least inhibits the valve 122 from pressing against the inner thighs during use which may cause discomfort.
The at least one inflation fluid added or removed from the interior region 120 may include any suitable fluid, such as any suitable liquid or any suitable gas. In an embodiment, the inflation fluids are formed from a generally regarded as safe (“GRAS”) material. Forming the inflation fluids from a GRAS materials may decrease health risks caused by inadvertently exposing the patient to the inflation fluids. Examples of GRAS materials that may form the inflation fluids includes water, saline solution, alcohol solution, atmospheric air, nitrogen, any other GRAS material, or combinations thereof.
Further examples of inflation devices are disclosed in U.S. Provisional Patent Application No. 63/030,685 filed on May 27, 2020, the disclosure of which is incorporated herein, in its entirety, by this reference.
As previously discussed, the fluid collection assembly 100 includes a fluid impermeable barrier 102. In the illustrated embodiment, the fluid impermeable barrier 102 is distinct from the inflation device 116.
The fluid impermeable barrier 102 may be formed of any suitable fluid impermeable material(s), such as a fluid impermeable polymer (e.g., silicone, polypropylene, polyethylene, polyethylene terephthalate, a polycarbonate, etc.), a metal film, natural rubber, another suitable material, or combinations thereof. The fluid impermeable barrier 102 substantially prevents the bodily fluids from passing through the fluid impermeable barrier 102. In an example, the fluid impermeable barrier 102 may be air permeable and fluid impermeable. In such an example, the fluid impermeable barrier 102 may be formed of a hydrophobic material that defines a plurality of pores. At least a surface of the fluid impermeable barrier 102 that may contact the patient may be formed from a soft and/or smooth material (e.g., silicone), thereby reducing chaffing. In an embodiment, the fluid impermeable barrier 102 may be formed from a flexible material, such as silicone, which allows the fluid impermeable barrier 102 to be bent into a shape that conforms the anatomy of the patient. Further, as shown in
In some examples, the fluid impermeable barrier 102 may be tubular (ignoring the opening), such as substantially cylindrical (as shown), oblong, prismatic, or flattened tubes. During use, the outer surface (e.g., at least a portion of one or more of the proximal surface 104, the distal surface 106, or the lateral surface 128) of the fluid impermeable barrier 102 may contact the patient. The fluid impermeable barrier 102 may be sized and shaped to fit in the gluteal cleft between the legs of a female user when the bladder 118 are in at least the second state.
The opening 110 provides an ingress route for fluids to enter the chamber 108. The opening 110 may be defined by the fluid impermeable barrier 102 such as by an inner edge of the fluid impermeable barrier 102. For example, the opening 110 is formed in and extends through the fluid impermeable barrier 102, from the proximal surface 104 to an inner surface 132 of the fluid impermeable barrier 102, thereby enabling bodily fluids to enter the chamber 108 from outside of the fluid collection assembly 100. The opening 110 may be an elongated hole in the fluid impermeable barrier 102. For example, the opening 110 may be defined as a cut-out in the fluid impermeable barrier 102. The opening 110 may be located and shaped to be positioned adjacent to a female urethral opening.
The fluid collection assembly 100 may be positioned proximate to the female urethral opening and urine or other bodily fluids may enter the chamber of the fluid collection assembly 100 via the opening 110. The fluid collection assembly 100 is configured to receive the bodily fluids into the chamber 108 via the opening 110. When in use, the opening 110 may have an elongated shape that extends from a first location below the urethral opening (e.g., at or near the anus or the vaginal opening) to a second location above the urethral opening (e.g., at or near the top of the vaginal opening or the pubic hair).
The opening 110 may have an elongated shape because the space between the legs of a female is relatively small when the legs of the female are closed, thereby only permitting the flow of the bodily fluids along a path that corresponds to the elongated shape of the opening 110 (e.g., longitudinally extending opening). The opening 110 in the fluid impermeable barrier 102 may exhibit a length measured along the longitudinal axis of the fluid collection assembly 100 that may be at least about 10% of the length of the fluid collection assembly 100, such as about 25% to about 50%, about 40% to about 60%, about 50% to about 75%, about 65% to about 85%, or about 75% to about 95% of the length of the fluid collection assembly 100.
The opening 110 in the fluid impermeable barrier 102 may exhibit a width measured transverse to the longitudinal axis of the fluid collection assembly 100 that may be at least about 10% of the circumference of the fluid collection assembly 100, such as about 25% to about 50%, about 40% to about 60%, about 50% to about 75%, about 65% to about 85%, or about 75% to about 100% of the circumference of the fluid collection assembly 100. The opening 110 may exhibit a width that is greater than 50% of the circumference of the fluid collection assembly 100 since the vacuum (e.g., suction) through the conduit 134 pulls the fluid through the porous material 114 and into the conduit 134.
In some examples, the opening 110 may be vertically oriented (e.g., having a major axis parallel to the longitudinal axis of the fluid collection assembly 100). In some examples (not shown), the opening 110 may be horizontally oriented (e.g., having a major axis perpendicular to the longitudinal axis of the fluid collection assembly 100). In an example, the fluid impermeable barrier 102 may be configured to be attached to the patient, such as adhesively attached (e.g., with a hydrogel adhesive) to the patient. According to an example, a suitable adhesive is a hydrogel layer.
As previously discussed, the fluid impermeable barrier 102 may define fluid outlet 112 configured to remove bodily fluids from the chamber 108. The fluid outlet 112 is distinct from the opening 110 and the valve 122. In some examples, the fluid outlet 112 is sized to receive the conduit 134. The conduit 134 may be disposed in the chamber 108 via the fluid outlet 112. The fluid outlet 112 may be sized and shaped to form an at least substantially fluid tight seal against the conduit 134 or the at least one tube substantially preventing the bodily fluids from escaping the chamber 108.
The fluid impermeable barrier 102 may include markings thereon, such as one or more markings to aid a user in aligning the fluid collection assembly 100 on the patient. For example, a line on the fluid impermeable barrier 102 (e.g., opposite the opening 110) may allow a healthcare professional to align the opening 110 over the urethral opening of the patient. In examples, the markings may include one or more of alignment guide or an orientation indicator, such as a stripe or hashes. Such markings may be positioned to align the fluid collection assembly 100 to one or more anatomical features such as a pubic bone, etc.
As previously discussed, the fluid collection assembly 100 includes porous material 114 disposed in the chamber 108. The porous material 114 may cover at least a portion (e.g., all) of the opening 110. The porous material 114 is exposed to the environment outside of the chamber 108 through the opening 110. The permeable properties referred to herein may be wicking, capillary action, absorption, diffusion, or other similar properties or processes, and are referred to herein as “permeable” and/or “porous.” The porous material 114 may also wick the bodily fluids generally towards an interior of the chamber 108, as discussed in more detail below. The porous material 114 may include one or more of a fluid permeable membrane 136 or a fluid permeable support 138.
In an embodiment, at least a portion of the porous material 114 may be a wicking material configured to wick and/or enable the bodily fluids to move away from the opening 110, thereby preventing bodily fluids from escaping the chamber 108. The porous material may not include absorption of the bodily fluids into the porous material. Put another way, substantially no absorption of the bodily fluids into the porous material may take place after the wicking material is exposed to the bodily fluids. While no absorption is desired, the term “substantially no absorption” may allow for nominal amounts of absorption of the bodily fluids into the porous material (e.g., absorbency), such as about 30 wt % of the dry weight of the porous material, about 20 wt %, about 10 wt %, about 7 wt %, about 5 wt %, about 3 wt %, about 2 wt %, about 1 wt %, or about 0.5 wt % of the dry weight of the porous material. In an embodiment, the porous material 114 may be at least one of an absorbent material or adsorbent material instead of or in addition to being a wicking material.
The fluid collection assembly 100 may include the fluid permeable membrane 136 disposed in the chamber 108. The fluid permeable membrane 136 may cover at least a portion (e.g., all) of the opening 110. The fluid permeable membrane 136 may be composed to pull/push the bodily fluids away from the opening 110, thereby promoting fluid flow into the chamber 108, prevent fluid remaining on the vulva of the patient, and preventing the bodily fluids from escaping the chamber 108.
The fluid permeable membrane 136 may include any material that may be permeable to the bodily fluids. For example, the fluid permeable membrane 136 may include fabric, such as a gauze (e.g., a silk, linen, or cotton gauze), another soft fabric, or another smooth fabric. Forming the fluid permeable membrane 136 from gauze, soft fabric, and/or smooth fabric may reduce chaffing caused by the fluid collection assembly 100 and makes wearing the fluid collection assembly more comfortable. In an embodiment, the fluid permeable membrane 136 may define a plurality of perforations or may be continuous (e.g., does not define perforations). In an embodiment, the fluid permeable membrane 136 defines at least one hole that is configured to allow the valve 122 to extend through the fluid permeable membrane 136.
The fluid collection assembly 100 may include the fluid permeable support 138 disposed in the chamber 108. The fluid permeable support 138 is configured to support the fluid permeable membrane 136 and maintain the shape of the chamber 108 since the fluid impermeable barrier 102 and the fluid permeable membrane 136 may be formed from a relatively foldable, flimsy, or otherwise easily deformable material. For example, the fluid permeable support 138 may be positioned so the fluid permeable membrane 136 is disposed between the fluid permeable support 138 and the fluid impermeable barrier 102. The fluid permeable support 138 may support and maintain the position of the fluid permeable membrane 136 and the shape of the chamber 108. The fluid permeable support 138 may include any material that may be permeable to the bodily fluids, such as any of the fluid permeable membrane 136 materials disclosed above. For example, the fluid permeable membrane 136 material(s) may be utilized in a more dense or rigid form than in the fluid permeable membrane 136 when used as the fluid permeable support 138. The fluid permeable support 138 may be formed from any fluid porous material that is less deformable than the fluid permeable membrane 136. For example, the fluid permeable support 138 may include a porous polymer (e.g., nylon, polyester, polyurethane, polyethylene, polypropylene, etc.) structure (e.g., spun fibers such as spun nylon fibers) or a foam (e.g., an open cell foam). In some examples, the fluid permeable support 138 may be formed from a natural material, such as cotton, wool, silk, or combinations thereof. In such examples, the material may have a coating to prevent or limit absorption of the bodily fluids into the material, such as a water repellent coating. In some examples, the fluid permeable support 138 may be formed from fabric, felt, gauze, or combinations thereof.
In some examples, the fluid permeable membrane 136 may be omitted. For example, the porous material 114 may include only the fluid permeable support 138. In such examples, the bladder 118 may be positioned within the fluid permeable support 138 since, for instance, at least some materials of the support 138 disclosed herein are flexible enough to accommodate the shape and/or size changes discussed herein. In some examples, the fluid permeable support 138 may be optionally omitted from the fluid collection assembly 100 and the porous material 114 may only include the fluid permeable membrane 136. In such examples, the bladder 118 may be positioned within the fluid permeable membrane 136.
In an embodiment, the fluid permeable membrane 136 and/or the fluid permeable support 138 are wicking materials. In such an embodiment, the fluid permeable support 138 may have a greater ability to wick the bodily fluids than the fluid permeable membrane 136. In some examples, the wicking ability of the fluid permeable support 138 and the fluid permeable membrane 136 may be substantially the same. In an embodiment, the fluid permeable membrane 136 and/or the fluid permeable support 138 are non-wicking materials (e.g., absorbent and/or adsorbent materials).
In an embodiment, not shown, the fluid permeable membrane 136 and the fluid permeable support 138 may at least substantially completely fill the portions of the chamber 108 not occupied by the inflation device 116 and the conduit 134. In an embodiment, as shown in
The fluid reservoir 140 is a substantially unoccupied portion of the chamber 108. The fluid reservoir 140 may be defined between the fluid impermeable barrier 102 and at least one of the inflation device 116, the fluid permeable membrane 136, or the fluid permeable support 138. The bodily fluids in the chamber 108 may flow through the fluid permeable membrane 136 and/or fluid permeable support 138 to the fluid reservoir 140. The fluid reservoir 140 may retain of the bodily fluids. The bodily fluids in the chamber 108 may flow through the fluid permeable membrane 136 and/or fluid permeable support 138 and, optionally, to the fluid reservoir 140. The fluid impermeable barrier 102 may retain the bodily fluids in the fluid reservoir 140. The fluid reservoir 140 may be in a portion of the chamber 108 designed to be in a gravimetrically low point of the fluid collection assembly 100 when the fluid collection assembly 100 is worn.
Referring to
The first region 224 exhibits a first thickness and an opposing portion of the second region 226 exhibits a second thickness that is different than the first thickness. For example, the first thickness may be greater than the second thickness, or vice versa, by at least about 1%, at least about 2%, at least about 3%, at least about 4%, at least about 5%, at least about 7.5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 100%, at least about 125%, at least about 150%, at least about 200%, at least about 250%, at least about 300%, at least about 350%, at least about 400%, at least about 500%, or in ranges of about 1% to about 3%, about 2%, to about 4%, about 3% to about 5%, about 4% to about 7.5%, about 5% to about 10%, about 7.5% to about 15%, about 10% to about 20%, about 15% to about 25%, about 20% to about 40%, about 30% to about 50%, about 40% to about 60%, about 50% to about 70%, about 60% to about 80%, about 70% to about 90%, about 80% to about 100%, about 90% to about 125%, about 100% to about 150%, about 125% to about 200%, about 150% to about 250%, about 200% to about 300%, about 250% to about 350%, about 300% to about 400%, or about 350% to about 500%. As will be discussed in more detail below, the different between the first thickness and the second thickness may be selected based on the desired expansion rates of the opposing portions of the first and second regions 224, 226 which, in turn, affects the shape that the bladder 218 assumes when switching between the first and second states.
In an example, as illustrated, the first thickness is greater than the second thickness. The greater thickness of the first region 224 relative to the second region 226 causes the first region 224 to exhibit a smaller expansion rate than the second region 226. As such, the length of the first region 224 increases less than the length of the second region 226 when the bladder 218 switches from the first state to the second state which causes the bladder 218 to bend towards the first region 224. In other words, if the bladder 218 is initially straight, the increased thickness of the first region 224 causes the bladder 218 to form a curved shape with the first region 224 forming the concaved portion of the curved shape. In an example, the first thickness is less than the second thickness. The smaller thickness of the first region 224 relative to the second region 226 causes the first region 224 to exhibit an expansion rate that is greater than the second region 226. In other words, the length of the first region 224 increases more than the length of the second region 226 when the bladder 218 switches from the first state to the second state which causes the bladder 218 to bend towards the second region 226. In other words, if the bladder 218 is initially curved such that the first region 224 is concavely curved, the decreases thickness of the first region 224 causes the bladder 218 to form a more straight shape.
The shape that the bladder 218 forms when switching the bladder 218 between the first and second states may be controlled at least partially based on the thicknesses of the first and second regions 224, 226. In an embodiment, the bladder 218 may form a generally circular arc when each of the thickness of the first region 224 and the thickness of the second region 226 are substantially constant along the length of the bladder 218. In an embodiment, the thickness of at least one of the first region 224 or the second region 226 may be selectively varied which causes the expansion rate of different portions of the first region 224 and/or the second region 226 to vary. In an example, decreasing the thickness of a portion of the first region 224 relative to another portion of the first region 224 may cause the thinner portion of the first region 224 to exhibit a greater expansion rate than the thicker portion of the first region 224. In such an example, using the illustrated embodiment, the thinner portion of the first region 224 may bend more (e.g., exhibit a smaller average radius of curvature) than the thicker portion of the first region 224. In an example, decreasing the thickness of a portion of the second region 226 relative to another portion of the second region 226 may cause the thinner portion of the second region 226 to exhibit an expansion rate that is greater than the thicker portion of the second region 226.
Referring to
The additional layer 342 effectively increases the thickness of the portion of the first region 324 and/or the second region 326 to which the additional layer 342 is adjacent. As such, similar to the different thicknesses discussed with regards to
In an embodiment, the additional layer 342 may exhibit a Young's modulus (modulus of elasticity) that is greater than the walls 317 of the bladder 318. The increased Young's modulus of the additional layer 342 allows the additional layer 342 to exhibit the same effect as a thicker region of the walls 317 but at a smaller thickness. As such, the additional layer 342 may decrease the amount that the bladder 318 extends from the fluid impermeable barrier 302 than if bladder 318 included a region with increased thickness. The decreased profile of the bladder 318 may make the bladder 318 more comfortable to wear, especially with larger thighs since there is not significant space between the larger thighs in which to position the fluid collection assembly 300. In an example, the additional layer 342 includes a substantially inflexible fabric. In an example, the additional layer 342 includes a wire, a plate, a substantially inflexible polymer, a metal, or a composite.
The shape that the bladder 318 forms when switching the bladder 318 between the first and second states may be controlled based on which portions of the bladder 318 to which the additional layer 342 is adjacent and the Young's modulus of the additional layer 342. In an embodiment, the bladder 318 may form a generally circular arc when the additional layer 342 is adjacent to one or more of the first region 324 or the second region 326 along an entire length thereof. In an embodiment, the additional layer 342 is selectively positioned adjacent to only a portion of the length of one or more of the first region 324 or the second region 326. The portion(s) of the first region 324 and/or second region 326 to which the additional layer 342 is adjacent may exhibit an expansion rate that is less than portion(s) of the first regions 324 and/or second region 326 that are not spaced from the additional layer 342. In an embodiment, the additional layer 342 may be selectively formed form two or more portions, where at least two of the two or more portions exhibit different Young's moduli. Each of the two or more portions may extend along different lengths of the additional layer 342. For instance, the additional layer 342 may include a first portion exhibiting a first Young's modulus and a second portion exhibiting a second Young's modulus that is greater than the first Young's modulus. In such an instance, the portions of the bladder 318 adjacent to the first portion of the additional layer 342 may exhibit an expansion rate that is greater than the portions of the bladder 318 adjacent to the second portion of the additional layer 342.
Referring to
The fluid impermeable barrier 402 may exhibit an expansion rate that is different than the walls 417. In an example, the fluid impermeable barrier 402 may exhibit an expansion rate that is less than the walls 417. The fluid impermeable barrier 402 may exhibit the lower expansion rate because at least one of the fluid impermeable barrier 402 is thicker than the walls 417, the fluid impermeable barrier 402 exhibits a Young's modulus that is greater than the walls 417, or the portions of the fluid impermeable barrier 402 that do not define the interior region 420 apply a force to the first region 424 that limits expansion of the portions of the fluid impermeable barrier 402 that define the interior region 420. In an example, the fluid impermeable barrier 402 may exhibit an expansion rate that is greater than the walls 417. In such an example, the fluid impermeable barrier 402 may exhibit the larger expansion rate because at least one of the fluid impermeable barrier 402 is thinner than the walls 417 or the fluid impermeable barrier 402 exhibits a Young's modulus that is less than the walls 417.
Referring to
The bladder 518 may be attached to the fluid impermeable barrier 502 using any suitable technique. For example, the bladder 518 may be attached to the fluid impermeable barrier 502 using an adhesive, radio frequency welding, ultrasonic welding, tape (e.g., double sided tape positioned between bladder 518 and the fluid impermeable barrier 502 or tape that wraps around at least a portion of the bladder 518 and is attached to the fluid impermeable barrier 502), or any other suitable attachment technique.
Referring to
In an embodiment, two or more portions of the bladder 618 are attached to the fluid impermeable barrier 602. For example, as illustrated, two or more portions of the bladder 618 at or near the terminal ends of the bladder 618 are attached to the fluid impermeable barrier 602. The expansion rate of a surface of the bladder 618 that is adjacent to the fluid impermeable barrier 602 (i.e., the first portion 624) and is between two or more portions of the bladder 618 that are attached to the fluid impermeable barrier 602 is limited because the two or more portions that are attached to the bladder 618 exhibits a compressive force that limit the expansion rate. In other words, the surface of the bladder 618 that is adjacent to the fluid impermeable barrier 602 and is between two or more portions of the bladder 618 exhibits an expansion rate that is less than an opposing portion of the bladder 618.
The embodiments illustrated and discussed in
The inflation device 716 includes a bladder 718 and at least one valve 722. The bladder 718 includes one or more walls 717 defining an interior region (not shown, obscured). The bladder 718 exhibits a “crinkle” structure (i.e., the bladder 718 is a crinkle shaped bladder). For example, the bladder 718 may include one or more peaks 744 (e.g., a plurality of circumferentially extending peaks 744 or a single helically extending peak 744). The bladder 718 also includes one or more valleys 746 (e.g., a plurality of circumferentially extending valleys 746 or a single helically extending valley 746) disposed between portions of the peaks 744 space apart along a longitudinal direction of the bladder 718. The peaks 744 and the valleys 746 allow the bladder 718 to bend when switching the bladder 718 from the first state to the second state. For example, adding inflation fluids to the bladder 718 may cause the distance between the peaks 744 on the second region 726 to increase while the distance between the peaks 744 on the first region 724 may decrease, remain constant, or increase at a rate that is less than the second region 726.
The inflation device 716 may be attached to the fluid impermeable barrier 702 using any suitable technique (e.g., adhesive, tape, ultrasonic welding, etc.) along at least a portion of a length thereof. In an example, only the terminal ends of the inflation device 716 (e.g., the terminal ends may not include the “crinkle structure”) may be attached to the fluid impermeable barrier 702. In an example, some or all of the peaks 744 may be attached to the fluid impermeable barrier 702. In an example, some or all of the valleys 746 may be attached to the fluid impermeable barrier 702. In an example, two or more of the terminal ends, at least some of the peaks 744, or at least some of the valleys 746 of the inflation device 716 are attached to the fluid impermeable barrier 702.
The embodiments illustrated in
As previously discussed, the fluid collection assembly 800 includes a plurality of inflation devices that may be independently inflated and/or deflated. For example, as illustrated, the fluid collection assembly includes a first inflation device 816a, a second inflation device 816b, and a third inflation device 816c. Each of the first inflation device 816a, the second inflation device 816b, and the third inflation device 816c may be the same or substantially similar to any of the inflation devices disclosed herein. For example, each of the first inflation device 816a, the second inflation device 816b, and the third inflation device 816c may a bladder having one or more walls defining and interior region and at least one valve. In an example, each of the first, second, and third inflation devices 816a, 816b, 816c are the same. In an example, at least two of the first, second, and third inflation devices 816a, 816b, 816c are different (e.g., exhibit different lengths, exhibit different expansion rates, limit the expansion rates thereof using different techniques, etc.).
Each of the first, second, and third inflation devices 816a, 816b, 816c are configured to control the shape of a corresponding portion of the fluid impermeable barrier 802. For example, the first inflation device 816a may be configured to control the shape of a first portion 848a of the fluid collection assembly 800, the second inflation device 816b may be configured to control the shape of a second portion 848b of the fluid collection assembly 800, and the third inflation device 816c may be configured to control the shape of a third portion 848c of the fluid collection assembly 800. As such, the first, second, and third inflation devices 816a, 816b, 816c allow for more control of the shape of the fluid collection assembly 800 that if the fluid collection assembly 800 included a single inflation device. In an example, one or two of the first, second, or third inflation devices 816a, 816b, 816c may be switched from the first state to the second state while the remainder of the first, second, or third inflation devices 816a, 816b, 816c remain in the first state. The inflation device(s) that are switched to the second state cause the corresponding portions of the fluid collection assembly to change shape while the inflation device(s) that remain in the first state cause the corresponding portions of the fluid collection assembly to remain in the original shape thereof. In an example, each of the first, second, or third inflation devices 816a, 816b, 816c are switched from the first state to the second state. In such an example, one or two of the first, second, or third inflation devices 816a, 816b, 816c may include changing (e.g., reducing) an average radius of curvature of a corresponding portion of the fluid collection assembly 800 more than the remaining one or two of the first, second, or third inflation devices 816a, 816b, 816c.
In an embodiment, the fluid collection assembly 800 may include two inflation devices or four or more inflation devices. In other words, the third inflation device 816c may be omitted from the fluid collection assembly 800 or the fluid collection assembly 800 may include one or more additional inflation devices in addition to the first, second, and third inflation devices 816a, 816b, 816c. In an embodiment, as shown, the first, second, and third portions 848a, 848b, 848c of the fluid impermeable barrier 802 may not overlap. However, it is noted that two or more of the first, second, or third portions 848a, 848b, 848c may overlap such that a shape of such overlapped portions may be controlled by two different inflation devices.
The system 950 also includes at least one pump 952 and at least one inflation fluid reservoir 954 configured to store one or more inflation fluids therein. The inflation fluid reservoir 954 may include a tank that stores the inflation fluids therein or may be the atmosphere (e.g., the inflation fluids are atmospheric air). The pump 952 and the inflation fluid reservoir 954 are in fluid communication to the inflation device 916 via at least one conduit 956. For example, the conduit 956 may extend from the pump 952 and/or the inflation fluid reservoir 954 to a valve 922 of the inflation device 916. In an embodiment, the pump 952 may be configured to provide the inflation fluids to the inflation device 916 from the inflation fluid reservoir 954. The inflation fluids provided to the inflation device 916 may flow through the valve 922 into the interior region defined by the bladder 918 to switch the bladder 918 from the first state to the second state. As such, the pump 952 and the inflation fluid reservoir 954 may change the shape of the fluid collection assembly 900 from a first (e.g., initial) shape to a second shape. In an embodiment, the pump 952 and the inflation fluid reservoir 954 may be configured to remove the inflation fluids from the inflation device 916 instead of or in addition to providing the inflation fluids to the inflation device 916. In such an embodiment, the pump 952 may provide a suction force that removes at least some of the inflation fluids from the interior region of the bladder 918 which switches the bladder 918 from the second state to the first state. Switching the bladder 918 from the second state to the first state may change the fluid collection assembly 900 from the second shape to the first state. The inflation fluids removed from the interior region of the bladder may be deposited in the inflation fluid reservoir 954.
In an embodiment, the system 950 may be controlled responsive to receiving input from a user of the system 950 (e.g., a medical practitioner or a patient). The input may include verbal commands, manipulating one or more actuators (e.g., buttons, levers, etc.), or one or more electronic instructions sent from a computer. The pump 952 and the inflation fluid reservoir 954 may provide and/or remove inflation fluids from the inflation device 916 responsive to receiving the one or more inputs. In an embodiment, the system 950 may be at least partially controlled without receiving one or more inputs from the user of the system 950. In such an embodiment, the system 950 may include one or more sensor 958 that are configured to detect contact between a portion of the fluid collection assembly 900 and the patient. For example, the sensors 958 may include an array of contact sensors arranged around the opening 910 which allows the sensors 958 to detect whether one or more gaps are formed between the portions of the fluid impermeable barrier 902 that define the opening 910. The sensors 958 may be communicably coupled to a controller 960 (e.g., computer) and configured to transmit one or more signals to the control electric circuitry 960. The signals transmitted from the sensors 958 to the control electric circuitry 960 may include the characteristics detected by the sensors 958. The control electric circuitry 960 may control the pump 952 responsive to receiving the one or more signals from the sensors 958. For example, the control electric circuitry 960 may cause the pump 952 to add or remove inflation fluids from the inflation device 916 when the sensor 958 indicate that there are gaps between the fluid impermeable barrier 902 and the patient.
The embodiments illustrated in
Referring to
Referring to
Referring to
It is noted that the inflation devices disclosed herein may have positions other that the positions illustrated in
In an embodiment, the conduit of any of the fluid collection assemblies disclosed herein (e.g., conduit 134 of
The fluid collection assemblies disclosed herein may include one or more structures that are configured to force the conduit to exhibit the desired shape change and minimize the normal force that is applied to the porous material.
The fluid collection assembly 1300 includes at least one brace 1364 that is configured to force the conduit 1334 to exhibit a shape change that corresponds more closely to the shape change of the inflation device 1316 than if the fluid collection assembly 1300 did not include the brace 1364. The brace 1364 also minimizes the normal force applied from the conduit 1334 to the porous material 1314. The brace 1364 is connected to the inflation device 1316 or a component of the fluid collection assembly 1300 that is connected to the inflation device 1316 (e.g., the fluid impermeable barrier 1302 when the inflation device 1316 is attached to an exterior surface of or embedded within the fluid impermeable barrier 1302). The brace 1364 extends from the inflation device 1316 or the component of the fluid collection assembly 1300 that is connected to the inflation device 1316 to the conduit 1334. For example, the brace 1364 may extend around the conduit 1334, as shown in
The fluid collection assembly 1300 may include any suitable number of braces 1364, such as 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or greater than 10 braces 1364. Generally increasing the number of braces 1364 causes the conduit 1334 to more accurately correspond to the shape of the inflation device 1316 and decreases the normal force that is applied to the porous material 1314.
It is noted that the braces 1364 may not always cause the conduit 1334 to exhibit the same shape change as the inflation device 1316. For example, when the braces 1364 are looped around and are not attached to the conduit 1334 (as shown), the braces 1364 may only cause the conduit 1334 to exhibit the shape change of the inflation device 1316 when the braces 1364 pull (e.g., the braces 1364 are in tension) the conduit 1334 towards the inflation device 1316 but not when the braces 1364 push (e.g., the braces 1364 are in compression) the conduit 1334 away from the inflation device 1316.
The suction force may be applied to the outlet of the conduit 1411 by the vacuum source 1409 either directly or indirectly. The suction force may be applied indirectly via the fluid storage container 1407. For example, the outlet of the conduit 1411 may be disposed within the fluid storage container 1407 and an additional conduit 1411 may extend from the fluid storage container 1407 to the vacuum source 1409. Accordingly, the vacuum source 1409 may apply suction to the fluid collection assembly 1400 via the fluid storage container 1407. The suction force may be applied directly via the vacuum source 1409. For example, the outlet of the conduit 1411 may be disposed within the vacuum source 1409. An additional conduit 1411 may extend from the vacuum source 1409 to a point outside of the fluid collection assembly 1400, such as to the fluid storage container 1407. In such examples, the vacuum source 1409 may be disposed between the fluid collection assembly 1400 and the fluid storage container 1407.
The fluid collection assembly 1400 may be similar or identical to any of the fluid collection assemblies disclosed herein in one or more aspects. The fluid collection assembly 1400 may be shaped and sized to be positioned adjacent to a female urethral opening. For example, the fluid collection assembly 1400 may include a fluid impermeable barrier at least partially defining a chamber (e.g., interior region) of the fluid collection assembly 1400. The fluid impermeable barrier also defines at least one opening extending therethrough from the external environment. The opening may be positioned adjacent to the female urethral opening. The fluid collection assembly 1400 may include porous material disposed in the chamber, such as one or more of a fluid permeable support and a fluid permeable membrane. The fluid collection assembly 1400 includes at least one inflation device on or incorporated in one or more components thereof. The inflation device include a bladder that is configured to change a shape thereof when the bladder is switched between the first and second states. The conduit 1411 may extend into the fluid collection assembly 1400 at a first end (e.g., proximal) region, through one or more of the fluid impermeable barrier or the porous material to a second end region of the fluid collection assembly 1400. The conduit 1411 includes an inlet and an outlet, the outlet being fluidly coupled to the fluid storage container and the inlet being positioned in a portion of the chamber selected to be at a gravimetrically low point of the fluid collection assembly when worn.
The fluid storage container 1407 is sized and shaped to retain a fluid therein. The fluid storage container 1407 may include a bag (e.g., drainage bag), a bottle or cup (e.g., collection jar), or any other enclosed container for storing bodily fluid(s) such as urine. In some examples, the conduit 1411 may extend from the fluid collection assembly 1400 and attach to the fluid storage container 1407 at a first point therein. An additional conduit 1411 may attach to the fluid storage container 1407 at a second point thereon and may extend and attach to the vacuum source 1409. Accordingly, a vacuum (e.g., suction) may be drawn through fluid collection assembly 1400 via the fluid storage container 1407. Fluid, such as urine, may be drained from the fluid collection assembly 1400 using the vacuum source 1409.
The vacuum source 1409 may include one or more of a manual vacuum pump, and electric vacuum pump, a diaphragm pump, a centrifugal pump, a displacement pump, a magnetically driven pump, a peristaltic pump, or any pump configured to produce a vacuum. The vacuum source 1409 may provide a vacuum or suction to remove fluid from the fluid collection assembly 1400. In some examples, the vacuum source 1409 may be powered by one or more of a power cord (e.g., connected to a power socket), one or more batteries, or even manual power (e.g., a hand operated vacuum pump). In some examples, the vacuum source 1409 may be sized and shaped to fit outside of, on, or within the fluid collection assembly 1400. For example, the vacuum source 1409 may include one or more miniaturized pumps or one or more micro pumps. The vacuum sources 1409 disclosed herein may include one or more of a switch, a button, a plug, a remote, or any other device suitable to activate the vacuum source 1409.
Acts 1510, 1520, 1530 of the method 1500 are for illustrative purposes. For example, the act 1510, 1520, 1530 of the method 1500 may be performed in different orders, split into multiple acts, modified, supplemented, or combined. In an example, one or more of the acts 1510, 1520, 1530 of the method 1500 may be omitted from the method 1500. Any of the acts 1510, 1520, or 1530 may include using any of the fluid collection assemblies or systems disclosed herein.
Act 1510 recites “positioning at least one opening of a fluid collection assembly adjacent to a female urethral opening.” The act 1510 of positioning the opening of a fluid collection assembly adjacent to a female urethral opening may include utilizing any of the fluid collection assemblies or systems disclosed herein. In some examples, act 1510 may include positioning the opening of a fluid collection assembly such that the fluid permeable membrane of the female fluid collection assembly abuts or is positioned proximate to the female urethral opening. In some examples, positioning an opening of a fluid collection assembly adjacent to a female urethral opening may include positioning the opening over the female urethral opening, such as positioning a longitudinally extending opening of the fluid collection assembly over the female urethral opening.
Act 1520 recites “flowing at least one inflation fluid through at least one valve and into an interior region defined by a bladder.” Flowing the inflation fluid into the interior region may switch the bladder between a first state and at least a second state which, in turn, shapes the bladder and at least a portion of the rest of the fluid collection assembly between a first (e.g., initial) shape and a second shape. For example, switching the bladder from the first state to the second state may include shaping a female fluid collection assembly to contour to the anatomy around the urethral opening. In some embodiments, switching the bladder from the first state to the second state may include forming the (e.g., a longitudinal shape of the) fluid collection assembly into an arcuate shape conforming to the perineal region of the patient. For example, switching the bladder from the first state to the second state may include forming the fluid collection assembly into an arcuate shape conforming to the vaginal and perineal region of a patient.
Act 1530 recites, “receiving one or more bodily fluids from the female urethral opening into a chamber of the fluid collection assembly.” In some examples, receiving bodily fluids from the female urethral opening into a chamber of the fluid collection assembly includes receiving the bodily fluids through the opening of the fluid collection assembly. Receiving bodily fluids from the female urethral opening into a chamber of the fluid collection assembly may include wicking the bodily fluids away from the opening using porous material, such as via a fluid permeable membrane and a fluid permeable support. Receiving bodily fluids from the female urethral opening into a chamber of the fluid collection assembly may include flowing the bodily fluids towards a portion of the chamber that is fluidly coupled to an inlet of a conduit in fluid communication a vacuum source. For instance, receiving bodily fluids from the female urethral opening into a chamber of the fluid collection assembly may include flowing the bodily fluids to a substantially unoccupied portion of the chamber (e.g., a fluid reservoir), to a gravimetrically low point of the chamber, etc., such as via gravity, wicking, or suction force. In some examples, wicking the bodily fluids into the chamber via the fluid permeable membrane and fluid permeable support may include wicking urine into a fluid reservoir in the fluid collection assembly.
The method 1500 may include applying suction with a vacuum source effective to suction the bodily fluids from the chamber via a conduit disposed therein and fluidly coupled to the vacuum source may include using any of the vacuum sources disclosed herein. Applying suction with a vacuum source may include activating the vacuum source (e.g., suction device) in fluid communication with the inlet of the conduit in the fluid collection assembly. In some examples, activating the vacuum source in fluid communication with the inlet of the conduit in the fluid collection assembly may include supplying power to the vacuum source by one or more of flipping an on/off switch, pressing a button, plugging the vacuum source into a power outlet, putting batteries into the vacuum source, etc. In some examples, the vacuum source may include a hand operated vacuum pump and applying suction with a vacuum source may include manually operating the hand operated vacuum pump effective to suction the bodily fluids from the chamber via the conduit disposed therein that is fluidly coupled to the vacuum source.
In some examples, applying suction with a vacuum source effective to suction the bodily fluids from the chamber via a conduit disposed therein and fluidly coupled to the vacuum source may be effective to remove at least some bodily fluids (e.g., urine) from the chamber (e.g., interior region) of the fluid collection assembly. In some examples, applying suction with a vacuum source effective to suction the bodily fluids from the chamber via a conduit disposed therein and fluidly coupled to the vacuum source may be effective to transfer at least some of the bodily fluids from the chamber to a fluid storage container (e.g., a bottle or bag), such as from one or more of a reservoir, fluid permeable support, or fluid permeable membrane.
In some examples, the vacuum source (e.g., suction device) may be disposed on or within the fluid collection assembly and applying suction with the vacuum source may include activating the vacuum source. In some examples, the vacuum source may be spaced from the fluid collection assembly and applying suction with the vacuum source may include activating the vacuum source.
In some examples, applying suction with a vacuum source effective to suction the bodily fluids from the chamber via a conduit disposed therein and fluidly coupled to the vacuum source may include detecting moisture in the chamber (e.g., via one or more moisture sensors) and responsive thereto, activating the vacuum source to provide suction in the chamber. The control of the vacuum source responsive to the signals indicating that moisture or a level thereof is present in the chamber may be automatic, such as via a controller (e.g., computer programmed to perform the operation), or may merely provide an indication that a level of moisture is present that may necessitate removal of fluid from the chamber of the fluid collection assembly. In the latter case, a wearer may receive the indication (e.g., from the controller) and activate the vacuum pump manually.
In an example, the method 1500 may include collecting the bodily fluids that are removed from the fluid collection assembly, such as into a fluid storage container that is spaced from the fluid collection assembly and fluidly coupled to the conduit. The fluid storage container may include any of the fluid storage containers disclosed herein.
The fluid collection assemblies disclosed herein are configured to collect one or more bodily fluids from a female urethral opening. However, it is noted that any of the concepts disclosed herein, such as inflation devices, may be configured to collect one or more bodily fluids from a male urethral opening (e.g., penis). Examples of fluid collection assemblies that are configured to collected bodily fluids from a male urethral opening and methods of using such fluid collection assemblies are disclosed in International Application No. PCT/US20/42262 filed on Jul. 14, 2020, U.S. patent application Ser. No. 14/433,773 filed on Apr. 3, 2020, and U.S. Provisional Patent Application No. 63/047,374 filed on Jul. 2, 2020, the disclosure of each of which is incorporated herein, in its entirety, by this reference.
While various aspects and embodiments have been disclosed herein, other aspects and embodiments are contemplated. The various aspects and embodiments disclosed herein are for purposes of illustration and are not intended to be limiting.
Terms of degree (e.g., “about,” “substantially,” “generally,” etc.) indicate structurally or functionally insignificant variations. In an example, when the term of degree is included with a term indicating quantity, the term of degree is interpreted to mean±10%, ±5%, or ±2% of the term indicating quantity. In an example, when the term of degree is used to modify a shape, the term of degree indicates that the shape being modified by the term of degree has the appearance of the disclosed shape. For instance, the term of degree may be used to indicate that the shape may have rounded corners instead of sharp corners, curved edges instead of straight edges, one or more protrusions extending therefrom, is oblong, is the same as the disclosed shape, etc.
This application claims priority to U.S. Provisional Patent Application No. 63/076,474 filed on Sep. 10, 2020, the disclosure of which is incorporated herein, in its entirety, by this reference.
| Number | Name | Date | Kind |
|---|---|---|---|
| 737443 | Mooers | Aug 1903 | A |
| 1032841 | Koenig | Jul 1912 | A |
| 1178644 | Johnson | Apr 1916 | A |
| 1742080 | Jones | Dec 1929 | A |
| 1979899 | Obrien et al. | Nov 1934 | A |
| 2241010 | Chipley | May 1941 | A |
| 2262772 | Peder | Nov 1941 | A |
| 2326881 | Packer | Aug 1943 | A |
| 2379346 | Farrell | Jun 1945 | A |
| 2485555 | Bester | Oct 1949 | A |
| 2613670 | Edward | Oct 1952 | A |
| 2616426 | Adele | Nov 1952 | A |
| 2644234 | Earl | Jul 1953 | A |
| 2648335 | Chambers | Aug 1953 | A |
| 2859786 | Tupper | Nov 1958 | A |
| 2944551 | Carl | Jul 1960 | A |
| 2968046 | Duke | Jan 1961 | A |
| 2971512 | Reinhardt | Feb 1961 | A |
| 3032038 | Swinn | May 1962 | A |
| 3077883 | Hill | Feb 1963 | A |
| 3087938 | Hans et al. | Apr 1963 | A |
| 3169528 | Knox et al. | Feb 1965 | A |
| 3171506 | Therkel | Mar 1965 | A |
| 3194238 | Breece | Jul 1965 | A |
| 3198994 | Hildebrandt et al. | Aug 1965 | A |
| 3221742 | Egon | Dec 1965 | A |
| 3312221 | Overment | Apr 1967 | A |
| 3312981 | Mcguire et al. | Apr 1967 | A |
| 3349768 | Keane | Oct 1967 | A |
| 3362590 | Gene | Jan 1968 | A |
| 3366116 | Huck | Jan 1968 | A |
| 3398848 | Donovan | Aug 1968 | A |
| 3400717 | Bruce et al. | Sep 1968 | A |
| 3406688 | Bruce | Oct 1968 | A |
| 3424163 | Gravdahl | Jan 1969 | A |
| 3425471 | Yates | Feb 1969 | A |
| 3511241 | Lee | May 1970 | A |
| 3512185 | Ellis | May 1970 | A |
| 3520300 | Flower | Jul 1970 | A |
| 3528423 | Lee | Sep 1970 | A |
| 3613123 | Langstrom | Oct 1971 | A |
| 3648700 | Warner | Mar 1972 | A |
| 3651810 | Ormerod | Mar 1972 | A |
| 3661155 | Lindan | May 1972 | A |
| 3683918 | Pizzella | Aug 1972 | A |
| 3699815 | Holbrook | Oct 1972 | A |
| 3726277 | Hirschman | Apr 1973 | A |
| 3742952 | Magers | Jul 1973 | A |
| 3757355 | Allen et al. | Sep 1973 | A |
| 3788324 | Lim | Jan 1974 | A |
| 3843016 | Bornhorst et al. | Oct 1974 | A |
| 3863638 | Rogers et al. | Feb 1975 | A |
| 3863798 | Kurihara et al. | Feb 1975 | A |
| 3864759 | Horiuchi | Feb 1975 | A |
| 3881486 | Fenton | May 1975 | A |
| 3881489 | Hartwell | May 1975 | A |
| 3915189 | Holbrook et al. | Oct 1975 | A |
| 3998228 | Poidomani | Dec 1976 | A |
| 3999550 | Martin | Dec 1976 | A |
| 4015604 | Csillag | Apr 1977 | A |
| 4020843 | Kanall | May 1977 | A |
| 4022213 | Stein | May 1977 | A |
| 4027776 | Douglas | Jun 1977 | A |
| 4064962 | Hunt | Dec 1977 | A |
| 4116197 | Bermingham | Sep 1978 | A |
| 4180178 | Turner | Dec 1979 | A |
| 4187953 | Turner | Feb 1980 | A |
| 4194508 | Anderson | Mar 1980 | A |
| 4200102 | Duhamel et al. | Apr 1980 | A |
| 4202058 | Anderson | May 1980 | A |
| 4203503 | Bertotti et al. | May 1980 | A |
| 4209076 | Bertotti et al. | Jun 1980 | A |
| 4233025 | Larson et al. | Nov 1980 | A |
| 4233978 | Hickey | Nov 1980 | A |
| 4246901 | Frosch et al. | Jan 1981 | A |
| 4253542 | Ruspa et al. | Mar 1981 | A |
| 4257418 | Hessner | Mar 1981 | A |
| 4270539 | Frosch et al. | Jun 1981 | A |
| 4281655 | Terauchi | Aug 1981 | A |
| 4292916 | Bradley et al. | Oct 1981 | A |
| 4330239 | Gannaway | May 1982 | A |
| 4352356 | Tong | Oct 1982 | A |
| 4360933 | Kimura et al. | Nov 1982 | A |
| 4365363 | Windauer | Dec 1982 | A |
| 4375841 | Vielbig | Mar 1983 | A |
| 4387726 | Denard | Jun 1983 | A |
| 4425130 | Desmarais | Jan 1984 | A |
| 4446986 | Bowen et al. | May 1984 | A |
| 4453938 | Brendling | Jun 1984 | A |
| 4457314 | Knowles | Jul 1984 | A |
| 4476879 | Jackson | Oct 1984 | A |
| 4526688 | Schmidt et al. | Jul 1985 | A |
| 4528703 | Kraus | Jul 1985 | A |
| D280438 | Wendt | Sep 1985 | S |
| 4551141 | Mcneil | Nov 1985 | A |
| 4553968 | Komis | Nov 1985 | A |
| 4581026 | Schneider | Apr 1986 | A |
| 4589516 | Inoue et al. | May 1986 | A |
| 4601716 | Smith | Jul 1986 | A |
| 4610675 | Triunfol | Sep 1986 | A |
| 4620333 | Ritter | Nov 1986 | A |
| 4626250 | Schneider | Dec 1986 | A |
| 4627846 | Ternstroem | Dec 1986 | A |
| 4631061 | Martin | Dec 1986 | A |
| 4650477 | Johnson | Mar 1987 | A |
| 4655754 | Richmond et al. | Apr 1987 | A |
| 4656675 | Fajnsztajn | Apr 1987 | A |
| 4681570 | Dalton | Jul 1987 | A |
| 4681577 | Stern et al. | Jul 1987 | A |
| 4692160 | Nussbaumer | Sep 1987 | A |
| 4707864 | Ikematsu et al. | Nov 1987 | A |
| 4713065 | Koot | Dec 1987 | A |
| 4713066 | Komis | Dec 1987 | A |
| 4723953 | Rosenbaum | Feb 1988 | A |
| 4735841 | Sourdet | Apr 1988 | A |
| 4743236 | Manschot | May 1988 | A |
| 4747166 | Kuntz | May 1988 | A |
| 4752944 | Conrads et al. | Jun 1988 | A |
| 4769215 | Ehrenkranz | Sep 1988 | A |
| 4771484 | Mozell | Sep 1988 | A |
| 4772280 | Rooyakkers | Sep 1988 | A |
| 4790830 | Hamacher | Dec 1988 | A |
| 4790835 | Elias | Dec 1988 | A |
| 4791686 | Taniguchi et al. | Dec 1988 | A |
| 4795449 | Schneider et al. | Jan 1989 | A |
| 4798603 | Meyer et al. | Jan 1989 | A |
| 4799928 | Crowley | Jan 1989 | A |
| 4804377 | Hanifl et al. | Feb 1989 | A |
| 4812053 | Bhattacharjee | Mar 1989 | A |
| 4813943 | Smith | Mar 1989 | A |
| 4820297 | Kaufman et al. | Apr 1989 | A |
| 4846818 | Keldahl et al. | Jul 1989 | A |
| 4846909 | Klug et al. | Jul 1989 | A |
| 4865595 | Heyden | Sep 1989 | A |
| 4880417 | Yabrov et al. | Nov 1989 | A |
| 4882794 | Stewart | Nov 1989 | A |
| 4883465 | Brennan | Nov 1989 | A |
| 4886498 | Newton | Dec 1989 | A |
| 4886508 | Washington | Dec 1989 | A |
| 4886509 | Mattsson | Dec 1989 | A |
| 4889532 | Metz et al. | Dec 1989 | A |
| 4889533 | Beecher | Dec 1989 | A |
| 4890691 | Ching-ho | Jan 1990 | A |
| 4903254 | Haas | Feb 1990 | A |
| 4904248 | Vaillancourt | Feb 1990 | A |
| 4905692 | More | Mar 1990 | A |
| 4936838 | Cross et al. | Jun 1990 | A |
| 4955922 | Terauchi | Sep 1990 | A |
| 4957487 | Gerow | Sep 1990 | A |
| 4965460 | Tanaka et al. | Oct 1990 | A |
| 4987849 | Sherman | Jan 1991 | A |
| 5002541 | Conkling et al. | Mar 1991 | A |
| 5004463 | Nigay | Apr 1991 | A |
| 5031248 | Kemper | Jul 1991 | A |
| 5045077 | Blake | Sep 1991 | A |
| 5045283 | Patel | Sep 1991 | A |
| 5049144 | Payton | Sep 1991 | A |
| 5053339 | Patel | Oct 1991 | A |
| 5057092 | Webster | Oct 1991 | A |
| 5058088 | Haas et al. | Oct 1991 | A |
| 5071347 | Mcguire | Dec 1991 | A |
| 5078707 | Peter | Jan 1992 | A |
| 5084037 | Barnett | Jan 1992 | A |
| 5100396 | Zamierowski | Mar 1992 | A |
| 5112324 | Wallace | May 1992 | A |
| 5147301 | Ruvio | Sep 1992 | A |
| 5176667 | Debring | Jan 1993 | A |
| 5195997 | Carns | Mar 1993 | A |
| 5196654 | Diflora et al. | Mar 1993 | A |
| 5203699 | Mcguire | Apr 1993 | A |
| 5244458 | Takasu | Sep 1993 | A |
| 5246454 | Peterson | Sep 1993 | A |
| 5267988 | Farkas | Dec 1993 | A |
| 5275307 | Freese | Jan 1994 | A |
| 5294983 | Ersoz et al. | Mar 1994 | A |
| 5295983 | Kubo | Mar 1994 | A |
| 5300052 | Kubo | Apr 1994 | A |
| 5304749 | Crandell | Apr 1994 | A |
| 5312383 | Kubalak | May 1994 | A |
| 5318550 | Cermak et al. | Jun 1994 | A |
| 5330459 | Lavon | Jul 1994 | A |
| 5340840 | Park et al. | Aug 1994 | A |
| 5382244 | Telang | Jan 1995 | A |
| 5409014 | Napoli et al. | Apr 1995 | A |
| 5411495 | Willingham | May 1995 | A |
| 5423784 | Metz | Jun 1995 | A |
| 5456246 | Schmieding et al. | Oct 1995 | A |
| 5466229 | Elson et al. | Nov 1995 | A |
| 5478334 | Bernstein | Dec 1995 | A |
| 5499977 | Marx | Mar 1996 | A |
| 5543042 | Filan et al. | Aug 1996 | A |
| D373928 | Green | Sep 1996 | S |
| 5582604 | Ahr | Dec 1996 | A |
| 5592950 | Kopelowicz | Jan 1997 | A |
| 5605161 | Cross | Feb 1997 | A |
| 5618277 | Goulter | Apr 1997 | A |
| 5628735 | Skow | May 1997 | A |
| 5636643 | Argenta et al. | Jun 1997 | A |
| 5637104 | Ball et al. | Jun 1997 | A |
| 5674212 | Osborn et al. | Oct 1997 | A |
| 5678564 | Lawrence et al. | Oct 1997 | A |
| 5678654 | Uzawa | Oct 1997 | A |
| 5687429 | Rahlff | Nov 1997 | A |
| 5695485 | Duperret et al. | Dec 1997 | A |
| 5700254 | Mcdowall et al. | Dec 1997 | A |
| 5705777 | Flanigan et al. | Jan 1998 | A |
| 5752944 | Dann et al. | May 1998 | A |
| 5772644 | Bark et al. | Jun 1998 | A |
| 5792132 | Garcia | Aug 1998 | A |
| 5827243 | Palestrant | Oct 1998 | A |
| 5827247 | Kay | Oct 1998 | A |
| 5827250 | Fujioka et al. | Oct 1998 | A |
| 5827257 | Fujioka et al. | Oct 1998 | A |
| D401699 | Herchenbach et al. | Nov 1998 | S |
| 5859393 | Cummins et al. | Jan 1999 | A |
| 5865378 | Hollinshead et al. | Feb 1999 | A |
| 5876393 | Ahr | Mar 1999 | A |
| 5887291 | Bellizzi | Mar 1999 | A |
| 5891125 | Plumley | Apr 1999 | A |
| 5894608 | Birbara | Apr 1999 | A |
| D409303 | Oepping | May 1999 | S |
| 5911222 | Lawrence et al. | Jun 1999 | A |
| 5957904 | Holland | Sep 1999 | A |
| 5968026 | Osborn et al. | Oct 1999 | A |
| 5972505 | Phillips et al. | Oct 1999 | A |
| 6039060 | Rower | Mar 2000 | A |
| 6050983 | Moore et al. | Apr 2000 | A |
| 6059762 | Boyer et al. | May 2000 | A |
| 6063064 | Tuckey et al. | May 2000 | A |
| 6098625 | Winkler | Aug 2000 | A |
| 6105174 | Karlsten et al. | Aug 2000 | A |
| 6113582 | Dwork | Sep 2000 | A |
| 6117163 | Bierman | Sep 2000 | A |
| 6123398 | Arai et al. | Sep 2000 | A |
| 6129718 | Wada et al. | Oct 2000 | A |
| 6131964 | Sareshwala | Oct 2000 | A |
| 6152902 | Christian et al. | Nov 2000 | A |
| 6164569 | Hollinshead et al. | Dec 2000 | A |
| 6177606 | Etheredge et al. | Jan 2001 | B1 |
| 6209142 | Mattsson et al. | Apr 2001 | B1 |
| 6220050 | Cooksey | Apr 2001 | B1 |
| 6244311 | Hand et al. | Jun 2001 | B1 |
| 6248096 | Dwork et al. | Jun 2001 | B1 |
| 6263887 | Dunn | Jul 2001 | B1 |
| 6283246 | Nishikawa | Sep 2001 | B1 |
| 6311339 | Kraus | Nov 2001 | B1 |
| 6336919 | Davis et al. | Jan 2002 | B1 |
| 6338729 | Wada et al. | Jan 2002 | B1 |
| 6352525 | Wakabayashi | Mar 2002 | B1 |
| 6394988 | Hashimoto | May 2002 | B1 |
| 6398742 | Kim | Jun 2002 | B1 |
| 6406463 | Brown | Jun 2002 | B1 |
| 6409712 | Dutari et al. | Jun 2002 | B1 |
| 6416500 | Wada et al. | Jul 2002 | B1 |
| 6423045 | Wise | Jul 2002 | B1 |
| 6428521 | Droll | Aug 2002 | B1 |
| 6428522 | DiPalma | Aug 2002 | B1 |
| 6446454 | Lee et al. | Sep 2002 | B1 |
| 6475198 | Lipman et al. | Nov 2002 | B1 |
| 6479726 | Cole et al. | Nov 2002 | B1 |
| 6491673 | Palumbo et al. | Dec 2002 | B1 |
| 6508794 | Palumbo et al. | Jan 2003 | B1 |
| 6524292 | DiPalma | Feb 2003 | B1 |
| 6540729 | Wada et al. | Apr 2003 | B1 |
| 6547771 | Robertson et al. | Apr 2003 | B2 |
| 6569133 | Cheng et al. | May 2003 | B2 |
| D476518 | Doppelt | Jul 2003 | S |
| 6592560 | Snyder et al. | Jul 2003 | B2 |
| 6610038 | DiPalma | Aug 2003 | B1 |
| 6618868 | Minnick | Sep 2003 | B2 |
| 6620142 | Flueckiger | Sep 2003 | B1 |
| 6629651 | Male et al. | Oct 2003 | B1 |
| 6635038 | Scovel | Oct 2003 | B2 |
| 6652495 | Walker | Nov 2003 | B1 |
| 6666850 | Ahr | Dec 2003 | B1 |
| 6685684 | Falconer | Feb 2004 | B1 |
| 6695828 | DiPalma | Feb 2004 | B1 |
| 6700034 | Lindsay | Mar 2004 | B1 |
| 6702793 | Sweetser et al. | Mar 2004 | B1 |
| 6706027 | Harvie et al. | Mar 2004 | B2 |
| 6732384 | Scott | May 2004 | B2 |
| 6736977 | Hall et al. | May 2004 | B1 |
| 6740066 | Wolff et al. | May 2004 | B2 |
| 6764477 | Chen et al. | Jul 2004 | B1 |
| 6783519 | Samuelsson | Aug 2004 | B2 |
| 6796974 | Palumbo et al. | Sep 2004 | B2 |
| 6814547 | Childers et al. | Nov 2004 | B2 |
| 6849065 | Schmidt et al. | Feb 2005 | B2 |
| 6857137 | Otto | Feb 2005 | B2 |
| 6885690 | Aggerstam et al. | Apr 2005 | B2 |
| 6888044 | Fell et al. | May 2005 | B2 |
| 6893425 | Dunn et al. | May 2005 | B2 |
| 6912737 | Ernest et al. | Jul 2005 | B2 |
| 6918899 | Harvie | Jul 2005 | B2 |
| 6979324 | Bybordi et al. | Dec 2005 | B2 |
| 7018366 | Easter | Mar 2006 | B2 |
| 7066411 | Male et al. | Jun 2006 | B2 |
| 7122023 | Hinoki | Oct 2006 | B1 |
| 7125399 | Miskie | Oct 2006 | B2 |
| 7131964 | Harvie | Nov 2006 | B2 |
| 7135012 | Harvie | Nov 2006 | B2 |
| 7141043 | Harvie | Nov 2006 | B2 |
| D533972 | La | Dec 2006 | S |
| 7160273 | Greter et al. | Jan 2007 | B2 |
| 7171699 | Ernest et al. | Feb 2007 | B2 |
| 7171871 | Kozak | Feb 2007 | B2 |
| 7179951 | Krishnaswamy-mirle et al. | Feb 2007 | B2 |
| 7181781 | Trabold et al. | Feb 2007 | B1 |
| 7186245 | Cheng et al. | Mar 2007 | B1 |
| 7192424 | Cooper | Mar 2007 | B2 |
| 7219764 | Forbes | May 2007 | B1 |
| 7220250 | Suzuki et al. | May 2007 | B2 |
| D562975 | Otto | Feb 2008 | S |
| 7335189 | Harvie | Feb 2008 | B2 |
| 7358282 | Krueger et al. | Apr 2008 | B2 |
| 7390320 | Machida et al. | Jun 2008 | B2 |
| 7438706 | Koizumi et al. | Oct 2008 | B2 |
| 7488310 | Yang | Feb 2009 | B2 |
| 7491194 | Oliwa | Feb 2009 | B1 |
| D591106 | Dominique et al. | Apr 2009 | S |
| 7513381 | Heng et al. | Apr 2009 | B2 |
| 7520872 | Biggie et al. | Apr 2009 | B2 |
| D593801 | Wilson et al. | Jun 2009 | S |
| 7540364 | Sanderson | Jun 2009 | B2 |
| 7549512 | Newberry | Jun 2009 | B2 |
| 7585293 | Vermaak | Sep 2009 | B2 |
| 7588560 | Dunlop | Sep 2009 | B1 |
| 7665359 | Barber | Feb 2010 | B2 |
| 7682347 | Parks et al. | Mar 2010 | B2 |
| 7687004 | Allen | Mar 2010 | B2 |
| 7695459 | Gilbert et al. | Apr 2010 | B2 |
| 7695460 | Wada et al. | Apr 2010 | B2 |
| 7699818 | Gilbert | Apr 2010 | B2 |
| 7699831 | Bengtson et al. | Apr 2010 | B2 |
| 7722584 | Tanaka et al. | May 2010 | B2 |
| 7727206 | Gorres | Jun 2010 | B2 |
| 7740620 | Gilbert et al. | Jun 2010 | B2 |
| 7749205 | Tazoe | Jul 2010 | B2 |
| 7755497 | Wada et al. | Jul 2010 | B2 |
| 7766887 | Burns et al. | Aug 2010 | B2 |
| D625407 | Koizumi et al. | Oct 2010 | S |
| 7806879 | Brooks et al. | Oct 2010 | B2 |
| 7811272 | Lindsay et al. | Oct 2010 | B2 |
| 7815067 | Matsumoto et al. | Oct 2010 | B2 |
| 7833169 | Hannon | Nov 2010 | B2 |
| 7857806 | Karpowicz et al. | Dec 2010 | B2 |
| 7866942 | Harvie | Jan 2011 | B2 |
| 7871385 | Levinson et al. | Jan 2011 | B2 |
| 7875010 | Frazier et al. | Jan 2011 | B2 |
| 7901389 | Mombrinie | Mar 2011 | B2 |
| 7927320 | Goldwasser et al. | Apr 2011 | B2 |
| 7927321 | Marland | Apr 2011 | B2 |
| 7931634 | Swiecicki et al. | Apr 2011 | B2 |
| 7939706 | Okabe et al. | May 2011 | B2 |
| 7946443 | Stull et al. | May 2011 | B2 |
| 7947025 | Buglino et al. | May 2011 | B2 |
| 7963419 | Burney et al. | Jun 2011 | B2 |
| 7976519 | Bubb et al. | Jul 2011 | B2 |
| 7993318 | Olsson et al. | Aug 2011 | B2 |
| 8015627 | Baker et al. | Sep 2011 | B2 |
| 8016071 | Martinus et al. | Sep 2011 | B1 |
| 8028460 | Williams | Oct 2011 | B2 |
| 8047398 | Dimartino et al. | Nov 2011 | B2 |
| 8083094 | Caulfield et al. | Dec 2011 | B2 |
| 8128608 | Thevenin | Mar 2012 | B2 |
| 8181651 | Pinel | May 2012 | B2 |
| 8181819 | Burney et al. | May 2012 | B2 |
| 8211063 | Bierman et al. | Jul 2012 | B2 |
| 8221369 | Parks et al. | Jul 2012 | B2 |
| 8241262 | Mahnensmith | Aug 2012 | B2 |
| 8277426 | Wilcox et al. | Oct 2012 | B2 |
| 8287508 | Sanchez | Oct 2012 | B1 |
| 8303554 | Tsai et al. | Nov 2012 | B2 |
| 8322565 | Caulfield et al. | Dec 2012 | B2 |
| 8337477 | Parks et al. | Dec 2012 | B2 |
| D674241 | Bickert et al. | Jan 2013 | S |
| 8343122 | Gorres | Jan 2013 | B2 |
| 8353074 | Krebs | Jan 2013 | B2 |
| 8353886 | Bester et al. | Jan 2013 | B2 |
| D676241 | Merrill | Feb 2013 | S |
| 8388588 | Wada et al. | Mar 2013 | B2 |
| D679807 | Burgess et al. | Apr 2013 | S |
| 8425482 | Khoubnazar | Apr 2013 | B2 |
| 8434586 | Pawelski et al. | May 2013 | B2 |
| 8449510 | Martini et al. | May 2013 | B2 |
| D684260 | Lund et al. | Jun 2013 | S |
| 8470230 | Caulfield et al. | Jun 2013 | B2 |
| 8479941 | Matsumoto et al. | Jul 2013 | B2 |
| 8479949 | Henkel | Jul 2013 | B2 |
| 8500719 | Simpson et al. | Aug 2013 | B1 |
| 8512301 | Ma | Aug 2013 | B2 |
| 8529530 | Koch et al. | Sep 2013 | B2 |
| 8535284 | Joder et al. | Sep 2013 | B2 |
| 8546639 | Wada et al. | Oct 2013 | B2 |
| 8551075 | Bengtson | Oct 2013 | B2 |
| 8568376 | Delattre et al. | Oct 2013 | B2 |
| D694404 | Burgess et al. | Nov 2013 | S |
| 8585683 | Bengtson et al. | Nov 2013 | B2 |
| 8652112 | Johannison et al. | Feb 2014 | B2 |
| D702973 | Norland et al. | Apr 2014 | S |
| 8703032 | Menon et al. | Apr 2014 | B2 |
| D704330 | Cicatelli | May 2014 | S |
| D704510 | Mason et al. | May 2014 | S |
| D705423 | Walsh Cutler | May 2014 | S |
| D705926 | Burgess et al. | May 2014 | S |
| 8714394 | Wulf | May 2014 | B2 |
| 8715267 | Bengtson et al. | May 2014 | B2 |
| 8757425 | Copeland | Jun 2014 | B2 |
| 8777032 | Biesecker et al. | Jul 2014 | B2 |
| 8808260 | Koch et al. | Aug 2014 | B2 |
| 8864730 | Conway et al. | Oct 2014 | B2 |
| 8881923 | Higginson | Nov 2014 | B2 |
| 8882731 | Suzuki et al. | Nov 2014 | B2 |
| 8936585 | Carson et al. | Jan 2015 | B2 |
| D729581 | Boroski | May 2015 | S |
| 9028460 | Medeiros | May 2015 | B2 |
| 9056698 | Noer | Jun 2015 | B2 |
| 9078792 | Ruiz | Jul 2015 | B2 |
| 9145879 | Pirovano et al. | Sep 2015 | B2 |
| 9173602 | Gilbert | Nov 2015 | B2 |
| 9173799 | Tanimoto et al. | Nov 2015 | B2 |
| 9187220 | Biesecker et al. | Nov 2015 | B2 |
| 9199772 | Krippendorf | Dec 2015 | B2 |
| 9233020 | Matsumiya | Jan 2016 | B2 |
| 9248058 | Conway et al. | Feb 2016 | B2 |
| 9308118 | Dupree et al. | Apr 2016 | B1 |
| 9309029 | Incorvia et al. | Apr 2016 | B2 |
| 9333281 | Giezendanner et al. | May 2016 | B2 |
| 9381108 | Longoni et al. | Jul 2016 | B2 |
| 9382047 | Schmidtner et al. | Jul 2016 | B2 |
| 9456937 | Ellis | Oct 2016 | B2 |
| 9480595 | Baham et al. | Nov 2016 | B2 |
| 9517865 | Albers et al. | Dec 2016 | B2 |
| D777941 | Piramoon | Jan 2017 | S |
| 9533806 | Ding et al. | Jan 2017 | B2 |
| 9550611 | Hodge | Jan 2017 | B2 |
| 9555930 | Campbell et al. | Jan 2017 | B2 |
| 9623159 | Locke | Apr 2017 | B2 |
| D789522 | Burgess et al. | Jun 2017 | S |
| 9687849 | Bruno et al. | Jun 2017 | B2 |
| 9694949 | Hendricks et al. | Jul 2017 | B2 |
| 9709048 | Kinjo | Jul 2017 | B2 |
| 9713547 | Lee et al. | Jul 2017 | B2 |
| 9732754 | Huang et al. | Aug 2017 | B2 |
| 9752564 | Arceno et al. | Sep 2017 | B2 |
| 9788992 | Harvie | Oct 2017 | B2 |
| D804907 | Sandoval | Dec 2017 | S |
| 9868564 | Mcgirr et al. | Jan 2018 | B2 |
| D814239 | Arora | Apr 2018 | S |
| D817484 | Lafond | May 2018 | S |
| 10037640 | Gordon | Jul 2018 | B2 |
| 10058470 | Phillips | Aug 2018 | B2 |
| 10098990 | Koch et al. | Oct 2018 | B2 |
| D835264 | Mozzicato et al. | Dec 2018 | S |
| D835779 | Mozzicato et al. | Dec 2018 | S |
| D840533 | Mozzicato et al. | Feb 2019 | S |
| D840534 | Mozzicato et al. | Feb 2019 | S |
| 10225376 | Perez Martinez | Mar 2019 | B2 |
| 10226376 | Sanchez et al. | Mar 2019 | B2 |
| D848612 | Mozzicato et al. | May 2019 | S |
| 10307305 | Hodges | Jun 2019 | B1 |
| 10335121 | Desai | Jul 2019 | B2 |
| D856512 | Cowart et al. | Aug 2019 | S |
| 10376406 | Newton | Aug 2019 | B2 |
| 10376407 | Newton | Aug 2019 | B2 |
| 10390989 | Sanchez et al. | Aug 2019 | B2 |
| D858144 | Fu | Sep 2019 | S |
| 10406039 | Villarreal | Sep 2019 | B2 |
| 10407222 | Allen | Sep 2019 | B2 |
| 10478356 | Griffin | Nov 2019 | B2 |
| 10538366 | Pentelovitch et al. | Jan 2020 | B2 |
| 10569938 | Zhao et al. | Feb 2020 | B2 |
| 10577156 | Dagnelie et al. | Mar 2020 | B2 |
| RE47930 | Cho | Apr 2020 | E |
| 10618721 | Vazin | Apr 2020 | B2 |
| D884390 | Wang | May 2020 | S |
| 10669079 | Freedman et al. | Jun 2020 | B2 |
| D892315 | Airy | Aug 2020 | S |
| 10730672 | Bertram et al. | Aug 2020 | B2 |
| 10737848 | Philip et al. | Aug 2020 | B2 |
| 10765854 | Law et al. | Sep 2020 | B2 |
| 10766670 | Kittmann | Sep 2020 | B2 |
| 10799386 | Harrison | Oct 2020 | B1 |
| D901214 | Hu | Nov 2020 | S |
| 10857025 | Davis et al. | Dec 2020 | B2 |
| 10865017 | Cowart et al. | Dec 2020 | B1 |
| 10889412 | West et al. | Jan 2021 | B2 |
| 10913581 | Stahlecker | Feb 2021 | B2 |
| D912244 | Rehm et al. | Mar 2021 | S |
| 10952889 | Newton et al. | Mar 2021 | B2 |
| 10973378 | Ryu et al. | Apr 2021 | B2 |
| 10973678 | Newton et al. | Apr 2021 | B2 |
| 10974874 | Ragias et al. | Apr 2021 | B2 |
| 11000401 | Ecklund et al. | May 2021 | B2 |
| D923365 | Wang | Jun 2021 | S |
| 11026829 | Harvie | Jun 2021 | B2 |
| 11027900 | Liu | Jun 2021 | B2 |
| 11045346 | Argent et al. | Jun 2021 | B2 |
| D928946 | Sanchez et al. | Aug 2021 | S |
| 11168420 | Kinugasa et al. | Nov 2021 | B2 |
| 11179506 | Barr et al. | Nov 2021 | B2 |
| 11226376 | Yamauchi et al. | Jan 2022 | B2 |
| 11326586 | Milner et al. | May 2022 | B2 |
| 11369508 | Ecklund et al. | Jun 2022 | B2 |
| 11376152 | Sanchez et al. | Jul 2022 | B2 |
| 11382786 | Sanchez et al. | Jul 2022 | B2 |
| 11382788 | Hjorth | Jul 2022 | B2 |
| 11389318 | Radl et al. | Jul 2022 | B2 |
| 11395871 | Radl et al. | Jul 2022 | B2 |
| 11426303 | Davis et al. | Aug 2022 | B2 |
| 11504265 | Godinez et al. | Nov 2022 | B2 |
| 11529252 | Glithero et al. | Dec 2022 | B2 |
| 11547788 | Radl et al. | Jan 2023 | B2 |
| 11806266 | Sanchez et al. | Nov 2023 | B2 |
| D1010109 | Ecklund et al. | Jan 2024 | S |
| 11857716 | Lee et al. | Jan 2024 | B2 |
| 11890221 | Ulreich et al. | Feb 2024 | B2 |
| 11925575 | Newton | Mar 2024 | B2 |
| 20010037097 | Cheng | Nov 2001 | A1 |
| 20010054426 | Knudson et al. | Dec 2001 | A1 |
| 20020019614 | Woon | Feb 2002 | A1 |
| 20020026161 | Grundke | Feb 2002 | A1 |
| 20020087131 | Wolff et al. | Jul 2002 | A1 |
| 20020091364 | Prabhakar | Jul 2002 | A1 |
| 20020189992 | Schmidt et al. | Dec 2002 | A1 |
| 20020193760 | Thompson | Dec 2002 | A1 |
| 20030004436 | Schmidt et al. | Jan 2003 | A1 |
| 20030032931 | Grundke et al. | Feb 2003 | A1 |
| 20030032944 | Cawood | Feb 2003 | A1 |
| 20030073964 | Palumbo et al. | Apr 2003 | A1 |
| 20030120178 | Heki | Jun 2003 | A1 |
| 20030157859 | Ishikawa | Aug 2003 | A1 |
| 20030181880 | Schwartz | Sep 2003 | A1 |
| 20030195484 | Harvie | Oct 2003 | A1 |
| 20030204173 | Burns et al. | Oct 2003 | A1 |
| 20030233079 | Parks et al. | Dec 2003 | A1 |
| 20040006321 | Cheng et al. | Jan 2004 | A1 |
| 20040015141 | Cheng | Jan 2004 | A1 |
| 20040056122 | Male et al. | Mar 2004 | A1 |
| 20040084465 | Luburic | May 2004 | A1 |
| 20040127872 | Petryk et al. | Jul 2004 | A1 |
| 20040128749 | Scott | Jul 2004 | A1 |
| 20040143229 | Easter | Jul 2004 | A1 |
| 20040147863 | Diaz | Jul 2004 | A1 |
| 20040147894 | Mizutani et al. | Jul 2004 | A1 |
| 20040158221 | Mizutani et al. | Aug 2004 | A1 |
| 20040176731 | Cheng et al. | Sep 2004 | A1 |
| 20040176746 | Forral | Sep 2004 | A1 |
| 20040191919 | Unger et al. | Sep 2004 | A1 |
| 20040207530 | Nielsen | Oct 2004 | A1 |
| 20040236292 | Tazoe | Nov 2004 | A1 |
| 20040243075 | Harvie | Dec 2004 | A1 |
| 20040254547 | Okabe et al. | Dec 2004 | A1 |
| 20050010182 | Parks et al. | Jan 2005 | A1 |
| 20050033248 | Machida et al. | Feb 2005 | A1 |
| 20050065471 | Kuntz | Mar 2005 | A1 |
| 20050070861 | Okabe et al. | Mar 2005 | A1 |
| 20050070862 | Tazoe et al. | Mar 2005 | A1 |
| 20050082300 | Modrell et al. | Apr 2005 | A1 |
| 20050097662 | Leimkuhler et al. | May 2005 | A1 |
| 20050101924 | Elson et al. | May 2005 | A1 |
| 20050119630 | Harvie | Jun 2005 | A1 |
| 20050137557 | Swiecicki et al. | Jun 2005 | A1 |
| 20050154360 | Harvie | Jul 2005 | A1 |
| 20050177070 | Levinson et al. | Aug 2005 | A1 |
| 20050197639 | Mombrinie | Sep 2005 | A1 |
| 20050273920 | Marinas | Dec 2005 | A1 |
| 20050277904 | Chase et al. | Dec 2005 | A1 |
| 20050279359 | LeBlanc et al. | Dec 2005 | A1 |
| 20060004332 | Marx | Jan 2006 | A1 |
| 20060015080 | Mahnensmith | Jan 2006 | A1 |
| 20060015081 | Suzuki et al. | Jan 2006 | A1 |
| 20060016778 | Park | Jan 2006 | A1 |
| 20060069359 | Dipalma et al. | Mar 2006 | A1 |
| 20060079854 | Kay et al. | Apr 2006 | A1 |
| 20060111648 | Vermaak | May 2006 | A1 |
| 20060155214 | Wightman | Jul 2006 | A1 |
| 20060171997 | Gruenbacher | Aug 2006 | A1 |
| 20060200102 | Cooper | Sep 2006 | A1 |
| 20060229575 | Boiarski | Oct 2006 | A1 |
| 20060229576 | Conway et al. | Oct 2006 | A1 |
| 20060231648 | Male et al. | Oct 2006 | A1 |
| 20060235266 | Nan | Oct 2006 | A1 |
| 20060235359 | Marland | Oct 2006 | A1 |
| 20060241553 | Harvie | Oct 2006 | A1 |
| 20060269439 | White | Nov 2006 | A1 |
| 20060277670 | Baker et al. | Dec 2006 | A1 |
| 20070006368 | Key et al. | Jan 2007 | A1 |
| 20070010797 | Nishtala et al. | Jan 2007 | A1 |
| 20070016152 | Karpowicz et al. | Jan 2007 | A1 |
| 20070038194 | Wada et al. | Feb 2007 | A1 |
| 20070055209 | Patel et al. | Mar 2007 | A1 |
| 20070073252 | Forgrave | Mar 2007 | A1 |
| 20070117880 | Elson et al. | May 2007 | A1 |
| 20070118993 | Bates | May 2007 | A1 |
| 20070135786 | Schmidt et al. | Jun 2007 | A1 |
| 20070137718 | Rushlander et al. | Jun 2007 | A1 |
| 20070149935 | Dirico | Jun 2007 | A1 |
| 20070191804 | Coley | Aug 2007 | A1 |
| 20070214553 | Carromba et al. | Sep 2007 | A1 |
| 20070225663 | Watt et al. | Sep 2007 | A1 |
| 20070225666 | Otto | Sep 2007 | A1 |
| 20070225668 | Otto | Sep 2007 | A1 |
| 20070266486 | Ramirez | Nov 2007 | A1 |
| 20070282309 | Bengtson et al. | Dec 2007 | A1 |
| 20080004576 | Tanaka et al. | Jan 2008 | A1 |
| 20080015526 | Reiner et al. | Jan 2008 | A1 |
| 20080015527 | House | Jan 2008 | A1 |
| 20080033386 | Okabe et al. | Feb 2008 | A1 |
| 20080041869 | Backaert | Feb 2008 | A1 |
| 20080091153 | Harvie | Apr 2008 | A1 |
| 20080091158 | Yang | Apr 2008 | A1 |
| 20080114327 | Barge | May 2008 | A1 |
| 20080167634 | Kouta et al. | Jul 2008 | A1 |
| 20080183157 | Walters | Jul 2008 | A1 |
| 20080215031 | Belfort et al. | Sep 2008 | A1 |
| 20080234642 | Patterson et al. | Sep 2008 | A1 |
| 20080269703 | Collins | Oct 2008 | A1 |
| 20080281282 | Finger et al. | Nov 2008 | A1 |
| 20080287894 | Van Den Heuvel et al. | Nov 2008 | A1 |
| 20080312550 | Nishtala et al. | Dec 2008 | A1 |
| 20090025717 | Pinel | Jan 2009 | A1 |
| 20090048570 | Jensen | Feb 2009 | A1 |
| 20090056003 | Ivie et al. | Mar 2009 | A1 |
| 20090069761 | Vogel | Mar 2009 | A1 |
| 20090069765 | Wortham | Mar 2009 | A1 |
| 20090192482 | Dodge et al. | Jul 2009 | A1 |
| 20090234312 | Otoole et al. | Sep 2009 | A1 |
| 20090251510 | Noro et al. | Oct 2009 | A1 |
| 20090264840 | Virginio | Oct 2009 | A1 |
| 20090270822 | Medeiros | Oct 2009 | A1 |
| 20090281510 | Fisher | Nov 2009 | A1 |
| 20100004612 | Thevenin | Jan 2010 | A1 |
| 20100058660 | Williams | Mar 2010 | A1 |
| 20100121289 | Parks et al. | May 2010 | A1 |
| 20100160882 | Lowe | Jun 2010 | A1 |
| 20100174250 | Hu | Jul 2010 | A1 |
| 20100185168 | Graauw et al. | Jul 2010 | A1 |
| 20100198172 | Wada et al. | Aug 2010 | A1 |
| 20100211032 | Tsai et al. | Aug 2010 | A1 |
| 20100234820 | Tsai et al. | Sep 2010 | A1 |
| 20100241104 | Gilbert | Sep 2010 | A1 |
| 20100263113 | Shelton et al. | Oct 2010 | A1 |
| 20100310845 | Bond et al. | Dec 2010 | A1 |
| 20110028920 | Johannison | Feb 2011 | A1 |
| 20110028922 | Kay et al. | Feb 2011 | A1 |
| 20110034889 | Smith | Feb 2011 | A1 |
| 20110036837 | Shang | Feb 2011 | A1 |
| 20110040267 | Wada et al. | Feb 2011 | A1 |
| 20110040271 | Rogers et al. | Feb 2011 | A1 |
| 20110054426 | Stewart et al. | Mar 2011 | A1 |
| 20110060299 | Wada et al. | Mar 2011 | A1 |
| 20110060300 | Weig et al. | Mar 2011 | A1 |
| 20110077495 | Gilbert | Mar 2011 | A1 |
| 20110077606 | Wilcox et al. | Mar 2011 | A1 |
| 20110087337 | Forsell | Apr 2011 | A1 |
| 20110145993 | Rader et al. | Jun 2011 | A1 |
| 20110152802 | Dicamillo et al. | Jun 2011 | A1 |
| 20110164147 | Takahashi et al. | Jul 2011 | A1 |
| 20110172620 | Khambatta | Jul 2011 | A1 |
| 20110172625 | Wada et al. | Jul 2011 | A1 |
| 20110202024 | Cozzens | Aug 2011 | A1 |
| 20110238023 | Slayton | Sep 2011 | A1 |
| 20110240648 | Tucker | Oct 2011 | A1 |
| 20110251572 | Nishtala et al. | Oct 2011 | A1 |
| 20110265889 | Tanaka et al. | Nov 2011 | A1 |
| 20110276020 | Mitsui | Nov 2011 | A1 |
| 20120035577 | Tomes et al. | Feb 2012 | A1 |
| 20120041400 | Christensen | Feb 2012 | A1 |
| 20120059328 | Dikeman et al. | Mar 2012 | A1 |
| 20120066825 | Birbara et al. | Mar 2012 | A1 |
| 20120103347 | Wheaton et al. | May 2012 | A1 |
| 20120137420 | Gordon et al. | Jun 2012 | A1 |
| 20120165768 | Sekiyama et al. | Jun 2012 | A1 |
| 20120165786 | Chappa et al. | Jun 2012 | A1 |
| 20120210503 | Anzivino et al. | Aug 2012 | A1 |
| 20120233761 | Huang | Sep 2012 | A1 |
| 20120245541 | Suzuki et al. | Sep 2012 | A1 |
| 20120245542 | Suzuki et al. | Sep 2012 | A1 |
| 20120245547 | Wilcox et al. | Sep 2012 | A1 |
| 20120253303 | Suzuki et al. | Oct 2012 | A1 |
| 20120271259 | Ulert | Oct 2012 | A1 |
| 20120296305 | Barraza Khaled et al. | Nov 2012 | A1 |
| 20120316522 | Carter et al. | Dec 2012 | A1 |
| 20120330256 | Wilcox et al. | Dec 2012 | A1 |
| 20130006206 | Wada et al. | Jan 2013 | A1 |
| 20130045651 | Esteves et al. | Feb 2013 | A1 |
| 20130053804 | Soerensen et al. | Feb 2013 | A1 |
| 20130096523 | Chang et al. | Apr 2013 | A1 |
| 20130138064 | Stroebech et al. | May 2013 | A1 |
| 20130150813 | Gordon et al. | Jun 2013 | A1 |
| 20130245496 | Wells et al. | Sep 2013 | A1 |
| 20130245586 | Jha | Sep 2013 | A1 |
| 20130292537 | Dirico | Nov 2013 | A1 |
| 20140005647 | Shuffler et al. | Jan 2014 | A1 |
| 20140031774 | Bengtson | Jan 2014 | A1 |
| 20140039432 | Dunbar et al. | Feb 2014 | A1 |
| 20140157499 | Suzuki et al. | Jun 2014 | A1 |
| 20140171889 | Hopman et al. | Jun 2014 | A1 |
| 20140182051 | Tanimoto et al. | Jul 2014 | A1 |
| 20140196189 | Lee et al. | Jul 2014 | A1 |
| 20140303582 | Wright et al. | Oct 2014 | A1 |
| 20140316381 | Reglin | Oct 2014 | A1 |
| 20140325746 | Block | Nov 2014 | A1 |
| 20140348139 | Gomez Martinez | Nov 2014 | A1 |
| 20140352050 | Yao et al. | Dec 2014 | A1 |
| 20140371628 | Desai | Dec 2014 | A1 |
| 20150045757 | Lee et al. | Feb 2015 | A1 |
| 20150047114 | Ramirez | Feb 2015 | A1 |
| 20150048089 | Robertson | Feb 2015 | A1 |
| 20150135423 | Sharpe et al. | May 2015 | A1 |
| 20150157300 | Ealovega et al. | Jun 2015 | A1 |
| 20150209194 | Heyman | Jul 2015 | A1 |
| 20150290425 | Macy et al. | Oct 2015 | A1 |
| 20150320583 | Harvie | Nov 2015 | A1 |
| 20150329255 | Rzepecki | Nov 2015 | A1 |
| 20150342799 | Michiels et al. | Dec 2015 | A1 |
| 20150359660 | Harvie | Dec 2015 | A1 |
| 20150366699 | Nelson | Dec 2015 | A1 |
| 20160029998 | Brister et al. | Feb 2016 | A1 |
| 20160030228 | Jones | Feb 2016 | A1 |
| 20160038356 | Yao et al. | Feb 2016 | A1 |
| 20160058322 | Brister et al. | Mar 2016 | A1 |
| 20160060001 | Wada et al. | Mar 2016 | A1 |
| 20160100976 | Conway et al. | Apr 2016 | A1 |
| 20160106604 | Timm | Apr 2016 | A1 |
| 20160113809 | Kim | Apr 2016 | A1 |
| 20160183689 | Miner | Jun 2016 | A1 |
| 20160256022 | Le | Sep 2016 | A1 |
| 20160270982 | Raycheck et al. | Sep 2016 | A1 |
| 20160278662 | Brister et al. | Sep 2016 | A1 |
| 20160357400 | Penha et al. | Dec 2016 | A1 |
| 20160366699 | Zhang et al. | Dec 2016 | A1 |
| 20160367226 | Newton et al. | Dec 2016 | A1 |
| 20160367411 | Justiz et al. | Dec 2016 | A1 |
| 20160374848 | Sanchez | Dec 2016 | A1 |
| 20170007438 | Harvie | Jan 2017 | A1 |
| 20170014560 | Minskoff et al. | Jan 2017 | A1 |
| 20170100276 | Joh | Apr 2017 | A1 |
| 20170128638 | Giezendanner et al. | May 2017 | A1 |
| 20170143534 | Sanchez | May 2017 | A1 |
| 20170165405 | Muser et al. | Jun 2017 | A1 |
| 20170189225 | Voorhees et al. | Jul 2017 | A1 |
| 20170202692 | Laniado | Jul 2017 | A1 |
| 20170216081 | Accosta | Aug 2017 | A1 |
| 20170246026 | Laniado | Aug 2017 | A1 |
| 20170252014 | Siller Gonzalez et al. | Sep 2017 | A1 |
| 20170252202 | Sanchez et al. | Sep 2017 | A9 |
| 20170266031 | Sanchez | Sep 2017 | A1 |
| 20170266658 | Bruno et al. | Sep 2017 | A1 |
| 20170281399 | Vanmiddendorp et al. | Oct 2017 | A1 |
| 20170312116 | Laniado | Nov 2017 | A1 |
| 20170325788 | Ealovega et al. | Nov 2017 | A1 |
| 20170333244 | Laniado | Nov 2017 | A1 |
| 20170042748 | Griffin | Dec 2017 | A1 |
| 20170348139 | Newton et al. | Dec 2017 | A1 |
| 20170354532 | Holt | Dec 2017 | A1 |
| 20170367873 | Grannum | Dec 2017 | A1 |
| 20180002075 | Lee | Jan 2018 | A1 |
| 20180008451 | Stroebech | Jan 2018 | A1 |
| 20180008804 | Laniado | Jan 2018 | A1 |
| 20180021218 | Brosch et al. | Jan 2018 | A1 |
| 20180028349 | Newton et al. | Feb 2018 | A1 |
| 20180037384 | Archeny et al. | Feb 2018 | A1 |
| 20180049910 | Newton | Feb 2018 | A1 |
| 20180064572 | Wiltshire | Mar 2018 | A1 |
| 20180104131 | Killian | Apr 2018 | A1 |
| 20180127187 | Sewell | May 2018 | A1 |
| 20180193215 | Davies et al. | Jul 2018 | A1 |
| 20180200101 | Su | Jul 2018 | A1 |
| 20180228642 | Davis | Aug 2018 | A1 |
| 20180256384 | Kasirye | Sep 2018 | A1 |
| 20180271694 | Fernandez et al. | Sep 2018 | A1 |
| 20180317892 | Catlin | Nov 2018 | A1 |
| 20190001030 | Braga et al. | Jan 2019 | A1 |
| 20190021899 | Vlet | Jan 2019 | A1 |
| 20190038451 | Harvie | Feb 2019 | A1 |
| 20190046102 | Kushnir et al. | Feb 2019 | A1 |
| 20190100362 | Meyers et al. | Apr 2019 | A1 |
| 20190133814 | Tammen et al. | May 2019 | A1 |
| 20190142624 | Sanchez et al. | May 2019 | A1 |
| 20190224036 | Sanchez et al. | Jul 2019 | A1 |
| 20190247222 | Ecklund et al. | Aug 2019 | A1 |
| 20190247223 | Brun | Aug 2019 | A1 |
| 20190282391 | Johannes et al. | Sep 2019 | A1 |
| 20190314189 | Acosta | Oct 2019 | A1 |
| 20190314190 | Sanchez et al. | Oct 2019 | A1 |
| 20190321587 | Mcmenamin et al. | Oct 2019 | A1 |
| 20190344934 | Faerber et al. | Nov 2019 | A1 |
| 20190365307 | Laing et al. | Dec 2019 | A1 |
| 20190365561 | Newton et al. | Dec 2019 | A1 |
| 20200008985 | Nguyen et al. | Jan 2020 | A1 |
| 20200030595 | Boukidjian | Jan 2020 | A1 |
| 20200046544 | Godinez et al. | Feb 2020 | A1 |
| 20200055638 | Lau et al. | Feb 2020 | A1 |
| 20200070392 | Huber et al. | Mar 2020 | A1 |
| 20200085609 | Schelch et al. | Mar 2020 | A1 |
| 20200085610 | Cohn et al. | Mar 2020 | A1 |
| 20200086090 | Von Weymarn-schärli et al. | Mar 2020 | A1 |
| 20200129322 | Leuckel | Apr 2020 | A1 |
| 20200171217 | Braga et al. | Jun 2020 | A9 |
| 20200216989 | Kinugasa et al. | Jul 2020 | A1 |
| 20200229964 | Staali et al. | Jul 2020 | A1 |
| 20200231343 | Freedman et al. | Jul 2020 | A1 |
| 20200232841 | Satish et al. | Jul 2020 | A1 |
| 20200246172 | Ho | Aug 2020 | A1 |
| 20200255189 | Liu | Aug 2020 | A1 |
| 20200261280 | Heyman | Aug 2020 | A1 |
| 20200276046 | Staali et al. | Sep 2020 | A1 |
| 20200306075 | Newton et al. | Oct 2020 | A1 |
| 20200315837 | Radl et al. | Oct 2020 | A1 |
| 20200315838 | Eckert | Oct 2020 | A1 |
| 20200331672 | Bertram et al. | Oct 2020 | A1 |
| 20200345332 | Duval | Nov 2020 | A1 |
| 20200353135 | Gregory et al. | Nov 2020 | A1 |
| 20200367677 | Silsby et al. | Nov 2020 | A1 |
| 20200369444 | Silsby et al. | Nov 2020 | A1 |
| 20200375781 | Staali et al. | Dec 2020 | A1 |
| 20200385179 | Mccourt | Dec 2020 | A1 |
| 20200390591 | Glithero et al. | Dec 2020 | A1 |
| 20200390592 | Merrill | Dec 2020 | A1 |
| 20200405521 | Glasroe | Dec 2020 | A1 |
| 20210008771 | Huber et al. | Jan 2021 | A1 |
| 20210009323 | Markarian et al. | Jan 2021 | A1 |
| 20210020072 | Moehring et al. | Jan 2021 | A1 |
| 20210059853 | Davis et al. | Mar 2021 | A1 |
| 20210061523 | Bytheway | Mar 2021 | A1 |
| 20210069005 | Sanchez et al. | Mar 2021 | A1 |
| 20210069008 | Blabas et al. | Mar 2021 | A1 |
| 20210069009 | Im | Mar 2021 | A1 |
| 20210077993 | Nazareth et al. | Mar 2021 | A1 |
| 20210113749 | Radl et al. | Apr 2021 | A1 |
| 20210121318 | Pinlac | Apr 2021 | A1 |
| 20210137724 | Ecklund et al. | May 2021 | A1 |
| 20210138190 | Erbey et al. | May 2021 | A1 |
| 20210154055 | Villarreal | May 2021 | A1 |
| 20210170079 | Radl et al. | Jun 2021 | A1 |
| 20210178390 | Oueslati et al. | Jun 2021 | A1 |
| 20210186742 | Newton et al. | Jun 2021 | A1 |
| 20210212865 | Wallajapet et al. | Jul 2021 | A1 |
| 20210220162 | Jamison | Jul 2021 | A1 |
| 20210220163 | Mayrand | Jul 2021 | A1 |
| 20210228400 | Glithero | Jul 2021 | A1 |
| 20210228401 | Becker et al. | Jul 2021 | A1 |
| 20210228795 | Hughett et al. | Jul 2021 | A1 |
| 20210229877 | Ragias et al. | Jul 2021 | A1 |
| 20210236323 | Austermann et al. | Aug 2021 | A1 |
| 20210236324 | Sweeney | Aug 2021 | A1 |
| 20210267787 | Nazemi | Sep 2021 | A1 |
| 20210275343 | Sanchez et al. | Sep 2021 | A1 |
| 20210315727 | Jiang | Oct 2021 | A1 |
| 20210353450 | Sharma et al. | Nov 2021 | A1 |
| 20210361469 | Liu et al. | Nov 2021 | A1 |
| 20210369495 | Cheng | Dec 2021 | A1 |
| 20210386925 | Hartwell et al. | Dec 2021 | A1 |
| 20210393433 | Godinez et al. | Dec 2021 | A1 |
| 20220023091 | Ecklund et al. | Jan 2022 | A1 |
| 20220039995 | Johannes et al. | Feb 2022 | A1 |
| 20220047410 | Walthall | Feb 2022 | A1 |
| 20220062027 | Mitchell et al. | Mar 2022 | A1 |
| 20220062028 | Mitchell et al. | Mar 2022 | A1 |
| 20220062029 | Johannes et al. | Mar 2022 | A1 |
| 20220066825 | Saraf et al. | Mar 2022 | A1 |
| 20220071811 | Cheng et al. | Mar 2022 | A1 |
| 20220071826 | Kulkarni et al. | Mar 2022 | A1 |
| 20220104965 | Vaninetti et al. | Apr 2022 | A1 |
| 20220104981 | Jones | Apr 2022 | A1 |
| 20220117773 | Davis et al. | Apr 2022 | A1 |
| 20220117774 | Meyer et al. | Apr 2022 | A1 |
| 20220117775 | Jones et al. | Apr 2022 | A1 |
| 20220133524 | Davis | May 2022 | A1 |
| 20220151817 | Mann | May 2022 | A1 |
| 20220160949 | Simiele et al. | May 2022 | A1 |
| 20220193312 | Lee et al. | Jun 2022 | A1 |
| 20220211536 | Johannes et al. | Jul 2022 | A1 |
| 20220218510 | Metzger et al. | Jul 2022 | A1 |
| 20220229053 | Levin et al. | Jul 2022 | A1 |
| 20220241106 | Johannes et al. | Aug 2022 | A1 |
| 20220247407 | Yamamoto et al. | Aug 2022 | A1 |
| 20220248836 | Cagle et al. | Aug 2022 | A1 |
| 20220257407 | Johannes et al. | Aug 2022 | A1 |
| 20220265460 | Coker | Aug 2022 | A1 |
| 20220265462 | Alder et al. | Aug 2022 | A1 |
| 20220270711 | Feala et al. | Aug 2022 | A1 |
| 20220273482 | Johannes et al. | Sep 2022 | A1 |
| 20220280357 | Jagannathan et al. | Sep 2022 | A1 |
| 20220287689 | Johannes | Sep 2022 | A1 |
| 20220296408 | Evans et al. | Sep 2022 | A1 |
| 20220305191 | Joseph et al. | Sep 2022 | A1 |
| 20220313222 | Austermann et al. | Oct 2022 | A1 |
| 20220313474 | Kriscovich et al. | Oct 2022 | A1 |
| 20220331170 | Erdem et al. | Oct 2022 | A1 |
| 20220339024 | Johannes et al. | Oct 2022 | A1 |
| 20220354685 | Davis et al. | Nov 2022 | A1 |
| 20220362049 | Austermann et al. | Nov 2022 | A1 |
| 20220370231 | Wang et al. | Nov 2022 | A1 |
| 20220370234 | Hughett et al. | Nov 2022 | A1 |
| 20220370235 | Johannes et al. | Nov 2022 | A1 |
| 20220370237 | Parmar et al. | Nov 2022 | A1 |
| 20220387001 | Askenazi et al. | Dec 2022 | A1 |
| 20220395390 | Brooks | Dec 2022 | A1 |
| 20220395391 | Saunders et al. | Dec 2022 | A1 |
| 20230018845 | Lee | Jan 2023 | A1 |
| 20230020563 | Sharma et al. | Jan 2023 | A1 |
| 20230031640 | Hughett et al. | Feb 2023 | A1 |
| 20230037159 | Brennan et al. | Feb 2023 | A1 |
| 20230052238 | Oluwasogo | Feb 2023 | A1 |
| 20230062994 | Ecklund et al. | Mar 2023 | A1 |
| 20230070347 | Watson et al. | Mar 2023 | A1 |
| 20230073708 | Xu et al. | Mar 2023 | A1 |
| 20230089032 | Hughett et al. | Mar 2023 | A1 |
| 20230099821 | Radl et al. | Mar 2023 | A1 |
| 20230105001 | Whittome et al. | Apr 2023 | A1 |
| 20230138269 | Abdelal et al. | May 2023 | A1 |
| 20230145365 | Martin et al. | May 2023 | A1 |
| 20230210504 | Kuroda et al. | Jul 2023 | A1 |
| 20230218426 | Hughett | Jul 2023 | A1 |
| 20230248562 | Sanchez et al. | Aug 2023 | A1 |
| 20230255812 | Sanchez et al. | Aug 2023 | A1 |
| 20230255813 | Sanchez et al. | Aug 2023 | A1 |
| 20230255815 | Newton | Aug 2023 | A1 |
| 20230263650 | Sanchez et al. | Aug 2023 | A1 |
| 20230263655 | Johannes et al. | Aug 2023 | A1 |
| 20230277362 | Davis et al. | Sep 2023 | A1 |
| 20230293339 | James | Sep 2023 | A1 |
| 20230301846 | Greenwood | Sep 2023 | A1 |
| 20230355423 | Stevenson et al. | Nov 2023 | A1 |
| 20230404791 | Ecklund et al. | Dec 2023 | A1 |
| 20240009023 | Johannes et al. | Jan 2024 | A1 |
| 20240041638 | Johannes et al. | Feb 2024 | A1 |
| 20240058161 | Ulreich et al. | Feb 2024 | A1 |
| Number | Date | Country |
|---|---|---|
| 2018216821 | Aug 2018 | AU |
| 2021299304 | Feb 2023 | AU |
| 2165286 | Sep 1999 | CA |
| 2354132 | Jun 2000 | CA |
| 2488867 | Aug 2007 | CA |
| 3050918 | Aug 2018 | CA |
| 3098571 | Nov 2019 | CA |
| 2269203 | Dec 1997 | CN |
| 1332620 | Jan 2002 | CN |
| 1533755 | Oct 2004 | CN |
| 1602825 | Apr 2005 | CN |
| 1720888 | Jan 2006 | CN |
| 2936204 | Aug 2007 | CN |
| 101262836 | Sep 2008 | CN |
| 101522148 | Sep 2009 | CN |
| 102159159 | Aug 2011 | CN |
| 202184840 | Apr 2012 | CN |
| 102481441 | May 2012 | CN |
| 202463712 | Oct 2012 | CN |
| 103533968 | Jan 2014 | CN |
| 103717180 | Apr 2014 | CN |
| 204562697 | Aug 2015 | CN |
| 105411783 | Mar 2016 | CN |
| 105451693 | Mar 2016 | CN |
| 105534632 | May 2016 | CN |
| 205849719 | Jan 2017 | CN |
| 106726089 | May 2017 | CN |
| 107847384 | Mar 2018 | CN |
| 107920912 | Apr 2018 | CN |
| 209285902 | Aug 2019 | CN |
| 110381883 | Oct 2019 | CN |
| 211198839 | Aug 2020 | CN |
| 112566550 | Mar 2021 | CN |
| 112603184 | Apr 2021 | CN |
| 114007493 | Feb 2022 | CN |
| 114375187 | Apr 2022 | CN |
| 116096332 | May 2023 | CN |
| 1516466 | Jun 1969 | DE |
| 2721330 | Nov 1977 | DE |
| 2742298 | Mar 1978 | DE |
| 9407554.9 | May 1995 | DE |
| 4443710 | Jun 1995 | DE |
| 4416094 | Nov 1995 | DE |
| 4236097 | Oct 1996 | DE |
| 19619597 | Nov 1997 | DE |
| 102005037762 | Sep 2006 | DE |
| 102011103783 | Dec 2012 | DE |
| 202015104597 | Jul 2016 | DE |
| 9600118 | Nov 1996 | DK |
| 0032138 | Jul 1981 | EP |
| 0066070 | Dec 1982 | EP |
| 0140470 | May 1985 | EP |
| 0140471 | May 1988 | EP |
| 0274753 | Jul 1988 | EP |
| 0119143 | Nov 1988 | EP |
| 0483592 | May 1992 | EP |
| 0610638 | Aug 1994 | EP |
| 0613355 | Sep 1994 | EP |
| 0613355 | Jan 1997 | EP |
| 0787472 | Aug 1997 | EP |
| 0966936 | Dec 1999 | EP |
| 0987293 | Mar 2000 | EP |
| 1063953 | Jan 2001 | EP |
| 0653928 | Oct 2002 | EP |
| 1332738 | Aug 2003 | EP |
| 1382318 | Jan 2004 | EP |
| 1089684 | Oct 2004 | EP |
| 1616542 | Jan 2006 | EP |
| 1382318 | May 2006 | EP |
| 1063953 | Jan 2007 | EP |
| 1872752 | Jan 2008 | EP |
| 2180907 | May 2010 | EP |
| 2380532 | Oct 2011 | EP |
| 2389908 | Nov 2011 | EP |
| 2601916 | Jun 2013 | EP |
| 2676643 | Dec 2013 | EP |
| 2997950 | Mar 2016 | EP |
| 2879534 | Mar 2017 | EP |
| 3424471 | Jan 2019 | EP |
| 3169292 | Nov 2019 | EP |
| 3787570 | Mar 2020 | EP |
| 3753492 | Dec 2020 | EP |
| 3788992 | Mar 2021 | EP |
| 3576689 | Mar 2022 | EP |
| 3752110 | Mar 2022 | EP |
| 4025163 | Jul 2022 | EP |
| 3463180 | Mar 2023 | EP |
| 1011517 | Dec 1965 | GB |
| 1467144 | Mar 1977 | GB |
| 2106395 | Apr 1983 | GB |
| 2106784 | Apr 1983 | GB |
| 2148126 | May 1985 | GB |
| 2171315 | Aug 1986 | GB |
| 2181953 | May 1987 | GB |
| 2148126 | Jul 1987 | GB |
| 2191095 | Dec 1987 | GB |
| 2199750 | Jul 1988 | GB |
| 2260907 | May 1993 | GB |
| 2462267 | Feb 2010 | GB |
| 2469496 | Oct 2010 | GB |
| 2490327 | Oct 2012 | GB |
| 2507318 | Apr 2014 | GB |
| 2612752 | May 2023 | GB |
| 201800009129 | Apr 2020 | IT |
| S5410596 | Jan 1979 | JP |
| S5410596 | May 1979 | JP |
| S55155618 | Dec 1980 | JP |
| S5888596 | Jun 1983 | JP |
| S63107780 | Jul 1988 | JP |
| H0267530 | Mar 1990 | JP |
| H02103871 | Apr 1990 | JP |
| H02131422 | May 1990 | JP |
| H02131422 | Nov 1990 | JP |
| H0460220 | Feb 1992 | JP |
| H05123349 | May 1993 | JP |
| H05123350 | May 1993 | JP |
| 3087938 | Oct 1995 | JP |
| H085630 | Jan 1996 | JP |
| H1040141 | Feb 1998 | JP |
| H10225430 | Aug 1998 | JP |
| H11113946 | Apr 1999 | JP |
| H11290365 | Oct 1999 | JP |
| 2000116690 | Apr 2000 | JP |
| 2000185068 | Jul 2000 | JP |
| 2001054531 | Feb 2001 | JP |
| 2001070331 | Mar 2001 | JP |
| 2001224616 | Aug 2001 | JP |
| 2001276107 | Oct 2001 | JP |
| 2001276108 | Oct 2001 | JP |
| 2002028173 | Jan 2002 | JP |
| 2003505152 | Feb 2003 | JP |
| 2003180722 | Jul 2003 | JP |
| 2004130056 | Apr 2004 | JP |
| 2004267530 | Sep 2004 | JP |
| 2005066011 | Mar 2005 | JP |
| 2005066325 | Mar 2005 | JP |
| 2005518237 | Jun 2005 | JP |
| 3749097 | Dec 2005 | JP |
| 2006026108 | Feb 2006 | JP |
| 3123547 | Jun 2006 | JP |
| 2006136492 | Jun 2006 | JP |
| 2006204868 | Aug 2006 | JP |
| 2007044494 | Feb 2007 | JP |
| 3132659 | May 2007 | JP |
| 4039641 | Nov 2007 | JP |
| 2009509570 | Mar 2009 | JP |
| 2010081981 | Apr 2010 | JP |
| 4640772 | Dec 2010 | JP |
| 2010536439 | Dec 2010 | JP |
| 4747166 | May 2011 | JP |
| 2011087823 | May 2011 | JP |
| 4801218 | Aug 2011 | JP |
| 2011218130 | Nov 2011 | JP |
| 2011224070 | Nov 2011 | JP |
| 2012523869 | Oct 2012 | JP |
| 2013238608 | Nov 2013 | JP |
| 2014521960 | Aug 2014 | JP |
| 2015092945 | May 2015 | JP |
| 3198994 | Jul 2015 | JP |
| 2019525811 | Sep 2019 | JP |
| 2021120686 | Aug 2021 | JP |
| 2021522009 | Aug 2021 | JP |
| 7129493 | Aug 2022 | JP |
| 2023532132 | Jul 2023 | JP |
| 200290061 | Sep 2002 | KR |
| 20030047451 | Jun 2003 | KR |
| 20140039485 | Apr 2014 | KR |
| 101432639 | Aug 2014 | KR |
| 20180106659 | Oct 2018 | KR |
| 20180108774 | Oct 2018 | KR |
| 2068717 | Jun 2013 | PT |
| 8101957 | Jul 1981 | WO |
| 8804558 | Jun 1988 | WO |
| 9104714 | Apr 1991 | WO |
| 9104714 | Jun 1991 | WO |
| 9220299 | Feb 1993 | WO |
| 9307839 | Apr 1993 | WO |
| 9309736 | May 1993 | WO |
| 9309736 | Jun 1993 | WO |
| 9514448 | Jun 1995 | WO |
| 9600096 | Jan 1996 | WO |
| 9634636 | Nov 1996 | WO |
| 9817211 | Apr 1998 | WO |
| 9830336 | Jul 1998 | WO |
| 0000112 | Jan 2000 | WO |
| 0000113 | Jan 2000 | WO |
| 0025651 | May 2000 | WO |
| 0033773 | Jun 2000 | WO |
| 0057784 | Oct 2000 | WO |
| 0069377 | Nov 2000 | WO |
| 0079497 | Dec 2000 | WO |
| 0145618 | Jun 2001 | WO |
| 0145621 | Jun 2001 | WO |
| 02094160 | Nov 2002 | WO |
| 03013967 | Feb 2003 | WO |
| 03024824 | Mar 2003 | WO |
| 03055423 | Jul 2003 | WO |
| 03071931 | Sep 2003 | WO |
| 03079942 | Oct 2003 | WO |
| 03071931 | Feb 2004 | WO |
| 2004019836 | Mar 2004 | WO |
| 2004024046 | Mar 2004 | WO |
| 2005051252 | Jun 2005 | WO |
| 2005074571 | Sep 2005 | WO |
| 2005089687 | Sep 2005 | WO |
| 2005107661 | Nov 2005 | WO |
| 2006021220 | Mar 2006 | WO |
| 2006037140 | Apr 2006 | WO |
| 2007005851 | Jan 2007 | WO |
| 2007007845 | Jan 2007 | WO |
| 2007042823 | Apr 2007 | WO |
| 2007055651 | May 2007 | WO |
| 2006098950 | Nov 2007 | WO |
| 2007128156 | Feb 2008 | WO |
| 2008026106 | Mar 2008 | WO |
| 2008078117 | Jul 2008 | WO |
| 2008104019 | Sep 2008 | WO |
| 2008141471 | Nov 2008 | WO |
| 2009004368 | Jan 2009 | WO |
| 2009004369 | Jan 2009 | WO |
| 2009052496 | Apr 2009 | WO |
| 2009052502 | Apr 2009 | WO |
| 2009007702 | Jul 2009 | WO |
| 2009101738 | Aug 2009 | WO |
| 2010058192 | May 2010 | WO |
| 2010030122 | Jul 2010 | WO |
| 2010101915 | Jan 2011 | WO |
| 2011018132 | Feb 2011 | WO |
| 2011018133 | Feb 2011 | WO |
| 2011024864 | Mar 2011 | WO |
| 2011054118 | May 2011 | WO |
| 2011079132 | Jun 2011 | WO |
| 2011107972 | Sep 2011 | WO |
| 2011108972 | Sep 2011 | WO |
| 2011117292 | Sep 2011 | WO |
| 2011123219 | Oct 2011 | WO |
| 2011132043 | Oct 2011 | WO |
| 2012012908 | Feb 2012 | WO |
| 2012065274 | May 2012 | WO |
| 2012097462 | Jul 2012 | WO |
| 2012098796 | Jul 2012 | WO |
| 2012101288 | Aug 2012 | WO |
| 2012175916 | Dec 2012 | WO |
| 2013018435 | Feb 2013 | WO |
| 2013033429 | Mar 2013 | WO |
| 2013055434 | Apr 2013 | WO |
| 2013082397 | Jun 2013 | WO |
| 2013103291 | Jul 2013 | WO |
| 2013131109 | Sep 2013 | WO |
| 2013167478 | Nov 2013 | WO |
| 2013177716 | Dec 2013 | WO |
| 2014041534 | Mar 2014 | WO |
| 2014046420 | Mar 2014 | WO |
| 2014118518 | Aug 2014 | WO |
| 2014160852 | Oct 2014 | WO |
| 2015023599 | Feb 2015 | WO |
| 2015052348 | Apr 2015 | WO |
| 2015068384 | May 2015 | WO |
| 2015169403 | Nov 2015 | WO |
| 2015170307 | Nov 2015 | WO |
| 2015197462 | Dec 2015 | WO |
| 2016051385 | Apr 2016 | WO |
| 2016055989 | Apr 2016 | WO |
| 2016071894 | May 2016 | WO |
| 2016103242 | Jun 2016 | WO |
| 2016116915 | Jul 2016 | WO |
| 2016124203 | Aug 2016 | WO |
| 2016139448 | Sep 2016 | WO |
| 2016166562 | Oct 2016 | WO |
| 2016167535 | Oct 2016 | WO |
| 2016191574 | Dec 2016 | WO |
| 2016200088 | Dec 2016 | WO |
| 2016200361 | Dec 2016 | WO |
| 2016204731 | Dec 2016 | WO |
| 2017001532 | Jan 2017 | WO |
| 2017075226 | May 2017 | WO |
| 2017152198 | Sep 2017 | WO |
| 2017153357 | Sep 2017 | WO |
| 2017162559 | Sep 2017 | WO |
| 2017205446 | Nov 2017 | WO |
| 2017209779 | Dec 2017 | WO |
| 2017210524 | Dec 2017 | WO |
| 2018022414 | Feb 2018 | WO |
| 2018044781 | Mar 2018 | WO |
| 2018056953 | Mar 2018 | WO |
| 2018090550 | Mar 2018 | WO |
| 2018138513 | Aug 2018 | WO |
| 2018144318 | Aug 2018 | WO |
| 2018144463 | Aug 2018 | WO |
| 2018150263 | Aug 2018 | WO |
| 2018150268 | Aug 2018 | WO |
| 2018152156 | Aug 2018 | WO |
| 2018183791 | Oct 2018 | WO |
| 2018150267 | Nov 2018 | WO |
| 2018235026 | Dec 2018 | WO |
| 2018235065 | Dec 2018 | WO |
| 2019004404 | Jan 2019 | WO |
| 2019041005 | Mar 2019 | WO |
| 2019044217 | Mar 2019 | WO |
| 2019044218 | Mar 2019 | WO |
| 2019044219 | Mar 2019 | WO |
| 2019065541 | Apr 2019 | WO |
| 2019096845 | May 2019 | WO |
| 2019150385 | Aug 2019 | WO |
| 2019161094 | Aug 2019 | WO |
| 2019188566 | Oct 2019 | WO |
| 2019190593 | Oct 2019 | WO |
| 2019212949 | Nov 2019 | WO |
| 2019212950 | Nov 2019 | WO |
| 2019212951 | Nov 2019 | WO |
| 2019212952 | Nov 2019 | WO |
| 2019212955 | Nov 2019 | WO |
| 2019212956 | Nov 2019 | WO |
| 2019214787 | Nov 2019 | WO |
| 2019214788 | Nov 2019 | WO |
| 2019226826 | Nov 2019 | WO |
| WO-2019239433 | Dec 2019 | WO |
| 2020000994 | Jan 2020 | WO |
| 2020020618 | Jan 2020 | WO |
| 2020038822 | Jan 2020 | WO |
| 2020088409 | May 2020 | WO |
| 2020049394 | Jun 2020 | WO |
| 2020120657 | Jun 2020 | WO |
| 2020152575 | Jul 2020 | WO |
| 2020182923 | Sep 2020 | WO |
| 2020204967 | Oct 2020 | WO |
| 2020205939 | Oct 2020 | WO |
| 2020209898 | Oct 2020 | WO |
| 2020242790 | Dec 2020 | WO |
| 2020251893 | Dec 2020 | WO |
| 2020256865 | Dec 2020 | WO |
| 2021007144 | Jan 2021 | WO |
| 2021007345 | Jan 2021 | WO |
| 2021010844 | Jan 2021 | WO |
| 2021016026 | Jan 2021 | WO |
| 2021016300 | Jan 2021 | WO |
| 2021025919 | Feb 2021 | WO |
| 2021034886 | Feb 2021 | WO |
| 2021041123 | Mar 2021 | WO |
| 2021046501 | Mar 2021 | WO |
| 2021086868 | May 2021 | WO |
| 2021094352 | May 2021 | WO |
| 2021094639 | May 2021 | WO |
| 2021102296 | May 2021 | WO |
| 2021107025 | Jun 2021 | WO |
| 2021138411 | Jul 2021 | WO |
| 2021138414 | Jul 2021 | WO |
| 2021154686 | Aug 2021 | WO |
| 2021155206 | Aug 2021 | WO |
| 2021173436 | Sep 2021 | WO |
| 2021188817 | Sep 2021 | WO |
| 2021195384 | Sep 2021 | WO |
| 2021205995 | Oct 2021 | WO |
| 2021207621 | Oct 2021 | WO |
| 2021211568 | Oct 2021 | WO |
| 2021211801 | Oct 2021 | WO |
| 2021216419 | Oct 2021 | WO |
| 2021216422 | Oct 2021 | WO |
| 2021231532 | Nov 2021 | WO |
| 2021247523 | Dec 2021 | WO |
| 2021257202 | Dec 2021 | WO |
| 2022006256 | Jan 2022 | WO |
| 2022031943 | Feb 2022 | WO |
| 2022035745 | Feb 2022 | WO |
| 2022051360 | Mar 2022 | WO |
| 2022054613 | Mar 2022 | WO |
| 2022066704 | Mar 2022 | WO |
| 2022076427 | Apr 2022 | WO |
| 2022086898 | Apr 2022 | WO |
| 2022098536 | May 2022 | WO |
| 2022115692 | Jun 2022 | WO |
| 2022125685 | Jun 2022 | WO |
| 2022140545 | Jun 2022 | WO |
| 2022150360 | Jul 2022 | WO |
| 2022150463 | Jul 2022 | WO |
| 2022159392 | Jul 2022 | WO |
| 2022170182 | Aug 2022 | WO |
| 2022182385 | Sep 2022 | WO |
| 2022187152 | Sep 2022 | WO |
| 2022192188 | Sep 2022 | WO |
| 2022192347 | Sep 2022 | WO |
| 2022216507 | Oct 2022 | WO |
| 2022222030 | Oct 2022 | WO |
| 2023014639 | Feb 2023 | WO |
| 2023014641 | Feb 2023 | WO |
| 2023018475 | Feb 2023 | WO |
| 2023034453 | Mar 2023 | WO |
| 2023038945 | Mar 2023 | WO |
| 2023038950 | Mar 2023 | WO |
| 2023049109 | Mar 2023 | WO |
| 2023049175 | Mar 2023 | WO |
| 2023086394 | May 2023 | WO |
| 2023149884 | Aug 2023 | WO |
| 2023149902 | Aug 2023 | WO |
| 2023149903 | Aug 2023 | WO |
| 2023154390 | Aug 2023 | WO |
| 2023191764 | Oct 2023 | WO |
| 2023244238 | Dec 2023 | WO |
| Entry |
|---|
| US 9,908,683 B2, 03/2018, Sandhausen et al. (withdrawn) |
| Advisory Action for U.S. Appl. No. 14/722,613 mailed Mar. 4, 2019. |
| Advisory Action for U.S. Appl. No. 14/952,591 mailed Jun. 1, 2018. |
| Advisory Action for U.S. Appl. No. 15/238,427 mailed Apr. 10, 2019. |
| Advisory Action for U.S. Appl. No. 16/899,956 mailed Jul. 9, 2021. |
| Advisory Action for U.S. Appl. No. 16/904,868 mailed Jul. 2, 2021. |
| Advisory Action for U.S. Appl. No. 16/905,400 mailed Jun. 9, 2021. |
| Corrected International Search Report and Written Opinion for International Application No. PCT/US2017/043025 mailed Jan. 11, 2018. |
| Corrected Notice of Allowability for U.S. Appl. No. 15/221,106 mailed Jul. 2, 2019. |
| Corrected Notice of Allowability for U.S. Appl. No. 15/612,325 mailed Mar. 17, 2021. |
| Final Office Action for U.S. Appl. No. 14/722,613 mailed on Nov. 29, 2018. |
| Final Office Action for U.S. Appl. No. 14/947,759 mailed Apr. 8, 2016. |
| Final Office Action for U.S. Appl. No. 14/952,591 mailed Feb. 23, 2018. |
| Final Office Action for U.S. Appl. No. 14/952,591 mailed Nov. 1, 2019. |
| Final Office Action for U.S. Appl. No. 14/952,591 mailed Nov. 27, 2020. |
| Final Office Action for U.S. Appl. No. 15/171,968 mailed Feb. 14, 2020. |
| Final Office Action for U.S. Appl. No. 15/171,968 mailed Mar. 19, 2019. |
| Final Office Action for U.S. Appl. No. 15/221,106 mailed Jan. 23, 2019. |
| Final Office Action for U.S. Appl. No. 15/238,427 mailed Jan. 2, 2019. |
| Final Office Action for U.S. Appl. No. 15/260,103 mailed Feb. 14, 2019. |
| Final Office Action for U.S. Appl. No. 15/612,325 mailed Sep. 17, 2020. |
| Final Office Action for U.S. Appl. No. 16/899,956 mailed Apr. 19, 2021. |
| Final Office Action for U.S. Appl. No. 16/904,868 mailed Mar. 26, 2021. |
| Final Office Action for U.S. Appl. No. 16/905,400 mailed Apr. 6, 2021. |
| Final Office Action for U.S. Appl. No. 17/088,272 mailed May 25, 2021. |
| Final Office Action for U.S. Appl. No. 29/624,661 mailed Feb. 18, 2020. |
| International Search Report and Written Opinion from International Application No. PCT/US2016/049274 mailed Dec. 1, 2016. |
| International Search Report and Written Opinion from International Application No. PCT/US2017/035625 mailed Aug. 15, 2017. |
| International Search Report and Written Opinion from International Application No. PCT/US2017/043025 mailed Oct. 18, 2017. |
| International Search Report and Written Opinion from International Application No. PCT/US2018/015968 mailed Apr. 6, 2018. |
| International Search Report and Written Opinion from International Application No. PCT/US2019/029608 mailed Sep. 3, 2019. |
| International Search Report and Written Opinion from International Application No. PCT/US2019/029609 mailed Sep. 3, 2019. |
| International Search Report and Written Opinion from International Application No. PCT/US2019/029610 mailed Sep. 3, 2019. |
| International Search Report and Written Opinion from International Application No. PCT/US2019/029611 mailed Jul. 3, 2019. |
| International Search Report and Written Opinion from International Application No. PCT/US2019/029613 mailed Jul. 3, 2019. |
| International Search Report and Written Opinion from International Application No. PCT/US2019/029614 mailed Sep. 26, 2019. |
| International Search Report and Written Opinion from International Application No. PCT/US2019/029616 mailed Aug. 30, 2019. |
| International Search Report and Written Opinion from International Application No. PCT/US2020/023572 mailed Jul. 6, 2020. |
| International Search Report and Written Opinion from International Application No. PCT/US2020/033064 mailed Aug. 31, 2020. |
| International Search Report and Written Opinion from International Application No. PCT/US2020/033122 mailed Aug. 31, 2020. |
| International Search Report and Written Opinion from International Application No. PCT/US2020/040860 mailed Oct. 2, 2020. |
| International Search Report and Written Opinion from International Application No. PCT/US2020/041242 mailed Nov. 17, 2020. |
| International Search Report and Written Opinion from International Application No. PCT/US2020/041249 mailed Oct. 2, 2020. |
| International Search Report and Written Opinion from International Application No. PCT/US2020/042262 mailed Oct. 14, 2020. |
| International Search Report and Written Opinion from International Application No. PCT/US2020/043059 mailed Oct. 6, 2020. |
| International Search Report and Written Opinion from International Application No. PCT/US2020/044024 mailed Nov. 12, 2020. |
| International Search Report and Written Opinion from International Application No. PCT/US2020/046914 mailed Dec. 1, 2020. |
| International Search Report and Written Opinion from International Application No. PCT/US2020/055680 mailed Dec. 15, 2020. |
| International Search Report and Written Opinion from International Application No. PCT/US2020/061563 mailed Feb. 19, 2021. |
| International Search Report and Written Opinion from International Application No. PCT/US2020/065234 mailed Apr. 12, 2021. |
| International Search Report and Written Opinion from International Application No. PCT/US2020/067451 mailed Mar. 25, 2021. |
| International Search Report and Written Opinion from International Application No. PCT/US2020/067454 mailed Mar. 29, 2021. |
| International Search Report and Written Opinion from International Application No. PCT/US2020/067455 mailed Mar. 26, 2021. |
| International Search Report and Written Opinion from International Application No. PCT/US2021/015787 mailed May 27, 2021. |
| International Search Report and Written Opinion from International Application No. PCT/US2021/023001 mailed Jun. 21, 2021. |
| International Search Report and Written Opinion from International Application No. PCT/US2021/027061 mailed Jul. 19, 2021. |
| International Search Report and Written Opinion from International Application No. PCT/US2021/027104 mailed Jul. 6, 2021. |
| International Search Report and Written Opinion from International Application No. PCT/US2021/027314 mailed Jul. 6, 2021. |
| International Search Report and Written Opinion from International Application No. PCT/US2021/027422 mailed Aug. 12, 2021. |
| International Search Report and Written Opinion from International Application No. PCT/US2021/027425 mailed Aug. 11, 2021. |
| International Search Report and Written Opinion from International Application No. PCT/US2021/027913 mailed Jul. 12, 2021. |
| International Search Report and Written Opinion from International Application No. PCT/US2021/027917 mailed Aug. 19, 2021. |
| Issue Notification for U.S. Appl. No. 14/952,591 mailed Jul. 28, 2021. |
| Issue Notification for U.S. Appl. No. 15/171,968 mailed Mar. 3, 2021. |
| Issue Notification for U.S. Appl. No. 15/221,106 mailed Jul. 24, 2019. |
| Issue Notification for U.S. Appl. No. 15/238,427 mailed Jul. 24, 2019. |
| Issue Notification for U.S. Appl. No. 15/260,103 mailed Aug. 7, 2019. |
| Issue Notification for U.S. Appl. No. 15/611,587 mailed Feb. 20, 2019. |
| Issue Notification for U.S. Appl. No. 15/612,325 mailed Mar. 24, 2021. |
| Issue Notification for U.S. Appl. No. 29/624,661 mailed Aug. 4, 2021. |
| Non-Final Office Action for U.S. Appl. No. 14/592,591 mailed Mar. 20, 2020. |
| Non-Final Office Action for U.S. Appl. No. 14/722,613 mailed Jun. 13, 2019. |
| Non-Final Office Action for U.S. Appl. No. 14/947,759 mailed Mar. 17, 2016. |
| Non-Final Office Action for U.S. Appl. No. 14/952,591 mailed Aug. 1, 2017. |
| Non-Final Office Action for U.S. Appl. No. 14/952,591 mailed Mar. 20, 2020. |
| Non-Final Office Action for U.S. Appl. No. 14/952,591 mailed Mar. 21, 2019. |
| Non-Final Office Action for U.S. Appl. No. 14/952,591 mailed Sep. 28, 2018. |
| Non-Final Office Action for U.S. Appl. No. 15/171,968 mailed May 11, 2020. |
| Non-Final Office Action for U.S. Appl. No. 15/171,968 mailed Aug. 20, 2019. |
| Non-Final Office Action for U.S. Appl. No. 15/171,968 mailed Jun. 12, 2018. |
| Non-Final Office Action for U.S. Appl. No. 15/221,106 mailed Jun. 5, 2018. |
| Non-Final Office Action for U.S. Appl. No. 15/238,427 mailed Aug. 8, 2018. |
| Non-Final Office Action for U.S. Appl. No. 15/260,103 mailed Sep. 26, 2018. |
| Non-Final Office Action for U.S. Appl. No. 15/611,587 mailed Dec. 29, 2017. |
| Non-Final Office Action for U.S. Appl. No. 15/611,587 mailed Jul. 13, 2018. |
| Non-Final Office Action for U.S. Appl. No. 15/612,325 mailed Mar. 19, 2020. |
| Non-Final Office Action for U.S. Appl. No. 16/899,956 mailed Oct. 16, 2020. |
| Non-Final Office Action for U.S. Appl. No. 16/899,956 mailed Sep. 2, 2021. |
| Non-Final Office Action for U.S. Appl. No. 16/904,868 mailed Nov. 25, 2020. |
| Non-Final Office Action for U.S. Appl. No. 16/905,400 mailed Dec. 2, 2020. |
| Non-Final Office Action for U.S. Appl. No. 16/905,400 mailed Jul. 22, 2021. |
| Non-Final Office Action for U.S. Appl. No. 17/088,272 mailed Jan. 25, 2021. |
| Non-Final Office Action for U.S. Appl. No. 29/624,661 mailed Jul. 18, 2019. |
| Non-Final Office Action for U.S. Appl. No. 29/694,002 mailed Jun. 24, 2020. |
| Notice of Allowance for U.S. Appl. No. 14/952,591 mailed Apr. 5, 2021. |
| Notice of Allowance for U.S. Appl. No. 14/952,591 mailed Jul. 8, 2021. |
| Notice of Allowance for U.S. Appl. No. 15/171,968 mailed Feb. 16, 2021. |
| Notice of Allowance for U.S. Appl. No. 15/171,968 mailed Nov. 6, 2020. |
| Notice of Allowance for U.S. Appl. No. 15/221,106 mailed May 1, 2019. |
| Notice of Allowance for U.S. Appl. No. 15/238,427 mailed May 23, 2019. |
| Notice of Allowance for U.S. Appl. No. 15/260,103 mailed Jun. 7, 2019. |
| Notice of Allowance for U.S. Appl. No. 15/611,587 mailed Dec. 21, 2018. |
| Notice of Allowance for U.S. Appl. No. 15/612,325 mailed Feb. 19, 2021. |
| Notice of Allowance for U.S. Appl. No. 15/612,325 mailed Jan. 21, 2021. |
| Notice of Allowance for U.S. Appl. No. 17/088,272 mailed Aug. 5, 2021. |
| Notice of Allowance for U.S. Appl. No. 29/624,661 mailed Apr. 28, 2021. |
| Notice of Allowance for U.S. Appl. No. 29/624,661 mailed Jul. 10, 2020. |
| Notice of Allowance for U.S. Appl. No. 29/624,661 mailed May 14, 2020. |
| Notice of Allowance for U.S. Appl. No. 29/624,661 mailed Sep. 29, 2020. |
| Notice of Allowance for U.S. Appl. No. 29/694,002 mailed Apr. 29, 2021. |
| Notice of Allowance for U.S. Appl. No. 29/694,002 mailed Jan. 29, 2021. |
| Notice of Allowance for U.S. Appl. No. 29/694,002 mailed Oct. 16, 2020. |
| Notice to File Missing Parts for U.S. Appl. No. 17/179,116 mailed Mar. 3, 2021. |
| Restriction Requirement for U.S. Appl. No. 16/478,180 mailed May 25, 2021. |
| U.S. Appl. No. 15/171,968, filed Jun. 2, 2016. |
| U.S. Appl. No. 15/221,106, filed Jul. 27, 2016. |
| U.S. Appl. No. 15/260,103, filed Sep. 8, 2016. |
| U.S. Appl. No. 15/611,587, filed Jun. 1, 2017. |
| U.S. Appl. No. 15/612,325, filed Jun. 2, 2017. |
| U.S. Appl. No. 16/369,676, filed Mar. 29, 2019. |
| U.S. Appl. No. 16/433,773, filed Jun. 6, 2019. |
| U.S. Appl. No. 16/449,039, filed Jun. 21, 2019. |
| U.S. Appl. No. 16/452,145, filed Jun. 25, 2019. |
| U.S. Appl. No. 16/452,258, filed Jun. 25, 2019. |
| U.S. Appl. No. 16/478,180, filed Jul. 16, 2019. |
| U.S. Appl. No. 16/904,868, filed Jun. 18, 2020. |
| U.S. Appl. No. 16/905,400, filed Jun. 18, 2020. |
| U.S. Appl. No. 17/051,550, filed Oct. 29, 2020. |
| U.S. Appl. No. 17/051,554, filed Oct. 29, 2020. |
| U.S. Appl. No. 17/051,585, filed Oct. 29, 2020. |
| U.S. Appl. No. 17/051,600, filed Oct. 29, 2020. |
| U.S. Appl. No. 17/088,272, filed Nov. 3, 2020. |
| U.S. Appl. No. 17/179,116, filed Feb. 18, 2021. |
| U.S. Appl. No. 17/330,657, filed May 26, 2021. |
| U.S. Appl. No. 17/378,015, filed Jul. 16, 2021. |
| U.S. Appl. No. 17/444,825, filed Aug. 10, 2021. |
| U.S. Appl. No. 17/446,256, filed Aug. 27, 2021. |
| U.S. Appl. No. 17/446,654, filed Sep. 1, 2021. |
| U.S. Appl. No. 17/461,036 mailed Aug. 30, 2021. |
| U.S. Appl. No. 29/741,751, filed Jul. 15, 2020. |
| U.S. Appl. No. 62/452,437, filed Jan. 31, 2017. |
| U.S. Appl. No. 62/665,297, filed May 1, 2018. |
| U.S. Appl. No. 62/665,302, filed May 1, 2018. |
| U.S. Appl. No. 62/665,317, filed May 1, 2018. |
| U.S. Appl. No. 62/665,321, filed May 1, 2018. |
| U.S. Appl. No. 62/665,331, filed May 1, 2018. |
| U.S. Appl. No. 62/665,335, filed May 1, 2018. |
| U.S. Appl. No. 62/853,279, filed May 28, 2019. |
| U.S. Appl. No. 62/853,889, filed May 29, 2019. |
| U.S. Appl. No. 62/864,656, filed Jun. 21, 2019. |
| U.S. Appl. No. 62/873,045, filed Jul. 11, 2019. |
| U.S. Appl. No. 62/873,048, filed Jul. 11, 2019. |
| U.S. Appl. No. 62/876,500, filed Jul. 19, 2019. |
| U.S. Appl. No. 62/877,558, filed Jul. 23, 2019. |
| U.S. Appl. No. 62/883,172, filed Aug. 6, 2019. |
| U.S. Appl. No. 62/889,149, filed Aug. 20, 2019. |
| U.S. Appl. No. 62/938,447, filed Nov. 21, 2019. |
| U.S. Appl. No. 62/949,187, filed Dec. 17, 2019. |
| U.S. Appl. No. 62/956,756, filed Jan. 3, 2020. |
| U.S. Appl. No. 62/956,767, filed Jan. 3, 2020. |
| U.S. Appl. No. 62/956,770, filed Jan. 3, 2020. |
| U.S. Appl. No. 62/994,912, filed Mar. 26, 2020. |
| U.S. Appl. No. 63/011,445, filed Apr. 17, 2020. |
| U.S. Appl. No. 63/011,487, filed Apr. 17, 2020. |
| U.S. Appl. No. 63/011,571, filed Apr. 17, 2020. |
| U.S. Appl. No. 63/011,657, filed Apr. 17, 2020. |
| U.S. Appl. No. 63/011,760, filed Apr. 17, 2020. |
| U.S. Appl. No. 63/012,347, filed Apr. 20, 2020. |
| U.S. Appl. No. 63/012,384, filed Apr. 20, 2020. |
| U.S. Appl. No. 63/030,685, filed May 27, 2020. |
| U.S. Appl. No. 63/061,241, filed Aug. 5, 2020. |
| U.S. Appl. No. 63/061,244, filed Aug. 5, 2020. |
| U.S. Appl. No. 63/061,834, filed Aug. 6, 2020. |
| U.S. Appl. No. 63/064,017, filed Aug. 11, 2020. |
| U.S. Appl. No. 63/064,126, filed Aug. 11, 2020. |
| U.S. Appl. No. 63/067,542, filed Aug. 19, 2020. |
| U.S. Appl. No. 63/071,438, filed Aug. 28, 2020. |
| U.S. Appl. No. 63/073,545, filed Sep. 2, 2020. |
| U.S. Appl. No. 63/074,051, filed Sep. 3, 2020. |
| U.S. Appl. No. 63/074,066, filed Sep. 3, 2020. |
| U.S. Appl. No. 63/076,032, filed Sep. 9, 2020. |
| U.S. Appl. No. 63/076,474, filed Sep. 10, 2020. |
| U.S. Appl. No. 63/076,477, filed Sep. 10, 2020. |
| U.S. Appl. No. 63/082,261, filed Sep. 23, 2020. |
| U.S. Appl. No. 63/088,506, filed Oct. 7, 2020. |
| U.S. Appl. No. 63/088,511, filed Oct. 7, 2020. |
| U.S. Appl. No. 63/094,464, filed Oct. 21, 2020. |
| U.S. Appl. No. 63/094,498, filed Oct. 21, 2020. |
| U.S. Appl. No. 63/094,594, filed Oct. 21, 2020. |
| U.S. Appl. No. 63/094,608, filed Oct. 21, 2020. |
| U.S. Appl. No. 63/094,626, filed Oct. 21, 2020. |
| U.S. Appl. No. 63/109,066, filed Nov. 3, 2020. |
| U.S. Appl. No. 63/112,417, filed Nov. 11, 2020. |
| U.S. Appl. No. 63/119,161, filed Nov. 30, 2020. |
| U.S. Appl. No. 63/124,271, filed Dec. 11, 2020. |
| U.S. Appl. No. 63/134,287, filed Jan. 6, 2021. |
| U.S. Appl. No. 63/134,450, filed Jan. 6, 2021. |
| U.S. Appl. No. 63/134,631, filed Jan. 7, 2021. |
| U.S. Appl. No. 63/134,632, filed Jan. 7, 2021. |
| U.S. Appl. No. 63/134,754, filed Jan. 7, 2021. |
| U.S. Appl. No. 63/146,946, filed Feb. 8, 2021. |
| U.S. Appl. No. 63/147,013, filed Feb. 8, 2021. |
| U.S. Appl. No. 63/147,299, filed Feb. 9, 2021. |
| U.S. Appl. No. 63/148,723, filed Feb. 12, 2021. |
| U.S. Appl. No. 63/154,248, filed Feb. 26, 2021. |
| U.S. Appl. No. 63/155,395, filed Mar. 2, 2021. |
| U.S. Appl. No. 63/157,007, filed Mar. 5, 2021. |
| U.S. Appl. No. 63/157,014, filed Mar. 5, 2021. |
| U.S. Appl. No. 63/159,142, filed Mar. 10, 2021. |
| U.S. Appl. No. 63/159,210, filed Mar. 10, 2021. |
| U.S. Appl. No. 63/165,273, filed Mar. 24, 2021. |
| U.S. Appl. No. 63/165,384, filed Mar. 24, 2021. |
| U.S. Appl. No. 63/171,165, filed Apr. 6, 2021. |
| U.S. Appl. No. 63/172,975, filed Apr. 9, 2021. |
| U.S. Appl. No. 63/181,695, filed Apr. 29, 2021. |
| U.S. Appl. No. 63/192,274, filed May 24, 2021. |
| U.S. Appl. No. 63/193,235, filed May 26, 2021. |
| U.S. Appl. No. 63/193,406, filed May 26, 2021. |
| U.S. Appl. No. 63/214,551, filed Jun. 24, 2021. |
| U.S. Appl. No. 63/214,570, filed Jun. 24, 2021. |
| U.S. Appl. No. 63/228,252, filed Aug. 2, 2021. |
| U.S. Appl. No. 63/228,258, filed Aug. 2, 2021. |
| U.S. Appl. No. 63/230,894, filed Aug. 9, 2021. |
| U.S. Appl. No. 63/241,562, filed Sep. 8, 2021. |
| U.S. Appl. No. 63/241,564, filed Sep. 8, 2021. |
| U.S. Appl. No. 63/241,575, filed Sep. 8, 2021. |
| Defendant and Counterclaim Plaintiff Sage Products, LLC's Answer, Defenses, and Counterclaims to Plaintiff's Amended Complaint, Nov. 1, 2019. |
| Memorandum Order, Feb. 2021, 14 pgs. |
| Sage's Initial Invalidity Contentions Regarding U.S. Pat. Nos. 8,287,508; 10,226,375; and 10,390,989, May 29, 2020, 193 pages. |
| Sage's Supplemental and Initial Invalidity Contentions Regarding U.S. Pat. Nos. 8,287,508; 10,226,375; 10,390,989 and Initial Invalidity Contentions Regarding U.S. Pat. No. 10,376,407, Aug. 21, 2020, 277 pages. |
| Sage's Second Supplemental Invalidity Contentions Regarding U.S. Pat. Nos. 8,287,508, 10,226,375, 10,390,989, and 10,376,407, 292 pages. |
| Boehringer CareDry System—Second Generation for Non-Invasive Urinary Management for Females, Mar. 2021, 3 pgs |
| Excerpts from the 508 (U.S. Pat. No. 8,278,508) Patent's Prosecution History, 2020, 99 pages. |
| Plaintiff's Opening Claim Construction Brief, Case No. 19-1508-MN, Oct. 16, 2020, 26 pages. |
| Plaintiff's Identification of Claim Terms and Proposed Constructions, Case No. 19-1508-MN, 3 pages. |
| PureWick's Response to Interrogatory No. 9 in PureWick, LLC v. Sage Products, LLC, Case No. 19-1508-MN, Mar. 23, 2020, 6 pages. |
| Sage's Preliminary Identification of Claim Elements and Proposed Constructions for U.S. Pat. Nos. 8,287,508, 10,226,376, 10,390,989 and 10,376,407, Case No. 19-1508-MN, 7 pages. |
| Decision Granting Institution of Inter Partes Review for U.S. Pat. No. 8,287,508, Case No. 2020-01426, Feb. 17, 2021, 39 pages. |
| Corrected Certificate of Service, Case No. IPR2020-01426, U.S. Pat. No. 8,287,508, 2020, 2 pages. |
| Declaration of Diane K. Newman Curriculum Vitae, Petition for Interparties Review, 2020, pp. 1-199. |
| “3 Devices Take Top Honors in Dare-To-Dream Medtech Design Contest”, R+D Digest, Nov. 2013, 1 page. |
| “Advanced Mission Extender Device (AMDX) Products”, Omni Medical Systems, Inc., 15 pages. |
| “AMXD Control Starter Kit Brochure”, https://www.omnimedicalsys.com/index.php?page=products, Omni Medical, 8 pages. |
| “AMXDmax In-Flight Bladder Relief”, Omni Medical; Omni Medical Systems, Inc., 2015. |
| “AMXDX—Advanced Mission Extender Device Brochure”, Omni Medical, Omni Brochure—http://www.omnimedicalsys.com/uploads/AMXDFixedWing.pdf, 2 pages. |
| “External Urine Management for Female Anatomy”, https://www.stryker.com/us/en/sage/products/sage-primafit.html, Jul. 2020, 4 pages. |
| “High Absorbancy Cellulose Acetate Electrospun Nanofibers for Feminine Hygiene Application”, https://www.sciencedirect.com/science/article/abs/pii/S2352940716300701?via%3Dihub, Jul. 2016, 3 pages. |
| “How Period Panties Work”, www.shethinx.com/pages/thinx-itworks, 2020, 10 pages. |
| “Hydrogel properties of electrospun polyvinylpyrrolidone and polyvinylpyrrolidone/poly(acrylic acid) blend nanofibers”, https://pubs.rsc.org/en/content/articlelanding/2015/ra/c5ra07514a#!divAbstract, 2015, 5 pages. |
| “In Flight Bladder Relief”, Omni Medical, Omni Presentation https://www.omnimedicalsys.com/uploads/AMXDmax_HSD.pdf, 14 pages. |
| “Making Women's Sanitary Products Safer and Cheaper”, https://www.elsevier.com/connect/making-womens-sanitary-products-safer-and-cheaper, Sep. 2016, 10 pages. |
| “Novel Nanofibers Make Safe and Effective Absorbent for Sanitary Products”, https://www.materialstoday.com/nanomaterials/news/nanofibers-make-safe-and-effective-absorbent/, Oct. 2016, 3 pages. |
| “Research and Development Work Relating to Assistive Technology 2005-06”, British Department of Health, Nov. 2006, 40 pages. |
| “Step by Step How Ur24 WorksHome”, http://medicalpatentur24.com, last accessed Dec. 6, 2017, Aug. 30, 2017, 4 pages. |
| “Underwear that absorbs your period”, Thinx!, https://www.shethinx.com/pages/thinx-it-works last accessed Jun. 24, 2020, 7 pages. |
| “User & Maintenance Guide”, Omni Medical, 2007, 16 pages. |
| “Winners Announced for Dare-to-Dream Medtech Design Challenge”, https://www.mddionline.com/design-engineering/winners-announced-dare-dream-medtech-design-challenge, MD&DI, 2014, 4 pages. |
| Hollister, Female Urinary and Pouch and Male Urinary Pouch Brochure, 2011, 1 page. |
| Hollister, “Male Urinary Pouch External Collection Device”, http://www.hollister.com/en/products/Continence-Care-Products/Urine-Collectors/Urine-Collection-Accessories/Male-Urinary-Pouch-External-Collection-Device, last accessed Feb. 8, 2018. |
| Hollister, “Retracted Penis Pouch by Hollister”, Vitality Medical.com, https://www.vitalitymedical.com/hollister-retracted-penis-pouch.html last accessed Jun. 24, 2020, 6 pages. |
| Macaulay, et al., “A Noninvasive Continence Management System: Development and Evaluation of a Novel Toileting Device for Women”, The Wound, Ostomy and Continence Nurses Society, vol. 34 No. 6, 2007, pp. 641-648. |
| Newman, et al., “The Urinary Incontinence Sourcebook”, Petition for Interparties Review, 1997, 23 pages. |
| Newton, et al., “Measuring Safety, Effectiveness and Ease of Use of PureWick in the Management of Urinary Incontinence in Bedbound Women: Case Studies”, Jan. 8, 2016, 11 pages. |
| Parmar, “10 Finalists Chosen for Dare-to-Dream Medtech Design Challenge (PureWick)”, Design Services, Nov. 10, 2014, 3 pages. |
| Purewick, “Incontinence Relief for Women”, Presentation, Sep. 23, 2015, 7 pages. |
| Pytlik, “Super Absorbent Polymers”, University of Buffalo, http://www.courses.sens.buffalo.edu/ce435/Diapers/Diapers.html, accessed on Feb. 17, 2017. |
| Sachtman, “New Relief for Pilots? It Depends”, Wired, https://www.wired.com/2008/05/pilot-relief/, 2008, 2 pages. |
| Advisory Action for U.S. Appl. No. 16/245,726 mailed Apr. 19, 2023. |
| Advisory Action for U.S. Appl. No. 16/369,676 mailed Mar. 24, 2023. |
| Advisory Action for U.S. Appl. No. 16/433,773 mailed Dec. 29, 2023. |
| Advisory Action for U.S. Appl. No. 16/433,773 mailed Feb. 15, 2023. |
| Advisory Action for U.S. Appl. No. 16/449,039 mailed Jan. 25, 2024. |
| Advisory Action for U.S. Appl. No. 16/452,258 mailed Apr. 8, 2024. |
| Advisory Action for U.S. Appl. No. 16/452,258 mailed Oct. 26, 2022. |
| Advisory Action for U.S. Appl. No. 16/478,180 mailed Sep. 21, 2022. |
| Advisory Action for U.S. Appl. No. 16/478,180 mailed Sep. 7, 2023. |
| Advisory Action for U.S. Appl. No. 16/904,868 mailed Jan. 2, 2024. |
| Advisory Action for U.S. Appl. No. 16/904,868 mailed Jun. 15, 2022. |
| Advisory Action for U.S. Appl. No. 16/905,400 mailed Feb. 16, 2022. |
| Advisory Action for U.S. Appl. No. 17/051,550 mailed Sep. 8, 2023. |
| Advisory Action for U.S. Appl. No. 17/051,585 mailed Oct. 17, 2023. |
| Advisory Action for U.S. Appl. No. 17/179,116 mailed Jan. 8, 2024. |
| Advisory Action for U.S. Appl. No. 17/444,792 mailed Aug. 25, 2023. |
| Advisory Action for U.S. Appl. No. 17/446,256 mailed Dec. 8, 2023. |
| Advisory Action for U.S. Appl. No. 17/446,654 mailed Apr. 15, 2024. |
| Advisory Action for U.S. Appl. No. 17/448,811 mailed Nov. 15, 2023. |
| Advisory Action for U.S. Appl. No. 17/450,864 mailed on Mar. 21, 2024. |
| Advisory Action for U.S. Appl. No. 17/451,345 mailed Oct. 20, 2023. |
| Advisory Action for U.S. Appl. No. 17/451,354 mailed Jan. 30, 2024. |
| Advisory Action for U.S. Appl. No. 17/453,260 mailed Dec. 22, 2023. |
| Advisory Action for U.S. Appl. No. 17/501,591 mailed Feb. 22, 2024. |
| Advisory Action for U.S. Appl. No. 17/646,771 mailed Feb. 29, 2024. |
| Advisory Action for U.S. Appl. No. 17/653,137 mailed Dec. 1, 2023. |
| Advisory Action for U.S. Appl. No. 17/655,464 mailed Dec. 13, 2023. |
| Advisory Action for U.S. Appl. No. 17/661,090 mailed Feb. 26, 2024. |
| Advisory Action for U.S. Appl. No. 17/662,700 mailed Jan. 30, 2023. |
| Advisory Action for U.S. Appl. No. 17/663,330 mailed Feb. 27, 2024. |
| Advisory Action for U.S. Appl. No. 17/664,487 mailed Mar. 13, 2024. |
| Advisory Action for U.S. Appl. No. 18/164,800 mailed Feb. 12, 2024. |
| Communication of Notice of Opposition of European Application No. 17807547.9 mailed Jan. 5, 2024. |
| Corrected Notice of Allowability for U.S. Appl. No. 16/369,676 mailed Dec. 7, 2023. |
| Corrected Notice of Allowability for U.S. Appl. No. 17/326,980 mailed Feb. 8, 2024. |
| Corrected Notice of Allowability for U.S. Appl. No. 17/330,657 mailed Dec. 9, 2021. |
| Corrected Notice of Allowability for U.S. Appl. No. 17/657,474 mailed Mar. 13, 2024. |
| Final Office Action for U.S. Appl. No. 16/245,726 mailed Nov. 25, 2022. |
| Final Office Action for U.S. Appl. No. 16/369,676 mailed Aug. 31, 2023. |
| Final Office Action for U.S. Appl. No. 16/369,676 mailed Dec. 5, 2022. |
| Final Office Action for U.S. Appl. No. 16/433,773 mailed Oct. 10, 2023. |
| Final Office Action for U.S. Appl. No. 16/433,773 mailed Oct. 25, 2022. |
| Final Office Action for U.S. Appl. No. 16/449,039 mailed Aug. 1, 2022. |
| Final Office Action for U.S. Appl. No. 16/449,039 mailed Nov. 21, 2023. |
| Final Office Action for U.S. Appl. No. 16/452,145 mailed Mar. 25, 2022. |
| Final Office Action for U.S. Appl. No. 16/452,258 mailed Dec. 21, 2023. |
| Final Office Action for U.S. Appl. No. 16/452,258 mailed Jun. 14, 2022. |
| Final Office Action for U.S. Appl. No. 16/478,180 mailed Feb. 28, 2024. |
| Final Office Action for U.S. Appl. No. 16/478,180 mailed Jun. 22, 2022. |
| Final Office Action for U.S. Appl. No. 16/478,180 mailed May 31, 2023. |
| Final Office Action for U.S. Appl. No. 16/904,868 mailed Mar. 10, 2022. |
| Final Office Action for U.S. Appl. No. 16/904,868 mailed Nov. 2, 2023. |
| Final Office Action for U.S. Appl. No. 16/905,400 mailed Dec. 9, 2021. |
| Final Office Action for U.S. Appl. No. 17/051,399 mailed Jan. 8, 2024. |
| Final Office Action for U.S. Appl. No. 17/051,399 mailed Mar. 9, 2023. |
| Final Office Action for U.S. Appl. No. 17/051,550 mailed May 23, 2023. |
| Final Office Action for U.S. Appl. No. 17/051,585 mailed Jul. 27, 2023. |
| Final Office Action for U.S. Appl. No. 17/179,116 mailed Oct. 31, 2023. |
| Final Office Action for U.S. Appl. No. 17/444,792 mailed Apr. 3, 2024. |
| Final Office Action for U.S. Appl. No. 17/444,792 mailed Jun. 15, 2023. |
| Final Office Action for U.S. Appl. No. 17/446,256 mailed Sep. 19, 2023. |
| Final Office Action for U.S. Appl. No. 17/446,654 mailed Jan. 31, 2024. |
| Final Office Action for U.S. Appl. No. 17/448,811 mailed Aug. 3, 2023. |
| Final Office Action for U.S. Appl. No. 17/450,864 mailed Dec. 28, 2023. |
| Final Office Action for U.S. Appl. No. 17/451,345 mailed May 3, 2023. |
| Final Office Action for U.S. Appl. No. 17/451,354 mailed Oct. 30, 2023. |
| Final Office Action for U.S. Appl. No. 17/453,260 mailed Oct. 5, 2023. |
| Final Office Action for U.S. Appl. No. 17/501,591 mailed Nov. 14, 2023. |
| Final Office Action for U.S. Appl. No. 17/645,821 mailed Apr. 3, 2024. |
| Final Office Action for U.S. Appl. No. 17/646,771 mailed Dec. 21, 2023. |
| Final Office Action for U.S. Appl. No. 17/653,137 mailed Sep. 21, 2023. |
| Final Office Action for U.S. Appl. No. 17/655,464 mailed Sep. 1, 2023. |
| Final Office Action for U.S. Appl. No. 17/661,090 mailed Dec. 11, 2023. |
| Final Office Action for U.S. Appl. No. 17/662,700 mailed Sep. 30, 2022. |
| Final Office Action for U.S. Appl. No. 17/663,330 mailed Dec. 12, 2023. |
| Final Office Action for U.S. Appl. No. 17/664,487 mailed Jan. 4, 2024. |
| Final Office Action for U.S. Appl. No. 17/808,354 mailed Apr. 10, 2024. |
| Final Office Action for U.S. Appl. No. 18/139,523 mailed Dec. 22, 2023. |
| Final Office Action for U.S. Appl. No. 18/140,163 mailed Mar. 27, 2024. |
| Final Office Action for U.S. Appl. No. 18/140,751 mailed Jan. 17, 2024. |
| Final Office Action for U.S. Appl. No. 18/164,800 mailed Dec. 6, 2023. |
| International Search Report and Written Opinion from International Application No. PCT/IB2021/057173 mailed Nov. 5, 2021. |
| International Search Report and Written Opinion from International Application No. PCT/US2020/057562 mailed Jan. 27, 2021. |
| International Search Report and Written Opinion from International Application No. PCT/US2021/015024 mailed May 18, 2021. |
| International Search Report and Written Opinion from International Application No. PCT/US2021/024162 mailed Jul. 8, 2021. |
| International Search Report and Written Opinion from International Application No. PCT/US2021/026607 mailed Jul. 29, 2021. |
| International Search Report and Written Opinion from International Application No. PCT/US2021/039866 mailed Oct. 7, 2021. |
| International Search Report and Written Opinion from International Application No. PCT/US2021/043893 mailed Nov. 22, 2021. |
| International Search Report and Written Opinion from International Application No. PCT/US2021/044699 mailed Nov. 22, 2021. |
| International Search Report and Written Opinion from International Application No. PCT/US2021/045188 mailed Jan. 26, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2021/047536 mailed Dec. 23, 2021. |
| International Search Report and Written Opinion from International Application No. PCT/US2021/048211 mailed Dec. 22, 2021. |
| International Search Report and Written Opinion from International Application No. PCT/US2021/048661 mailed Feb. 14, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2021/049404 mailed Jan. 18, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2021/051456 mailed Jan. 19, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2021/053593 mailed Apr. 11, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2021/055515 mailed Jan. 28, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2021/056566 mailed Feb. 11, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2021/060993 mailed Mar. 18, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2021/062440 mailed Mar. 28, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/011108 mailed Apr. 22, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/011281 mailed Apr. 25, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/011419 mailed Jun. 7, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/011421 mailed Jun. 13, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/012794 mailed May 3, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/014285 mailed Sep. 28, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/014749 mailed Sep. 28, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/015026 mailed Oct. 31, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/015045 mailed Sep. 9, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/015073 mailed Sep. 8, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/015418 mailed Nov. 11, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/015420 mailed Nov. 18, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/015471 mailed May 16, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/015492 mailed Apr. 26, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/015781 mailed May 6, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/016942 mailed Jun. 8, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/018159 mailed Dec. 12, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/018170 mailed May 31, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/019254 mailed Jun. 7, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/019480 mailed Jun. 13, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/021103 mailed Jun. 23, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/022111 mailed Oct. 26, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/023594 mailed Jul. 12, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/026667 mailed Aug. 22, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/030685 mailed Oct. 31, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/031032 mailed Sep. 9, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/032424 mailed Oct. 11, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/034457 mailed Oct. 12, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/034744 mailed Dec. 9, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/039018 mailed Jan. 10, 2023. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/039022 mailed Jan. 10, 2023. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/039711 mailed Jan. 12, 2023. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/039714 mailed Nov. 22, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/041085 mailed Mar. 16, 2023. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/041688 mailed Nov. 21, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/042719 mailed Dec. 5, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/042725 mailed Dec. 19, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/043818 mailed Mar. 24, 2023. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/044107 mailed Dec. 23, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/044208 mailed May 8, 2023. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/044212 mailed Jan. 20, 2023. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/044243 mailed Feb. 24, 2023. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/049300 mailed Jun. 6, 2023. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/050909 mailed Jul. 24, 2023. |
| International Search Report and Written Opinion from International Application No. PCT/US2023/012696 mailed Jul. 6, 2023. |
| International Search Report and Written Opinion from International Application No. PCT/US2023/018474 mailed Sep. 11, 2023. |
| International Search Report and Written Opinion from International Application No. PCT/US2023/024805 mailed Dec. 14, 2023. |
| International Search Report and Written Opinion from International Application No. PCT/US2023/025192 mailed Feb. 7, 2024. |
| International Search Report and Written Opinion from International Application No. PCT/US2023/025939 mailed Feb. 7, 2024. |
| International Search Report and Written Opinion from International Application No. PCT/US2023/030373 mailed Mar. 13, 2024. |
| International Search Report and Written Opinion from International Application No. PCT/US2023/031433 mailed Mar. 4, 2024. |
| International Search Report and Written Opinion from International Application No. PCT/US2023/031740 mailed Mar. 4, 2024. |
| Issue Notification for U.S. Appl. No. 16/245,726 mailed Oct. 18, 2023. |
| Issue Notification for U.S. Appl. No. 16/899,956 mailed Mar. 29, 2023. |
| Issue Notification for U.S. Appl. No. 16/905,400 mailed Nov. 30, 2022. |
| Issue Notification for U.S. Appl. No. 17/051,550 mailed Mar. 13, 2024. |
| Issue Notification for U.S. Appl. No. 17/051,554 mailed Mar. 6, 2024. |
| Issue Notification for U.S. Appl. No. 17/088,272 mailed Jun. 15, 2022. |
| Issue Notification for U.S. Appl. No. 17/330,657 mailed Jun. 22, 2022. |
| Issue Notification for U.S. Appl. No. 17/461,036 mailed Oct. 11, 2023. |
| Issue Notification for U.S. Appl. No. 17/663,046 mailed Dec. 20, 2023. |
| Issue Notification for U.S. Appl. No. 18/299,788 mailed Feb. 21, 2024. |
| Non-Final Office Action for U.S. Appl. No. 16/245,726 mailed Jan. 21, 2022. |
| Non-Final Office Action for U.S. Appl. No. 16/369,676 mailed Feb. 29, 2024. |
| Non-Final Office Action for U.S. Appl. No. 16/369,676 mailed Mar. 31, 2022. |
| Non-Final Office Action for U.S. Appl. No. 16/433,773 mailed Apr. 11, 2023. |
| Non-Final Office Action for U.S. Appl. No. 16/433,773 mailed Apr. 21, 2022. |
| Non-Final Office Action for U.S. Appl. No. 16/433,773 mailed Feb. 26, 2024. |
| Non-Final Office Action for U.S. Appl. No. 16/449,039 mailed Apr. 27, 2023. |
| Non-Final Office Action for U.S. Appl. No. 16/449,039 mailed Dec. 8, 2021. |
| Non-Final Office Action for U.S. Appl. No. 16/452,145 mailed Mar. 28, 2023. |
| Non-Final Office Action for U.S. Appl. No. 16/452,145 mailed Nov. 2, 2023. |
| Non-Final Office Action for U.S. Appl. No. 16/452,145 mailed Sep. 28, 2021. |
| Non-Final Office Action for U.S. Appl. No. 16/452,258 mailed Apr. 26, 2023. |
| Non-Final Office Action for U.S. Appl. No. 16/452,258 mailed Sep. 28, 2021. |
| Non-Final Office Action for U.S. Appl. No. 16/478,180 mailed Dec. 20, 2022. |
| Non-Final Office Action for U.S. Appl. No. 16/478,180 mailed Nov. 7, 2023. |
| Non-Final Office Action for U.S. Appl. No. 16/478,180 mailed Oct. 22, 2021. |
| Non-Final Office Action for U.S. Appl. No. 16/904,868 mailed Mar. 12, 2024. |
| Non-Final Office Action for U.S. Appl. No. 16/904,868 mailed Mar. 15, 2023. |
| Non-Final Office Action for U.S. Appl. No. 16/904,868 mailed Oct. 5, 2021. |
| Non-Final Office Action for U.S. Appl. No. 16/905,400 mailed Apr. 27, 2022. |
| Non-Final Office Action for U.S. Appl. No. 17/051,399 mailed Aug. 18, 2023. |
| Non-Final Office Action for U.S. Appl. No. 17/051,550 mailed Dec. 15, 2022. |
| Non-Final Office Action for U.S. Appl. No. 17/051,550 mailed Oct. 24, 2023. |
| Non-Final Office Action for U.S. Appl. No. 17/051,585 mailed Jan. 8, 2024. |
| Non-Final Office Action for U.S. Appl. No. 17/051,585 mailed Mar. 29, 2023. |
| Non-Final Office Action for U.S. Appl. No. 17/051,600 mailed Jan. 17, 2024. |
| Non-Final Office Action for U.S. Appl. No. 17/179,116 mailed Feb. 26, 2024. |
| Non-Final Office Action for U.S. Appl. No. 17/179,116 mailed Mar. 24, 2023. |
| Non-Final Office Action for U.S. Appl. No. 17/326,980 mailed Jul. 11, 2023. |
| Non-Final Office Action for U.S. Appl. No. 17/330,657 mailed Aug. 11, 2021. |
| Non-Final Office Action for U.S. Appl. No. 17/444,792 mailed Feb. 10, 2023. |
| Non-Final Office Action for U.S. Appl. No. 17/444,792 mailed Nov. 17, 2023. |
| Non-Final Office Action for U.S. Appl. No. 17/446,256 mailed Apr. 13, 2023. |
| Non-Final Office Action for U.S. Appl. No. 17/446,256 mailed Feb. 13, 2024. |
| Non-Final Office Action for U.S. Appl. No. 17/446,654 mailed Sep. 8, 2023. |
| Non-Final Office Action for U.S. Appl. No. 17/448,811 mailed Jan. 17, 2024. |
| Non-Final Office Action for U.S. Appl. No. 17/448,811 mailed Mar. 1, 2023. |
| Non-Final Office Action for U.S. Appl. No. 17/450,864 mailed May 10, 2023. |
| Non-Final Office Action for U.S. Appl. No. 17/451,345 mailed Dec. 7, 2022. |
| Non-Final Office Action for U.S. Appl. No. 17/451,345 mailed Jan. 17, 2024. |
| Non-Final Office Action for U.S. Appl. No. 17/451,354 mailed Apr. 4, 2024. |
| Non-Final Office Action for U.S. Appl. No. 17/451,354 mailed May 3, 2023. |
| Non-Final Office Action for U.S. Appl. No. 17/453,260 mailed Mar. 14, 2023. |
| Non-Final Office Action for U.S. Appl. No. 17/453,560 mailed Oct. 16, 2023. |
| Non-Final Office Action for U.S. Appl. No. 17/501,591 mailed Apr. 25, 2023. |
| Non-Final Office Action for U.S. Appl. No. 17/597,673 mailed Mar. 20, 2024. |
| Non-Final Office Action for U.S. Appl. No. 17/645,821 mailed Oct. 25, 2023. |
| Non-Final Office Action for U.S. Appl. No. 17/646,771 mailed Jul. 5, 2023. |
| Non-Final Office Action for U.S. Appl. No. 17/653,137 mailed Apr. 7, 2023. |
| Non-Final Office Action for U.S. Appl. No. 17/653,137 mailed Jan. 18, 2024. |
| Non-Final Office Action for U.S. Appl. No. 17/653,920 mailed Mar. 15, 2024. |
| Non-Final Office Action for U.S. Appl. No. 17/655,464 mailed Mar. 14, 2023. |
| Non-Final Office Action for U.S. Appl. No. 17/655,464 mailed Mar. 26, 2024. |
| Non-Final Office Action for U.S. Appl. No. 17/657,474 mailed Sep. 12, 2023. |
| Non-Final Office Action for U.S. Appl. No. 17/661,090 mailed Jul. 6, 2023. |
| Non-Final Office Action for U.S. Appl. No. 17/662,700 mailed Jul. 22, 2022. |
| Non-Final Office Action for U.S. Appl. No. 17/663,330 mailed Jun. 29, 2023. |
| Non-Final Office Action for U.S. Appl. No. 17/664,487 mailed Jun. 8, 2023. |
| Non-Final Office Action for U.S. Appl. No. 17/664,914 mailed Jan. 31, 2024. |
| Non-Final Office Action for U.S. Appl. No. 17/808,354 mailed Nov. 28, 2023. |
| Non-Final Office Action for U.S. Appl. No. 18/003,029 mailed Mar. 26, 2024. |
| Non-Final Office Action for U.S. Appl. No. 18/134,857 mailed Jan. 25, 2024. |
| Non-Final Office Action for U.S. Appl. No. 18/139,523 mailed Aug. 17, 2023. |
| Non-Final Office Action for U.S. Appl. No. 18/140,163 mailed Nov. 9, 2023. |
| Non-Final Office Action for U.S. Appl. No. 18/140,751 mailed Sep. 14, 2023. |
| Non-Final Office Action for U.S. Appl. No. 18/164,800 mailed Mar. 22, 2024. |
| Non-Final Office Action for U.S. Appl. No. 18/198,464 mailed Dec. 7, 2023. |
| Non-Final Office Action for U.S. Appl. No. 29/741,751 mailed Jan. 18, 2022. |
| Notice of Allowance for U.S. Appl. No. 16/245,726 mailed Jul. 6, 2023. |
| Notice of Allowance for U.S. Appl. No. 16/369,676 mailed Nov. 14, 2023. |
| Notice of Allowance for U.S. Appl. No. 16/449,039 mailed Dec. 15, 2022. |
| Notice of Allowance for U.S. Appl. No. 16/449,039 mailed Mar. 28, 2024. |
| Notice of Allowance for U.S. Appl. No. 16/899,956 mailed Apr. 19, 2022. |
| Notice of Allowance for U.S. Appl. No. 16/899,956 mailed Aug. 10, 2022. |
| Notice of Allowance for U.S. Appl. No. 16/899,956 mailed Dec. 1, 2022. |
| Notice of Allowance for U.S. Appl. No. 16/899,956 mailed Dec. 29, 2021. |
| Notice of Allowance for U.S. Appl. No. 16/905,400 mailed Aug. 17, 2022. |
| Notice of Allowance for U.S. Appl. No. 17/051,550 mailed Feb. 7, 2024. |
| Notice of Allowance for U.S. Appl. No. 17/051,554 mailed Jul. 6, 2023. |
| Notice of Allowance for U.S. Appl. No. 17/051,554 mailed Oct. 18, 2023. |
| Notice of Allowance for U.S. Appl. No. 17/088,272 mailed Mar. 4, 2022. |
| Notice of Allowance for U.S. Appl. No. 17/088,272 mailed Nov. 24, 2021. |
| Notice of Allowance for U.S. Appl. No. 17/326,980 mailed Apr. 5, 2024. |
| Notice of Allowance for U.S. Appl. No. 17/326,980 mailed Jan. 29, 2024. |
| Notice of Allowance for U.S. Appl. No. 17/330,657 mailed Mar. 16, 2022. |
| Notice of Allowance for U.S. Appl. No. 17/330,657 mailed Nov. 26, 2021. |
| Notice of Allowance for U.S. Appl. No. 17/453,260 mailed Apr. 8, 2024. |
| Notice of Allowance for U.S. Appl. No. 17/453,560 mailed Jan. 31, 2024. |
| Notice of Allowance for U.S. Appl. No. 17/461,036 mailed Feb. 22, 2023. |
| Notice of Allowance for U.S. Appl. No. 17/461,036 mailed Jun. 30, 2023. |
| Notice of Allowance for U.S. Appl. No. 17/461,036 mailed Oct. 6, 2022. |
| Notice of Allowance for U.S. Appl. No. 17/657,474 mailed Mar. 5, 2024. |
| Notice of Allowance for U.S. Appl. No. 17/662,700 mailed Jul. 28, 2023. |
| Notice of Allowance for U.S. Appl. No. 17/662,700 mailed Mar. 28, 2023. |
| Notice of Allowance for U.S. Appl. No. 17/662,700 mailed Mar. 6, 2024. |
| Notice of Allowance for U.S. Appl. No. 17/662,700 mailed Nov. 15, 2023. |
| Notice of Allowance for U.S. Appl. No. 17/663,046 mailed Jan. 30, 2023. |
| Notice of Allowance for U.S. Appl. No. 18/299,788 mailed Jul. 24, 2023. |
| Notice of Allowance for U.S. Appl. No. 18/299,788 mailed Nov. 6, 2023. |
| Notice of Allowance for U.S. Appl. No. 29/741,751 mailed Jun. 9, 2022. |
| Restriction Requirement for U.S. Appl. No. 16/433,773 mailed Dec. 7, 2021. |
| Restriction Requirement for U.S. Appl. No. 17/051,600 mailed Sep. 21, 2023. |
| Restriction Requirement for U.S. Appl. No. 17/326,980 mailed Mar. 20, 2023. |
| Restriction Requirement for U.S. Appl. No. 17/446,256 mailed Jan. 23, 2023. |
| Restriction Requirement for U.S. Appl. No. 17/645,821 mailed Jul. 12, 2023. |
| Restriction Requirement for U.S. Appl. No. 17/646,771 mailed Apr. 6, 2023. |
| Restriction Requirement for U.S. Appl. No. 17/657,474 mailed Jun. 30, 2023. |
| Restriction Requirement for U.S. Appl. No. 17/667,097 mailed Mar. 20, 2024. |
| Restriction Requirement for U.S. Appl. No. 18/134,857 mailed Oct. 23, 2023. |
| Submission in Opposition Proceedings for European Application No. 17807547.9 filed Jan. 10, 2024. |
| Supplemental Notice of Allowance for U.S. Appl. No. 17/051,550 mailed Feb. 21, 2024. |
| Supplemental Notice of Allowance for U.S. Appl. No. 17/051,554 mailed Feb. 14, 2024. |
| Text Messages to Lorena Eckert Re Prototype PureWick Holder dated Apr. 16, 2022. |
| U.S. Appl. No. 14/625,469, filed Feb. 28, 2015. |
| U.S. Appl. No. 14/947,759, filed Nov. 20, 2015. |
| U.S. Appl. No. 14/952,591, filed Nov. 25, 2015. |
| U.S. Appl. No. 15/384,196, filed Dec. 19, 2016. |
| U.S. Appl. No. 16/245,726, filed Jan. 11, 2019. |
| U.S. Appl. No. 17/394,055, filed Aug. 4, 2021. |
| U.S. Appl. No. 17/444,792, filed Aug. 10, 2021. |
| U.S. Appl. No. 17/450,864, filed Oct. 14, 2021. |
| U.S. Appl. No. 17/451,345, filed Oct. 19, 2021. |
| U.S. Appl. No. 17/451,354, filed Oct. 19, 2021. |
| U.S. Appl. No. 17/451,719, filed Oct. 19, 2021. |
| U.S. Appl. No. 17/453,260, filed Nov. 2, 2021. |
| U.S. Appl. No. 17/453,560, filed Nov. 4, 2021. |
| U.S. Appl. No. 17/501,591, filed Oct. 14, 2021. |
| U.S. Appl. No. 17/595,747, filed Nov. 23, 2021. |
| U.S. Appl. No. 17/597,408, filed Jan. 5, 2022. |
| U.S. Appl. No. 17/597,673, filed Jan. 18, 2022. |
| U.S. Appl. No. 17/614,173, filed Nov. 24, 2021. |
| U.S. Appl. No. 17/631,619, filed Jan. 31, 2022. |
| U.S. Appl. No. 17/645,821, filed Dec. 23, 2021. |
| U.S. Appl. No. 17/646,771, filed Jan. 3, 2022. |
| U.S. Appl. No. 17/653,314, filed Mar. 3, 2022. |
| U.S. Appl. No. 17/653,920, filed Mar. 8, 2022. |
| U.S. Appl. No. 17/655,464, filed Mar. 18, 2022. |
| U.S. Appl. No. 17/657,474, filed Mar. 31, 2022. |
| U.S. Appl. No. 17/661,090, filed Apr. 28, 2022. |
| U.S. Appl. No. 17/662,700, filed May 10, 2022. |
| U.S. Appl. No. 17/663,046, filed May 12, 2022. |
| U.S. Appl. No. 17/664,487, filed May 23, 2022. |
| U.S. Appl. No. 17/664,914, filed May 25, 2022. |
| U.S. Appl. No. 17/749,340, filed May 20, 2022. |
| U.S. Appl. No. 17/754,736, filed Apr. 11, 2022. |
| U.S. Appl. No. 17/756,201, filed May 19, 2022. |
| U.S. Appl. No. 17/758,152, filed Jun. 29, 2022. |
| U.S. Appl. No. 17/758,316, filed Jul. 1, 2022. |
| U.S. Appl. No. 17/759,697, filed Jul. 28, 2022. |
| U.S. Appl. No. 17/878,268, filed Aug. 1, 2022. |
| U.S. Appl. No. 17/907,125, filed Sep. 23, 2022. |
| U.S. Appl. No. 17/912,147, filed Sep. 16, 2022. |
| U.S. Appl. No. 17/929,887, filed Sep. 6, 2022. |
| U.S. Appl. No. 17/930,238, filed Sep. 7, 2022. |
| U.S. Appl. No. 17/933,590, filed Sep. 20, 2022. |
| U.S. Appl. No. 17/996,064, filed Oct. 12, 2022. |
| U.S. Appl. No. 17/996,155, filed Oct. 13, 2022. |
| U.S. Appl. No. 17/996,253, filed Oct. 14, 2022. |
| U.S. Appl. No. 17/996,468, filed Oct. 18, 2022. |
| U.S. Appl. No. 17/996,556, filed Oct. 19, 2022. |
| U.S. Appl. No. 18/003,029, filed Dec. 22, 2022. |
| U.S. Appl. No. 18/006,807, filed Jan. 25, 2023. |
| U.S. Appl. No. 18/007,105, filed Jan. 27, 2023. |
| U.S. Appl. No. 18/041,109, filed Feb. 9, 2023. |
| U.S. Appl. No. 18/042,842, filed Feb. 24, 2023. |
| U.S. Appl. No. 18/043,618, filed Mar. 1, 2023. |
| U.S. Appl. No. 18/115,444, filed Feb. 28, 2023. |
| U.S. Appl. No. 18/134,857, filed Apr. 14, 2023. |
| U.S. Appl. No. 18/140,163, filed Apr. 27, 2023. |
| U.S. Appl. No. 18/140,751, filed Apr. 28, 2023. |
| U.S. Appl. No. 18/164,800, filed Feb. 6, 2023. |
| U.S. Appl. No. 18/198,464, filed May 17, 2023. |
| U.S. Appl. No. 18/246,121, filed Mar. 21, 2023. |
| U.S. Appl. No. 18/247,986, filed Apr. 5, 2023. |
| U.S. Appl. No. 18/249,577, filed Oct. 19, 2021. |
| U.S. Appl. No. 18/259,626, filed Jun. 28, 2023. |
| U.S. Appl. No. 18/260,122, filed Jun. 30, 2023. |
| U.S. Appl. No. 18/260,391, filed Jul. 5, 2023. |
| U.S. Appl. No. 18/260,394, filed Jul. 5, 2023. |
| U.S. Appl. No. 18/263,800, filed Aug. 1, 2023. |
| U.S. Appl. No. 18/264,004, filed Aug. 2, 2023. |
| U.S. Appl. No. 18/265,736, filed Jun. 7, 2023. |
| U.S. Appl. No. 18/294,370, filed Feb. 1, 2024. |
| U.S. Appl. No. 18/294,403, filed Feb. 1, 2024. |
| U.S. Appl. No. 18/299,788, filed Apr. 13, 2023. |
| U.S. Appl. No. 18/335,579, filed Jun. 15, 2023. |
| U.S. Appl. No. 18/373,424, filed Sep. 27, 2023. |
| U.S. Appl. No. 18/376,274, filed Oct. 3, 2023. |
| U.S. Appl. No. 18/389,009, filed Nov. 13, 2023. |
| U.S. Appl. No. 18/415,080, filed Jan. 17, 2024. |
| U.S. Appl. No. 18/426,795, filed Jan. 30, 2024. |
| U.S. Appl. No. 18/548,152, filed Aug. 28, 2023. |
| U.S. Appl. No. 18/549,387, filed Sep. 7, 2023. |
| U.S. Appl. No. 18/549,658, filed Sep. 8, 2023. |
| U.S. Appl. No. 18/553,625, filed Oct. 2, 2023. |
| U.S. Appl. No. 18/556,945, filed Oct. 24, 2023. |
| U.S. Appl. No. 18/558,502, filed Nov. 1, 2023. |
| U.S. Appl. No. 18/562,626, filed Nov. 20, 2023. |
| U.S. Appl. No. 18/563,672, filed Nov. 22, 2023. |
| U.S. Appl. No. 18/569,711, filed Dec. 13, 2023. |
| U.S. Appl. No. 18/569,778, filed Dec. 13, 2023. |
| U.S. Appl. No. 18/584,002, filed Feb. 22, 2024. |
| U.S. Appl. No. 18/610,523, filed Mar. 20, 2024. |
| U.S. Appl. No. 18/681,987, filed Feb. 7, 2024. |
| U.S. Appl. No. 18/682,006, filed Feb. 7, 2024. |
| U.S. Appl. No. 18/687,117, filed Feb. 27, 2024. |
| U.S. Appl. No. 18/688,023, filed Feb. 29, 2024. |
| U.S. Appl. No. 18/693,638, filed Mar. 20, 2024. |
| U.S. Appl. No. 18/694,090, filed Mar. 21, 2024. |
| U.S. Appl. No. 61/955,537, filed Mar. 19, 2014. |
| U.S. Appl. No. 62/082,279, filed Nov. 20, 2014. |
| U.S. Appl. No. 62/084,078, filed Nov. 25, 2014. |
| U.S. Appl. No. 62/414,963, filed Oct. 31, 2016. |
| U.S. Appl. No. 62/485,578, filed Apr. 14, 2017. |
| U.S. Appl. No. 62/923,279, filed Oct. 18, 2019. |
| U.S. Appl. No. 62/926,767, filed Oct. 28, 2019. |
| U.S. Appl. No. 62/935,337, filed Nov. 14, 2019. |
| U.S. Appl. No. 62/967,158, filed Jan. 26, 2020. |
| U.S. Appl. No. 62/967,977, filed Jan. 30, 2020. |
| U.S. Appl. No. 62/991,754, filed Mar. 19, 2020. |
| U.S. Appl. No. 63/008,112, filed Apr. 10, 2020. |
| U.S. Appl. No. 63/047,374, filed Jul. 2, 2020. |
| U.S. Appl. No. 63/073,553, filed Sep. 2, 2020. |
| U.S. Appl. No. 63/094,646, filed Oct. 21, 2020. |
| U.S. Appl. No. 63/109,084, filed Nov. 3, 2020. |
| U.S. Appl. No. 63/133,892, filed Jan. 5, 2021. |
| U.S. Appl. No. 63/138,878, filed Jan. 19, 2021. |
| U.S. Appl. No. 63/150,640, filed Feb. 18, 2021. |
| U.S. Appl. No. 63/159,186, filed Mar. 10, 2021. |
| U.S. Appl. No. 63/191,558, filed May 21, 2021. |
| U.S. Appl. No. 63/192,289, filed May 24, 2021. |
| U.S. Appl. No. 63/193,891, filed May 27, 2021. |
| U.S. Appl. No. 63/208,262, filed Jun. 8, 2021. |
| U.S. Appl. No. 63/215,017, filed Jun. 25, 2021. |
| U.S. Appl. No. 63/228,244, filed Aug. 2, 2021. |
| U.S. Appl. No. 63/230,897, filed Aug. 9, 2021. |
| U.S. Appl. No. 63/238,457, filed Aug. 30, 2021. |
| U.S. Appl. No. 63/238,477, filed Aug. 30, 2021. |
| U.S. Appl. No. 63/241,328, filed Sep. 7, 2021. |
| U.S. Appl. No. 63/246,972, filed Sep. 22, 2021. |
| U.S. Appl. No. 63/247,375, filed Sep. 23, 2021. |
| U.S. Appl. No. 63/247,478, filed Sep. 23, 2021. |
| U.S. Appl. No. 63/247,491, filed Sep. 23, 2021. |
| U.S. Appl. No. 63/299,208, filed Jan. 13, 2022. |
| U.S. Appl. No. 63/308,190, filed Feb. 9, 2022. |
| U.S. Appl. No. 63/561,893, filed Dec. 11, 2023. |
| U.S. Appl. No. 63/596,012, filed Nov. 3, 2023. |
| U.S. Appl. No. 63/608,553, filed Dec. 11, 2023. |
| PureWick Corporation v. Sage Products, LLC Transcripts vol. 2, Mar. 29, 2022. |
| PureWick Corporation v. Sage Products, LLC Transcripts vol. 3, Mar. 30, 2022. |
| PureWick Corporation v. Sage Products, LLC Transcripts vol. 4, Mar. 31, 2022. |
| PureWick Corporation v. Sage Products, LLC Transcripts vol. 5, Apr. 1, 2022. |
| PureWick Corporation v. Sage Products, LLC Transcripts vol. 1, Mar. 28, 2022. |
| “AMXD Control Starter Kit”, Omni Medical Systems, Inc., 1 page. |
| “AMXDmax Advanced Mission Extender Device User & Maintenance Guide”, Omni Medical, Jan. 11, 2010, 10 pages. |
| “AMXDmax Development History 2002-2014”, Omni Medical Systems, Inc., 2 pages. |
| “Combat Force Multiplier in Flight Bladder Relief Cockpit Essential Equipment Brochure”, Omni Medical, 20 pages. |
| “GSA Price List”, Omni Medical, Apr. 2011, 2 pages. |
| “How is Polypropylene Fiber Made”, https:www.yarnsandfibers.com/textile-resources/synthetic-fibers/polypropylene-fiber/polypropylene-fiber-production-raw-materials/how-is-polypropylene-fiber-made/ last accessed 2020, Oct. 7, 2020, 3 pages. |
| “Letter to Mark Harvie of Omni Measurement Systems”, Department of Veterans Affairs, Nov. 1, 2007, 11 pages. |
| “Revised AMXDmax Advanced Mission Extender Device User & Maintenance Guide”, Omni Medical Systems, Oct. 8, 2019, 52 pages. |
| “Rising Warrior Insulated Gallon Jug Cover”, https://www.amazon.com/Rising-Warrior-Insulated-Sleeve, 2021, 2 pages. |
| “Urine Bag Cover—Catheter Bag Cover 2000 ml Volume—Medline Style—Multiple Sclerosis—Spine Injury—Suprapublic Catheter—Bladder Incontinence”, https://www.etsy.com/listing/1142934658/urine-bag-cover-caatheter-bag-cover-2000, 2022, 1 page. |
| “Vinyl Dust Cover, Janome #741811000, Janome, Sewing Parts Online”, https://www.sewingpartsonline.com/vinyl-dust-cover-janome-74181000, 2020, 2 pages. |
| Ali, “Sustainability Assessment: Seventh Generation Diapers versus gDiapers”, The University of Vermont, Dec. 6, 2011, pp. 1-31. |
| Autumn, et al., “Frictional adhesion: a new angle on gecko attachment”, The Journal of Experimental Biology, 2006, pp. 3569-3579. |
| Cañas, et al., “Effect of nano- and micro-roughness on adhesion of bioinspired micropatterned surfaces”, Acta Biomaterialia 8, 2012, pp. 282-288. |
| Chaudhary, et al., “Bioinspired dry adhesive: Poly(dimethylsiloxane) grafted with poly(2-ethylhexyl acrylate) brushes”, European Polymer Journal, 2015, pp. 432-440. |
| Dai, et al., “Non-sticky and Non-slippery Biomimetic Patterned Surfaces”, Journal of Bionic Engineering, Mar. 2020, pp. 326-334. |
| Espinoza-Ramirez, “Nanobiodiversity and Biomimetic Adhesives Development: From Nature to Production and Application”, Journal of Biomaterials and Nanobiotechnology, pp. 78-101, 2019. |
| Hwang, et al., “Multifunctional Smart Skin Adhesive Patches for Advanced Health Care”, Adv. Healthcare Mater, 2018, pp. 1-20. |
| Jagota, et al., “Adhesion, friction, and compliance of bio-mimetic and bio-inspired structured interfaces”, Materials Science and Engineering, 2011, pp. 253-292. |
| Jeong, et al., “A nontransferring dry adhesive with hierarchical polymer nanohairs”, PNAS, Apr. 7, 2009, pp. 5639-5644. |
| Jeong, et al., “Nanohairs and nanotubes: Efficient structural elements for gecko-inspired artificial dry adhesives”, Science Direct, 2009, pp. 335-346. |
| Karp, et al., “Dry solution to a sticky problem”, Nature., 2011, pp. 42-43. |
| Lee, et al., “Continuous Fabrication of Wide-Tip Microstructures for Bio-Inspired Dry Adhesives via Tip Inking Process”, Journal of Chemistry, Jan. 2, 2019, pp. 1-5. |
| Merriam-Webster Dictionary, “Embed Definition & Meaning”, https://www.merriam-webster.com/dictionary/embed last accessed Aug. 3, 2023, 2003. |
| Parness, et al., “A microfabricated wedge-shaped adhesive array displaying gecko-like dynamic adhesion, directionality”, J.R. Soc. Interface, 2009, pp. 1223-1232. |
| Pieper, et al., “An external urine-collection device for women: A clinical trial”, Journal of ER Nursing, vol. 20, No. 2, Mar./Apr. 1993, pp. 51-55. |
| Tsipenyuk, et al., “Use of biomimetic hexagonal surface texture in friction against lubricated skin”, Journal of The Royal Society—Interface, 2014, pp. 1-6. |
| Vinas, “A Solution For An Awkward—But Serious—Subject”, http://www.aero-news.net/index.cfm?do=main.textpost&id=69ae2bb1-838b-4098-a7b5-7flbb2505688 last accessed Feb. 8, 2021. |
| Wikipedia Article, “Decibel”, https://web.archive.org/web/2020041521917/https://en.wikipedia/org/wiki/Decibel last accessed Mar. 11, 2024, 21 pages. |
| Wikipedia Article, “Fiberglass”, https://web.archive.org.web/20200309194847/https://en.wikipedia.org/wiki/Fiberglass last accessed Mar. 11, 2024. |
| Wikipedia Article, “Zylinder (Geometrie)”, https://de.wikipedia.org/w/index.php?title=Zylinder (Geometrie)&oldid=154862081, version of Jun. 1, 2016, 7 pages. |
| Number | Date | Country | |
|---|---|---|---|
| 20220071811 A1 | Mar 2022 | US |
| Number | Date | Country | |
|---|---|---|---|
| 63076474 | Sep 2020 | US |
